;Catalog Number;Product Name;Well_ID_384;Plate_ID_384;Row_ID_384;Col_ID_384;STATUS;Plate Location;Rack Number;M.w.;CAS Number;Target;DMSO (mg/mL)Max Solubility;DMSO (mM)Max Solubility;water (mg/mL)Max Solubility;water (mM)Max Solubility;URL;Information;Pathway;Formula;Form;Synonyms;SMILES;ALogP;HBA_Count;HBD_Count;RotatableBond;Rack_ID;Row_ID;Col_ID;robot.source;robot.source.position;robot.destination.vol;robot.destination;robot.destination.position;Library_ID
1;S1003;Linifanib (ABT-869);A01;1;A;1;NA;a1;L1200-01;37541;796967-16-3;PDGFR, VEGFR;75;1997815721;<1;NA;http://www.selleckchem.com/products/ABT-869.html;Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFR_ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.;Protein Tyrosine Kinase;C21H18FN5O;Free Base;AL-39324;CC1=CC(NC(=O)NC2=CC=C(C=C2)C2=C3C(N)=NNC3=CC=C2)=C(F)C=C1 |c:10,12,15,18,22,24,29,t:1,8,26|;4,169;2;4;3;1;a;1;L1200-01;a1;100;1;A01;2
2;S1049;Y-27632 2HCl;A02;1;A;2;NA;a1;L2100-01;32026;129830-38-2;ROCK;64;1998376319;14;4371448198;http://www.selleckchem.com/products/Y-27632.html;Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.;Others;C14H23Cl2N3O;Dihydrochloric;N/A;Cl.Cl.C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)NC1=CC=NC=C1 |r,c:15,17,t:13|;1,871;2;2;3;9;a;1;L2100-01;a1;100;1;A02;2
3;S1017;Cediranib (AZD2171);A03;1;A;3;NA;a2;L1200-01;45051;288383-20-0;VEGFR, Flt;90;1997735899;<1;NA;http://www.selleckchem.com/products/Cediranib.html;Cediranib (AZD2171) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/²3 nM, similar activity against c-Kit and PDGFR_, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-_, CSF-1R and Flt3 in HUVEC cells. Phase 3.;Protein Tyrosine Kinase;C25H27FN4O3;Free Base;Recentin;COC1=C(OCCCN2CCCC2)C=C2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1 |c:2,16,21,28,31,35,t:14,18,24|;4,761;5;1;8;1;a;2;L1200-01;a2;100;1;A03;2
4;S1262;Avagacestat (BMS-708163);A04;1;A;4;NA;a2;L2100-01;52088;1146699-66-2;Gamma-secretase;104;1996621103;<1;NA;http://www.selleckchem.com/products/BMS-708163.html;Avagacestat (BMS-708163) is a potent, selective, orally bioavailable _-secretase inhibitor of A_40 and A_42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2.;Proteases;C20H17ClF4N4O4S;Free Base;N/A;NC(=O)[C@@H](CCC(F)(F)F)N(CC1=C(F)C=C(C=C1)C1=NOC=N1)S(=O)(=O)C1=CC=C(Cl)C=C1 |r,c:12,15,17,23,34,t:20,29,31|;3,364;6;1;10;9;a;2;L2100-01;a2;100;1;A04;2
5;S1032;Motesanib Diphosphate (AMG-706);A05;1;A;5;NA;a3;L1200-01;56944;857876-30-3;VEGFR, PDGFR, c-Kit;100;1756111267;19;33,36611408;http://www.selleckchem.com/products/Motesanib-Diphosphate.html;"Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. Phase 3.";Protein Tyrosine Kinase;C22H29N5O9P2;Diphosphate;AMG-706;OP(O)(O)=O.OP(O)(O)=O.CC1(C)CNC2=CC(NC(=O)C3=C(NCC4=CC=NC=C4)N=CC=C3)=CC=C12 |c:19,25,27,30,32,34,t:13,23,36|;1,783;3;3;5;1;a;3;L1200-01;a3;100;1;A05;2
6;S1590;TWS119;A06;1;A;6;NA;a3;L2100-01;31833;601514-19-6;GSK-3;64;2010492256;<1;NA;http://www.selleckchem.com/products/TWS119.html;"TWS119 is a GSK-3_ inhibitor with IC50 of 30 nM; capable of inducing neuronal differentiation and may be useful to stem cell biology.";PI3K/Akt/mTOR;C18H14N4O2;Free Base;N/A;NC1=CC(=CC=C1)C1=CC2=C(N1)N=CN=C2OC1=CC=CC(O)=C1 |c:3,5,10,14,16,22,25,t:1,8,20|;3,464;3;3;3;9;a;3;L2100-01;a3;100;1;A06;2
7;S1042;Sunitinib Malate;A07;1;A;7;NA;a4;L1200-01;53256;341031-54-7;VEGFR, PDGFR, c-Kit, Flt;15;2816584047;<1;NA;http://www.selleckchem.com/products/Sunitinib-Malate-(Sutent).html;Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFR_ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.;Microbiology;C26H33FN4O7;Malate;SU-11248;O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=CC=C(F)C=C23)=C1C |r,c:18,36,t:28,30,33|;-1,049;4;4;10;1;a;4;L1200-01;a4;100;1;A07;2
8;S2214;AZ 960;A08;1;A;8;NA;a4;L2100-01;35436;905586-69-8;JAK;71;2003612146;<1;NA;http://www.selleckchem.com/products/AZ-960.html;AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.;JAK/STAT;C18H16F2N6;Free Base;N/A;C[C@H](NC1=NC(NC2=NNC(C)=C2)=C(F)C=C1C#N)C1=CC=C(F)C=C1 |r,c:11,16,26,t:3,7,13,21,23|;4,495;2;3;5;9;a;4;L2100-01;a4;100;1;A08;2
9;S1066;SL-327;A09;1;A;9;NA;a5;L1200-01;33535;305350-87-2;MEK;4;1192783659;<1;NA;http://www.selleckchem.com/products/SL327.html;"SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 _M/ 0.22 _M, no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII;capable of transport through the blood-brain barrier.";Others;C16H12F3N3S;Free Base;N/A;N\C(SC1=CC=C(N)C=C1)=C(\C#N)C1=C(C=CC=C1)C(F)(F)F |c:8,16,18,t:3,5,14|;3,705;0;2;4;1;a;5;L1200-01;a5;100;1;A09;2
10;S2660;MK-0752;A10;1;A;10;NA;a5;L2100-01;4429;471905-41-6;Gamma-secretase;89;2009482953;<1;NA;http://www.selleckchem.com/products/mk-0752.html;MK-0752 is a moderately potent _-secretase inhibitor, which reduces A_40 production with IC50 of 5 nM. Phase 1/2.;Proteases;C21H21ClF2O4S;Free Base;N/A;OC(=O)CC[C@H]1CC[C@@](CC1)(C1=C(F)C=CC(F)=C1)S(=O)(=O)C1=CC=C(Cl)C=C1 |r,c:12,15,18,29,t:24,26|;5,615;3;0;6;9;a;5;L2100-01;a5;100;1;A10;2
11;S1080;SU11274;A11;1;A;11;NA;a6;L1200-01;56809;658084-23-2;c-Met;92;1619461705;<1;NA;http://www.selleckchem.com/products/SU11274.html;SU11274 is a selective Met inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFR_, EGFR or Tie2.;Neuronal Signaling;C28H30ClN5O4S;Free Base;PKI-SU11274;CN(C1=CC(Cl)=CC=C1)S(=O)(=O)C1=CC2=C(NC(=O)\C2=C/C2=C(C)C(C(=O)N3CCN(C)CC3)=C(C)N2)C=C1 |c:5,7,23,41,t:2,13,15,36|;3,477;4;2;5;1;a;6;L1200-01;a6;100;1;A11;2
12;S2745;CHIR-98014;A12;1;A;12;NA;a6;L2100-01;486.31;252935-94-7;GSK-3;8;1645041229;<1;NA;http://www.selleckchem.com/products/chir-98014.html;CHIR-98014 is a potent <b>GSK-3_/_</b> inhibitor with <b>IC50</b> of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.;PI3K/Akt/mTOR;C20H17Cl2N9O2;Free Base;N/A;NC1=NC(NCCNC2=NC=C(N3C=CN=C3)C(=N2)C2=CC=C(Cl)C=C2Cl)=CC=C1[N+]([O-])=O |c:13,15,18,26,29,31,t:1,8,10,21,23|;3,859;4;3;8;9;a;6;L2100-01;a6;100;1;A12;2
13;S1101;Vatalanib (PTK787) 2HCl;A13;1;A;13;NA;a7;L1200-01;41973;212141-51-0;VEGFR, c-Kit, Flt;85;2025111381;10;23,82483978;http://www.selleckchem.com/products/Vatalanib,Dihydrochloride-Salt.html;Vatalanib (PTK787) 2HCl is an inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 3.;Others;C20H17Cl3N4;Dihydrochloride;ZK222584;Cl.Cl.ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1 |c:13,15,20,26,t:1,3,6,8,11,18,22|;5,469;3;1;4;1;a;7;L1200-01;a7;100;1;A13;2
14;S2867;WHI-P154;A14;1;A;14;NA;a7;L2100-01;3762;211555-04-3;JAK, EGFR;75;1993620415;<1;NA;http://www.selleckchem.com/products/whi-p154.html;WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 _M, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.;JAK/STAT;C16H14BrN3O3;Free Base;N/A;COC1=CC2=NC=NC(NC3=CC=C(O)C(Br)=C3)=C2C=C1OC |c:6,16,18,21,t:2,4,10,12|;3,95;4;2;4;9;a;7;L2100-01;a7;100;1;A14;2
15;S1111;Foretinib (GSK1363089);A15;1;A;15;NA;a8;L1200-01;63265;849217-64-7;c-Met, VEGFR;127;2007429068;<1;NA;http://www.selleckchem.com/products/XL880(GSK1363089,EXEL-2880).html;Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit, PDGFR_/_ and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.;Others;C34H34F2N4O6;Free Base;N/A;COC1=CC2=C(C=C1OCCCN1CCOCC1)N=CC=C2OC1=C(F)C=C(NC(=O)C2(CC2)C(=O)NC2=CC=C(F)C=C2)C=C1 |c:4,6,20,22,26,46,49,t:2,29,41,43|;4,437;7;2;12;1;a;8;L1200-01;a8;100;1;A15;2
16;S7086;IWR-1-endo;A16;1;A;16;NA;a8;L2100-01;40944;1127442-82-3;Wnt/beta-catenin;30;7327080891;<1;NA;http://www.selleckchem.com/products/iwr-1-endo.html;IWR-1 (endo-IWR 1) is a Wnt pathway inhibitor with IC50 of 180 nM, induces Axin2 protein levels and promotes _-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.;Stem Cells &  Wnt;C26H21N3O3;Free Base;IWR-1;[H][C@@]12[C@H]3C[C@H](C=C3)[C@]1(C)C(=O)N(C2=O)C1=CC=C(C=C1)C(=O)NC1=CC=CC2=C1N=CC=C2 |r,c:5,19,21,29,31,34,36,t:17,27|;3,075;4;1;3;9;a;8;L2100-01;a8;100;1;A16;2
17;S1134;AT9283;A17;1;A;17;NA;a9;L1200-01;38143;896466-04-9;Bcr-Abl, JAK, Aurora Kinase;76;1992501901;<1;NA;http://www.selleckchem.com/products/AT9283.html;"AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays; also potent to Aurora A/B, Abl(T315I). Phase 2.";Others;C19H23N7O2;Free Base;N/A;O=C(NC1CC1)NC1=CNN=C1C1=NC2=CC(CN3CCOCC3)=CC=C2N1 |c:11,26,28,t:8,14,16|;1,51;4;4;5;1;a;9;L1200-01;a9;100;1;A17;2
18;S7198;BIO;A18;1;A;18;NA;a9;L2100-01;35617;667463-62-9;GSK-3;71;1993430104;<1;NA;http://www.selleckchem.com/products/bio.html;BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3_/_, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.;PI3K/Akt/mTOR;C16H10BrN3O2;Free Base;GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime;O\N=C1C2=CC=CC=C2NC/1=C1\C(=O)NC2=C1C=CC(Br)=C2 |c:5,7,17,20,23,t:3|;2,692;2;2;0;9;a;9;L2100-01;a9;100;1;A18;2
19;S1164;Lenvatinib (E7080);A19;1;A;19;NA;a10;L1200-01;42685;417716-92-8;VEGFR;40;937097341;<1;NA;http://www.selleckchem.com/products/E7080.html;Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFR_/_ in cell-free assays. Phase 3.;Protein Tyrosine Kinase;C21H19ClN4O4;Free Base;N/A;COC1=C(C=C2C(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=CC=NC2=C1)C(N)=O |c:21,23,25,28,t:2,4,8,11|;2,832;5;3;6;1;a;10;L1200-01;a10;100;1;A19;2
20;S7359;K02288;A20;1;A;20;NA;a10;L2100-01;35238;1431985-92-0;TGF-beta/Smad;70;1986491855;<1;NA;http://www.selleckchem.com/products/k02288.html;K02288 is a potent, and selective type I BMP receptor inhibitor with IC50 of 1.1, 1.8, 6.4 nM for ALK2, ALK1 and ALK6, showing weaker inhibition on other ALKs (3, 4, 5) and ActRIIA.;TGF-beta/Smad;C20H20N2O4;Free Base;N/A;COC1=CC(=CC(OC)=C1OC)C1=C(N)N=CC(=C1)C1=CC=CC(O)=C1 |c:4,8,13,16,18,23,26,t:2,21|;3,217;4;2;5;9;a;10;L2100-01;a10;100;1;A20;2
21;S1179;WZ8040;A21;1;A;21;NA;a11;L1200-01;48101;1214265-57-2;EGFR;96;1995800503;<1;NA;http://www.selleckchem.com/products/WZ8040.html;WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).;Protein Tyrosine Kinase;C24H25ClN6OS;Free Base;N/A;CN1CCN(CC1)C1=CC=C(NC2=NC=C(Cl)C(SC3=CC(NC(=O)C=C)=CC=C3)=N2)C=C1 |c:27,29,31,34,t:8,10,13,15,20|;5,381;3;2;7;1;a;11;L1200-01;a11;100;1;A21;2
22;S7605;Filgotinib (GLPG0634);A22;1;A;22;NA;a11;L2100-01;4255;1206161-97-8;JAK;85;1997649824;<1;NA;http://www.selleckchem.com/products/filgotinib.html;Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.;JAK/STAT;C21H23N5O3S;Free Base;N/A;O=C(NC1=NN2C(C=CC=C2C2=CC=C(CN3CCS(=O)(=O)CC3)C=C2)=N1)C1CC1 |c:7,9,26,28,t:3,12,14|;2,461;5;1;5;9;a;11;L2100-01;a11;100;1;A22;2
23;NA;DMSO;A23;1;A;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;A23;2
24;NA;DMSO;A24;1;A;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;A24;2
25;S1234;AG-1024;B01;1;B;1;NA;a1;L1200-02;30517;65678-07-1;IGF-1R;61;1998885867;<1;NA;http://www.selleckchem.com/products/ag-1024-tyrphostin.html;AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 _M, is less potent to IR with IC50 of 57 _M and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).;Protein Tyrosine Kinase;C14H13BrN2O;Free Base;N/A;CC(C)(C)C1=C(O)C(Br)=CC(C=C(C#N)C#N)=C1 |c:4,8,16|;3,922;0;1;2;2;a;1;L1200-02;a1;100;1;B01;2
26;S7526;GNF-5;B02;1;B;2;NA;a1;L1200-05;41837;778277-15-9;Bcr-Abl;83;1983889858;<1;NA;http://www.selleckchem.com/products/gnf-5.html;GNF-5 is a selective and allosteric Bcr-Abl inhibitor with IC50 of 220 nM.;Angiogenesis;C20H17F3N4O3;Free Base;N/A;OCCNC(=O)C1=CC=CC(=C1)C1=CC(NC2=CC=C(OC(F)(F)F)C=C2)=NC=N1 |c:8,10,26,28,30,t:6,13,17,19|;4,876;4;3;8;5;a;1;L1200-05;a1;100;1;B02;2
27;S1275;BX-912;B03;1;B;3;NA;a2;L1200-02;47135;702674-56-4;PDK-1;94;1994271773;<1;NA;http://www.selleckchem.com/products/bx-912.html;BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3_, selectivity for PDK1 is 600-fold.;PI3K/Akt/mTOR;C20H23BrN8O;Free Base;N/A;BrC1=CN=C(NC2=CC(NC(=O)N3CCCC3)=CC=C2)N=C1NCCC1=CN=CN1 |c:17,19,22,30,t:1,3,6,28|;2,798;4;4;7;2;a;2;L1200-02;a2;100;1;B03;2
28;NA;DMSO;B04;1;B;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;B04;2
29;S1451;Aurora A Inhibitor I;B05;1;B;5;NA;a3;L1200-02;58807;1158838-45-9;Aurora Kinase;118;2006563844;<1;NA;http://www.selleckchem.com/products/Aurora-A-Inhibitor-I.html;Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.;Cell Cycle;C31H31ClFN7O2;Free Base;N/A;CCN1CCN(CC1)C(=O)CC1=CC=C(NC2=NC(NC3=CC=C(C=C3)C(=O)NC3=CC=CC=C3Cl)=C(F)C=N2)C=C1 |c:23,25,33,35,41,44,t:12,14,17,21,31,38|;5,621;4;3;9;2;a;3;L1200-02;a3;100;1;B05;2
30;S7709;VX-11e;B06;1;B;6;NA;a3;L1200-05;500.35;896720-20-0;ERK;100;19986;<1;NA;http://selleckchem.com/products/vx-11e.html;VX-11e is a potent, selective, and orally bioavailable ERK2 inhibitor with Ki of <2 nM, over 200-fold selective over other kinases tested.;MAPK;C24H20Cl2FN5O2;Free Base;VTX-11e, Vertex-11e;CC1=CN=C(NC2=C(Cl)C=C(F)C=C2)N=C1C1=CNC(=C1)C(=O)N[C@H](CO)C1=CC=CC(Cl)=C1 |r,c:6,12,15,21,32,35,t:1,3,9,18,30|;5,755;3;4;7;5;a;3;L1200-05;a3;100;1;B06;2
31;S1475;Pimasertib (AS-703026);B07;1;B;7;NA;a4;L1200-02;4312;1236699-92-5;MEK;86;1994434137;<1;NA;http://www.selleckchem.com/products/AS703026.html;Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 _M in MM cell lines. Phase 2.;MAPK;C15H15FIN3O3;Free Base;N/A;OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=C(F)C=C(I)C=C1 |r,c:10,12,16,22,t:8,19|;1,171;2;4;6;2;a;4;L1200-02;a4;100;1;B07;2
32;NA;DMSO;B08;1;B;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;B08;2
33;S1526;Quizartinib (AC220);B09;1;B;9;NA;a5;L1200-02;56067;950769-58-1;Flt;33.2;5921486793;<0.3;NA;http://www.selleckchem.com/products/AC-220.html;"Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFR_, PDGFR_, RET, and CSF-1R. Phase 3.";Angiogenesis;C29H32N6O4S;Free Base;N/A;CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1 |c:13,15,35,40,42,t:4,11,18,23,37|;5,064;6;2;8;2;a;5;L1200-02;a5;100;1;B09;2
34;S7871;LJI308;B10;1;B;10;NA;a5;L1200-05;368.38;1627709-94-7;S6 Kinase;73;19816;<1;NA;http://selleckchem.com/products/lji308.html;LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.;PI3K/Akt/mTOR;C21H18F2N2O2;Free Base;N/A;OC1=C(F)C=C(C=C1F)C1=C(C=CN=C1)C1=CC=C(C=C1)N1CCOCC1 |c:1,4,6,12,14,19,21,t:10,17|;3,735;2;1;3;5;a;5;L1200-05;a5;100;1;B10;2
35;S1556;PHT-427;B11;1;B;11;NA;a6;L1200-02;40961;1191951-57-1;Akt, PDK-1;82;200190425;<1;NA;http://www.selleckchem.com/products/PHT-427.html;PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 _M and 5.2 _M, respectively.;PI3K/Akt/mTOR;C20H31N3O2S2;Free Base;N/A;CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)NC1=NN=CS1 |c:14,16,25,t:12,23|;6,296;4;1;14;2;a;6;L1200-02;a6;100;1;B11;2
36;NA;DMSO;B12;1;B;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;B12;2
37;S1574;BIRB 796 (Doramapimod);B13;1;B;13;NA;a7;L1200-02;52766;285983-48-4;p38 MAPK;106;2008869348;<1;NA;http://www.selleckchem.com/products/BIRB-796-(Doramapimod).html;BIRB 796 (Doramapimod) is a  pan-p38 MAPK inhibitor with IC50 of  38 nM, 65 nM, 200 nM and 520 nM for p38_/_/_/_ in cell-free assays, and binds p38_ with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.;MAPK;C31H37N5O3;Free Base;N/A;CC1=CC=C(C=C1)N1N=C(C=C1NC(=O)NC1=CC=C(OCCN2CCOCC2)C2=C1C=CC=C2)C(C)(C)C |c:3,5,9,11,32,35,37,t:1,18,20|;5,907;4;2;8;2;a;7;L1200-02;a7;100;1;B13;2
38;S8007;VE-821;B14;1;B;14;NA;a7;L1200-05;36841;1232410-49-9;ATM/ATR;74;2008631688;<1;NA;http://www.selleckchem.com/products/ve-821.html;VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3K_.;DNA Damage;C18H16N4O3S;Free Base;N/A;CS(=O)(=O)C1=CC=C(C=C1)C1=CN=C(N)C(=N1)C(=O)NC1=CC=CC=C1 |c:6,8,16,24,26,t:4,11,13,22|;2,007;5;2;4;5;a;7;L1200-05;a7;100;1;B14;2
39;S2134;AZD8330;B15;1;B;15;NA;a8;L1200-02;46123;869357-68-6;MEK;92;1994666435;<1;NA;http://www.selleckchem.com/products/AZD8330(ARRY-424704).html;AZD8330 is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. Phase 1.;MAPK;C16H17FIN3O4;Free Base;N/A;CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=C(F)C=C(I)C=C1 |c:5,14,18,24,t:21|;1,653;3;3;6;2;a;8;L1200-02;a8;100;1;B15;2
40;NA;DMSO;B16;1;B;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;B16;2
41;S2193;GSK461364;B17;1;B;17;NA;a9;L1200-02;5436;929095-18-1;PLK;10;1839587932;<1;NA;http://www.selleckchem.com/products/GSK461364.html;GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.;Cell Cycle;C27H28F3N5O2S;Free Base;N/A;C[C@@H](OC1=C(SC(=C1)N1C=NC2=C1C=C(CN1CCN(C)CC1)C=C2)C(N)=O)C1=CC=CC=C1C(F)(F)F |r,c:6,10,12,26,34,36,t:3,15,32|;5,125;3;1;8;2;a;9;L1200-02;a9;100;1;B17;2
42;S8124;BMS-582949;B18;1;B;18;NA;a9;L1200-05;406.48;623152-17-0;p38 MAPK;81;19927;<1;NA;http://selleckchem.com/products/bms-582949.html;BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM,inhibiting both p38 kinase activity and activation of p38.;MAPK;C22H26N6O2;Free Base;PS540446;CCCNC(=O)C1=CN2N=CN=C(NC3=CC(=CC=C3C)C(=O)NC3CC3)C2=C1C |c:9,16,18,30,t:6,11,14|;3,269;4;3;7;5;a;9;L1200-05;a9;100;1;B18;2
43;S2216;Mubritinib (TAK 165);B19;1;B;19;NA;a10;L1200-02;46847;366017-09-6;HER2;13;2774990928;<1;NA;http://www.selleckchem.com/products/Mubritinib-TAK-165.html;"Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM in BT-474 cell; no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk in BT-474 cell line. Phase 1.";Protein Tyrosine Kinase;C25H23F3N4O2;Free Base;TAK 165, TAK165;FC(F)(F)C1=CC=C(\C=C\C2=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO2)C=C1 |c:24,26,29,31,35,t:4,6,10,15,17|;5,844;5;0;11;2;a;10;L1200-02;a10;100;1;B19;2
44;NA;DMSO;B20;1;B;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;B20;2
45;S2235;Volasertib (BI 6727);B21;1;B;21;NA;a11;L1200-02;61881;755038-65-4;PLK;20;3232009825;<1;NA;http://www.selleckchem.com/products/BI6727-Volasertib.html;Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.;Cell Cycle;C34H50N8O3;Free Base;N/A;CC[C@H]1N(C(C)C)C2=C(C=NC(NC3=CC=C(C=C3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)=N2)N(C)C1=O |r,c:9,15,17,43,t:7,13|;4,838;5;2;10;2;a;11;L1200-02;a11;100;1;B21;2
46;NA;DMSO;B22;1;B;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;B22;2
47;NA;DMSO;B23;1;B;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;B23;2
48;NA;DMSO;B24;1;B;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;B24;2
49;S1005;Axitinib;C01;1;C;1;NA;b1;L1200-01;38647;319460-85-0;VEGFR, PDGFR, c-Kit;35;9056330375;<1;NA;http://www.selleckchem.com/products/Axitinib.html;Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR_ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.;Protein Tyrosine Kinase;C22H18N4OS;Free Base;AG 013736;CNC(=O)C1=CC=CC=C1SC1=CC2=C(C=C1)C(\C=C\C1=CC=CC=N1)=NN2 |c:6,8,14,16,24,26,28,t:4,12,22|;4,492;3;2;5;1;b;1;L1200-01;b1;100;1;C01;2
50;S1055;Enzastaurin (LY317615);C02;1;C;2;NA;b1;L2100-01;51561;170364-57-5;PKC;30;5818351079;<1;NA;http://www.selleckchem.com/products/Enzastaurin.html;Enzastaurin (LY317615) is a potent PKC_ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKC_, PKC_ and PKC_. Phase 3.;Neuronal Signaling;C32H29N5O2;Free Base;N/A;CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=NC=CC=C3)CC2)C2=CC=CC=C12 |c:2,6,30,32,40,t:4,8,12,20,28,38,42|;4,32;3;1;5;9;b;1;L2100-01;b1;100;1;C02;2
51;S1018;Dovitinib (TKI-258, CHIR-258);C03;1;C;3;NA;b2;L1200-01;39243;405169-16-6;c-Kit, FGFR, Flt, VEGFR, PDGFR;30;7644675484;<1;NA;http://www.selleckchem.com/products/CHIR-258.html;Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.;Angiogenesis;C21H21FN6O;free base;CHIR-258;CN1CCN(CC1)C1=CC2=C(C=C1)N=C(N2)C1=C(N)C2=C(NC1=O)C=CC=C2F |c:10,12,15,19,22,28,30,t:8|;1,781;2;3;2;1;b;2;L1200-01;b2;100;1;C03;2
52;S1378;Ruxolitinib (INCB018424);C04;1;C;4;NA;b2;L2100-01;30637;941678-49-5;JAK;61;1991056566;<1;NA;http://www.selleckchem.com/products/INCB18424.html;INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.;JAK/STAT;C17H18N6;Free Base;N/A;N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |r,c:11,13,18,20,23,t:16|;2,88;3;1;4;9;b;2;L2100-01;b2;100;1;C04;2
53;S1033;Nilotinib (AMN-107);C05;1;C;5;NA;b3;L1200-01;52952;641571-10-0;Bcr-Abl;27;5098957546;<1;NA;http://www.selleckchem.com/products/Nilotinib.html;Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.;Angiogenesis;C28H22F3N7O;Free Base;Tasigna;CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F |c:4,22,24,29,31,33,35,37,t:1,7,13,15,20,27|;5,084;5;2;7;1;b;3;L1200-01;b3;100;1;C05;2
54;S1594;Semagacestat (LY450139);C06;1;C;6;NA;b3;L2100-01;36144;425386-60-3;Gamma-secretase;72;1992031873;<1;NA;http://www.selleckchem.com/products/Semagacestat(LY450139).html;Semagacestat (LY450139) is a _-secretase blocker for A_42, A_40 and A_38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM. Phase 3.;Proteases;C19H27N3O4;Free Base;LY-450139, LY450139;CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=C(CCN(C)C1=O)C=CC=C2 |r,c:14,23,25|;0,632;3;3;5;9;b;3;L2100-01;b3;100;1;C06;2
55;S1044;Temsirolimus (CCI-779, NSC 683864);C07;1;C;7;NA;b4;L1200-01;103029;162635-04-3;mTOR;75;7279503829;<1;NA;http://www.selleckchem.com/products/Temsirolimus.html;Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 _M in a cell-free assay.;Neuronal Signaling;C56H87NO16;Free Base;N/A;CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |r,c:14,33,t:29,31|;6,039;12;3;11;1;b;4;L1200-01;b4;100;1;C07;2
56;S2215;DAPT (GSI-IX);C08;1;C;8;NA;b4;L2100-01;43246;208255-80-5;Gamma-secretase, Beta Amyloid;86;1988623225;<1;NA;http://www.selleckchem.com/products/DAPT-GSI-IX.html;DAPT (GSI-IX) is a novel _-secretase inhibitor, which inhibits A_ production with IC50 of 20 nM in HEK 293 cells.;Proteases;C23H26F2N2O4;Free Base;GSI-IX;C[C@H](NC(=O)CC1=CC(F)=CC(F)=C1)C(=O)N[C@H](C(=O)OC(C)(C)C)C1=CC=CC=C1 |r,c:9,12,28,30,t:6,26|;3,385;4;2;9;9;b;4;L2100-01;b4;100;1;C08;2
57;S1068;Crizotinib (PF-02341066);C09;1;C;9;NA;b5;L1200-01;45034;877399-52-5, 877399-53-6 (acetate);c-Met, ALK;9;199849003;<1;NA;http://www.selleckchem.com/products/PF-2341066.html;Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.;Others;C21H22Cl2FN5O;Free Base;N/A;C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl |r,c:3,6,8,14,24,27,30,t:11|;3,693;3;2;5;1;b;5;L1200-01;b5;100;1;C09;2
58;S2662;ICG-001;C10;1;C;10;NA;b5;L2100-01;54863;780757-88-2;Wnt/beta-catenin;100;1822722053;<1;NA;http://www.selleckchem.com/products/icg-001.html;ICG-001 antagonizes Wnt/_-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC50 of 3 _M, but is not the related transcriptional coactivator p300.;Stem Cells &  Wnt;C33H32N4O4;Free Base;N/A;[H][C@]12CN(CC3=CC=CC4=C3C=CC=C4)C(=O)[C@H](CC3=CC=C(O)C=C3)N1C(=O)CCN2C(=O)NCC1=CC=CC=C1 |r,c:7,9,12,14,26,43,45,t:5,21,23,41|;4,065;3;2;6;9;b;5;L2100-01;b5;100;1;C10;2
59;S1084;Brivanib (BMS-540215);C11;1;C;11;NA;b6;L1200-01;37038;649735-46-6;VEGFR, FGFR;74;1997948053;<1;NA;http://www.selleckchem.com/products/Brivanib.html;Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-_. Phase 3.;GPCR & G Protein;C19H19FN4O3;Free Base;N/A;C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C |r,c:8,13,20,23,27,t:5,10,16|;3,481;4;2;5;1;b;6;L1200-01;b6;100;1;C11;2
60;S2750;GW788388;C12;1;C;12;NA;b6;L2100-01;42548;452342-67-5;TGF-beta/Smad;15;3525430102;<1;NA;http://www.selleckchem.com/products/gw788388.html;GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, also inhibits TGF-_ type II receptor and activin type II receptor activities, but does not inhibit BMP type II receptor.;TGF-beta/Smad;C25H23N5O2;Free Base;N/A;O=C(NC1CCOCC1)C1=CC=C(C=C1)C1=NC=CC(=C1)C1=CNN=C1C1=NC=CC=C1 |c:12,14,19,21,27,32,34,t:10,17,24,30|;2,862;5;2;5;9;b;6;L2100-01;b6;100;1;C12;2
61;S1102;U0126-EtOH;C13;1;C;13;NA;b7;L1200-01;42656;1173097-76-1;MEK;85;1992685671;<1;NA;http://www.selleckchem.com/products/U0126.html;U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 _M/0.06 _M in cell-free assays, 100-fold higher affinity for _N3-S218E/S222D MEK than PD98059.;Others;C20H22N6OS2;Free Base;N/A;CCO.N\C(SC1=CC=CC=C1N)=C(C#N)\C(C#N)=C(\N)SC1=CC=CC=C1N |c:7,9,24,26,t:5,22|;2,169;0;5;5;1;b;7;L1200-01;b7;100;1;C13;2
62;S2902;S-Ruxolitinib (INCB018424);C14;1;C;14;NA;b7;L2100-01;30637;941685-37-6;JAK;61;1991056566;5;1632013578;http://www.selleckchem.com/products/s-ruxolitinib.html;S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.;JAK/STAT;C17H18N6;Free Base;N/A;N#CC[C@@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |r,c:11,13,18,20,23,t:16|;2,88;3;1;4;9;b;7;L2100-01;b7;100;1;C14;2
63;S1113;GSK690693;C15;1;C;15;NA;b8;L1200-01;42548;937174-76-0;Akt;39;9166118266;<1;NA;http://www.selleckchem.com/products/GSK690693.html;GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.;Others;C21H27N7O3;Free Base;N/A;CCN1C(=NC2=C1C(OC[C@H]1CCCNC1)=CN=C2C#CC(C)(C)O)C1=NON=C1N |r,c:3,5,17,19,31,t:28|;1,839;6;2;7;1;b;8;L1200-01;b8;100;1;C15;2
64;S7092;SANT-1;C16;1;C;16;NA;b8;L2100-01;37349;304909-07-7;Smoothened;21;5622640499;<1;NA;http://www.selleckchem.com/products/sant-1.html;SANT-1 directly binds to Smoothened (Smo) receptor with Kd of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.;Stem Cells &  Wnt;C23H27N5;Free Base;N/A;CC1=NN(C(C)=C1\C=N\N1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1 |c:5,17,19,27,29,t:1,15,25|;3,759;2;0;5;9;b;8;L2100-01;b8;100;1;C16;2
65;S1138;Brivanib Alaninate (BMS-582664);C17;1;C;17;NA;b9;L1200-01;44146;649735-63-7;VEGFR, FGFR;88;1993385584;<1;NA;http://www.selleckchem.com/products/Brivanib-alaninate.html;Brivanib alaninate (BMS-582664) is the prodrug of BMS-540215, an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM.;Others;C22H24FN5O4;Alaninate;N/A;C[C@H](COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C)OC(=O)[C@H](C)N |r,c:7,12,19,22,26,t:4,9,15|;3,383;6;2;8;1;b;9;L1200-01;b9;100;1;C17;2
66;S7207;Ro 31-8220 Mesylate;C18;1;C;18;NA;b9;L2100-01;553.65;138489-18-6;PKC;100;18062;<1;NA;http://selleckchem.com/products/ro-31-8220-mesylate.html;Ro 31-8220 is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-_, PKC-_I, PKC-_II, PKC-_, and PKC-_, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3_ and S6K1.;TGF-beta/Smad;C26H27N5O5S2;Mesylate;Bisindolylmaleimide IX Mesylate;CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(CCCSC(N)=N)C2=CC=CC=C12 |c:6,10,36,t:8,12,16,24,34,38|;3,452;2;2;7;9;b;9;L2100-01;b9;100;1;C18;2
67;S1167;CP-724714;C19;1;C;19;NA;b10;L1200-01;46953;537705-08-1;EGFR, HER2;94;2002002002;<1;NA;http://www.selleckchem.com/products/CP-724714.html;CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2.;Protein Tyrosine Kinase;C27H27N5O3;Free Base;N/A;COCC(=O)NC\C=C\C1=CC=C2N=CN=C(NC3=CC=C(OC4=CC=C(C)N=C4)C(C)=C3)C2=C1 |c:13,28,32,36,t:9,11,15,18,20,23,25|;3,987;6;2;9;1;b;10;L1200-01;b10;100;1;C19;2
68;S7435;AR-A014418;C20;1;C;20;NA;b10;L2100-01;30831;487021-52-3;GSK-3;62;2010962992;<1;NA;http://www.selleckchem.com/products/ar-a014418.html;AR-A014418 is an ATP-competitive, and selective GSK3_ inhibitor with IC50 and Ki of 104 nM and 38 nM, without significant inhibition on 26 other kinases tested.;PI3K/Akt/mTOR;C12H12N4O4S;Free Base;GSK-3_ Inhibitor VIII;COC1=CC=C(CNC(=O)NC2=NC=C(S2)[N+]([O-])=O)C=C1 |c:13,20,t:2,4,11|;1,529;3;2;5;9;b;10;L2100-01;b10;100;1;C20;2
69;S1181;ENMD-2076;C21;1;C;21;NA;b11;L1200-01;37547;934353-76-1;Flt, Aurora Kinase, VEGFR;105;279649506;1;2,663328628;http://www.selleckchem.com/products/ENMD-2076.html;ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFR_. Phase 2.;Angiogenesis;C21H25N7;free base;N/A;CN1CCN(CC1)C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C2=CC=CC=C2)=N1 |c:16,18,25,27,29,t:8,12,23|;4,015;3;2;5;1;b;11;L1200-01;b11;100;1;C21;2
70;S7951;STA-21;C22;1;C;22;NA;b11;L2100-01;306.31;111540-00-2;STAT;61;19914;NA;NA;http://selleckchem.com/products/sta-21.html;STA-21 is a selective STAT3 inhibitor.;JAK/STAT;C19H14O4;Free Base;N/A;CC1CC(=O)C2=C(C1)C=CC1=C2C(=O)C2=C(C(O)=CC=C2)C1=O |c:5,9,11,19,21,t:16|;3,339;3;1;0;9;b;11;L2100-01;b11;100;1;C22;2
71;NA;DMSO;C23;1;C;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;C23;2
72;NA;DMSO;C24;1;C;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;C24;2
73;S1244;Amuvatinib (MP-470);D01;1;D;1;NA;b1;L1200-02;44751;850879-09-3;c-Met, c-Kit, PDGFR, Flt, c-RET;32;7150678197;<1;NA;http://www.selleckchem.com/products/MP-470.html;Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFR_ and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Phase 2.;Protein Tyrosine Kinase;C23H21N5O3S;Free Base;N/A;S=C(NCC1=CC=C2OCOC2=C1)N1CCN(CC1)C1=NC=NC2=C1OC1=CC=CC=C21 |c:12,24,26,32,t:4,6,22,30,34|;4,867;5;1;5;2;b;1;L1200-02;b1;100;1;D01;2
74;S7528;GNE-7915;D02;1;D;2;NA;b1;L1200-05;4434;1351761-44-8;LRRK;22;4961659901;<1;NA;http://www.selleckchem.com/products/gne-7915.html;GNE-7915 is a highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor,  with IC50 and Ki of 9 nM and 1 nM, respectively.;Autophagy;C19H21F4N5O3;Free Base;N/A;CCNC1=NC(NC2=CC(F)=C(C=C2OC)C(=O)N2CCOCC2)=NC=C1C(F)(F)F |c:10,12,25,27,t:3,7|;3,052;5;2;7;5;b;1;L1200-05;b1;100;1;D02;2
75;S1342;Genistein;D03;1;D;3;NA;b2;L1200-02;27024;446-72-0;EGFR;54;1998223801;<1;NA;http://www.selleckchem.com/products/Genistein.html;Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK)  which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12_M or by insulin with IC50 of 19 _M.;Protein Tyrosine Kinase;C15H10O5;Free Base;N/A;OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O |c:3,5,14,17,t:1,8,11|;2,14;2;3;1;2;b;2;L1200-02;b2;100;1;D03;2
76;NA;DMSO;D04;1;D;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;D04;2
77;S1454;PHA-680632;D05;1;D;5;NA;b3;L1200-02;50162;398493-79-3;Aurora Kinase;100;1993540927;<1;NA;http://www.selleckchem.com/products/PHA-680632.html;PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.;Cell Cycle;C28H35N7O2;Free Base;N/A;CCC1=CC=CC(CC)=C1NC(=O)N1CC2=C(C1)C(NC(=O)C1=CC=C(C=C1)N1CCN(C)CC1)=NN2 |c:4,8,16,26,28,38,t:2,24|;4,339;3;3;6;2;b;3;L1200-02;b3;100;1;D05;2
78;S7714;FIIN-2;D06;1;D;6;NA;b3;L1200-05;634.73;1633044-56-0;FGFR;69;1087076395;<1;NA;http://www.selleckchem.com/products/fiin-2.html;FIIN-2 is an irreversible, pan-FGFR inhibitor with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM for FGFR1/2/3/4, respectively.;Protein Tyrosine Kinase;C35H38N8O4;Free Base;N/A;COC1=CC(OC)=CC(=C1)N1CC2=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C2N(CC2=CC=C(NC(=O)C=C)C=C2)C1=O |c:6,8,20,22,33,47,t:2,13,15,18,38,40|;5,007;6;2;10;5;b;3;L1200-05;b3;100;1;D06;2
79;S1485;HMN-214;D07;1;D;7;NA;b4;L1200-02;42447;173529-46-9;PLK;12;2827054916;<1;NA;http://www.selleckchem.com/products/HMN-214.html;HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.;Cell Cycle;C22H20N2O5S;Free Base;N/A;COC1=CC=C(C=C1)S(=O)(=O)N(C(C)=O)C1=C(\C=C\C2=CC=[N+]([O-])C=C2)C=CC=C1 |c:4,6,16,25,28,30,t:2,20,22|;2,282;4;0;6;2;b;4;L1200-02;b4;100;1;D07;2
80;NA;DMSO;D08;1;D;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;D08;2
81;S1529;Hesperadin;D09;1;D;9;NA;b5;L1200-02;51665;422513-13-1;Aurora Kinase;103;1993612697;<1;NA;http://www.selleckchem.com/products/Hesperadin.html;Hesperadin potently inhibits Aurora B with IC50 of 250 nM in a cell-free assay. It markedly reduces the activity of AMPK, Lck, MKK1, MAPKAP-K1, CHK1 and PHK while it does not inhibit MKK1 activity in vivo.;Cell Cycle;C29H32N4O3S;Free Base;N/A;CCS(=O)(=O)NC1=CC=C2NC(=O)\C(C2=C1)=C(/NC1=CC=C(CN2CCCCC2)C=C1)C1=CC=CC=C1 |c:15,32,37,39,t:6,8,20,22,35|;4,071;3;3;8;2;b;5;L1200-02;b5;100;1;D09;2
82;S7877;ONO-4059;D10;1;D;10;NA;b5;L1200-05;456.5;1351635-67-0;BTK;20;4381161008;<1;NA;http://www.selleckchem.com/products/ono-4059.html;ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.;Angiogenesis;C25H24N6O3;Free Base;ONO-WG-307;NC1=C2N(C(=O)N(C3CCCN(C3)C(=O)C=C)C2=NC=N1)C1=CC=C(OC2=CC=CC=C2)C=C1 |c:1,19,21,31,33,36,t:24,26,29,@:6|;3,38;5;1;5;5;b;5;L1200-05;b5;100;1;D10;2
83;S1557;KRN 633;D11;1;D;11;NA;b6;L1200-02;41686;286370-15-8;VEGFR, PDGFR;9;2158998225;<1;NA;http://www.selleckchem.com/products/KRN-633.html;KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM, weakly inhibits PDGFR-_/_ and c-Kit, does not block the phosphorylation of FGFR-1, EGFR or c-Met in cell.;Protein Tyrosine Kinase;C20H21ClN4O4;Free Base;N/A;CCCNC(=O)NC1=CC=C(OC2=NC=NC3=CC(OC)=C(OC)C=C23)C=C1Cl |c:14,28,t:7,9,12,16,20,24|;4,107;6;2;7;2;b;6;L1200-02;b6;100;1;D11;2
84;NA;DMSO;D12;1;D;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;D12;2
85;S1577;Tie2 kinase inhibitor;D13;1;D;13;NA;b7;L1200-02;43953;948557-43-5;Tie-2;35;7963051441;<1;NA;http://www.selleckchem.com/products/Tie2-kinase-inhibitor.html;Tie2 kinase inhibitor is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 _M, 200-fold more potent than p38.;Protein Tyrosine Kinase;C26H21N3O2S;Free Base;N/A;COC1=CC2=C(C=C1)C=C(C=C2)C1=C(N=C(N1)C1=CC=C(C=C1)S(C)=O)C1=CC=NC=C1 |c:4,6,9,11,16,22,24,32,34,t:2,14,20,30|;4,57;4;1;5;2;b;7;L1200-02;b7;100;1;D13;2
86;S8009;AG-18;D14;1;D;14;NA;b7;L1200-05;18617;118409-57-7;EGFR;37;1987430843;<1;NA;http://www.selleckchem.com/products/ag-18-tyrphostin-23.html;AG-18 inhibits EGFR with IC50 of 35 _M.;Protein Tyrosine Kinase;C10H6N2O2;Free Base;RG-50810;OC1=C(O)C=C(C=C(C#N)C#N)C=C1 |c:1,12,t:4|;1,531;0;2;1;5;b;7;L1200-05;b7;100;1;D14;2
87;S2158;KW-2449;D15;1;D;15;NA;b8;L1200-02;3324;1000669-72-6;Flt, Bcr-Abl, Aurora Kinase;67;2015643803;<1;NA;http://www.selleckchem.com/products/KW-2449.html;"KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFR_, IGF-1R, EGFR. Phase 1.";Angiogenesis;C20H20N4O;Free Base;N/A;O=C(N1CCNCC1)C1=CC=C(\C=C\C2=NNC3=C2C=CC=C3)C=C1 |c:18,21,23,26,t:9,11,15|;2,723;2;2;3;2;b;8;L1200-02;b8;100;1;D15;2
88;NA;DMSO;D16;1;D;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;D16;2
89;S2194;R406;D17;1;D;17;NA;b9;L1200-02;62863;841290-81-1;Syk, Flt;126;2004358685;<1;NA;http://www.selleckchem.com/products/R406.html;R406 is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.;Angiogenesis;C28H29FN6O8S;Besylate;N/A;OS(=O)(=O)C1=CC=CC=C1.COC1=CC(NC2=NC(NC3=NC4=C(OC(C)(C)C(=O)N4)C=C3)=C(F)C=N2)=CC(OC)=C1OC |c:6,8,32,37,39,43,t:4,12,16,20,22,34|;5,044;8;3;8;2;b;9;L1200-02;b9;100;1;D17;2
90;S8167;AMG 337;D18;1;D;18;NA;b9;L1200-05;463.46;1173699-31-4;c-Met;95;20498;<1;NA;http://selleckchem.com/products/amg-337.html;AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.;Protein Tyrosine Kinase;C23H22FN7O3;Free Base;N/A;COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C3=CN(C)N=C3)C2=O)N=C1 |r,c:9,16,20,22,30,36,t:5,7,14,26|;1,188;7;0;7;5;b;9;L1200-05;b9;100;1;D18;2
91;S2218;PP242;D19;1;D;19;NA;b10;L1200-02;30834;1092351-67-1;mTOR;62;2010767335;<1;NA;http://www.selleckchem.com/products/PP242.html;"Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3K_ or PI3K_/_/_, respectively.";PI3K/Akt/mTOR;C16H16N6O;Free Base;TORKinib;CC(C)N1N=C(C2=CC3=C(N2)C=CC(O)=C3)C2=C(N)N=CN=C12 |c:8,12,15,18,21,t:4,6,23|;2,908;3;3;2;2;b;10;L1200-02;b10;100;1;D19;2
92;NA;DMSO;D20;1;D;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;D20;2
93;S2238;Palomid 529 (P529);D21;1;D;21;NA;b11;L1200-02;406.43;914913-88-5;mTOR;81;19930;<1;NA;http://selleckchem.com/products/Palomid-529-P529.html;Palomid 529 (P529) inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3_S9, and pS6 but no effect observed on pMAPK or pAktT308. Phase 1.;PI3K/Akt/mTOR;C24H22O6;Free Base;P529;COC1=CC=C(COC2=C(OC)C=C3C(OC(=O)C4=C3C=CC(=C4)C(C)O)=C2)C=C1 |c:8,12,18,21,23,28,31,t:2,4|;4,257;5;1;6;2;b;11;L1200-02;b11;100;1;D21;2
94;NA;DMSO;D22;1;D;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;D22;2
95;NA;DMSO;D23;1;D;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;D23;2
96;NA;DMSO;D24;1;D;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;D24;2
97;S1006;Saracatinib (AZD0530);E01;1;E;1;NA;c1;L1200-01;54203;379231-04-6;Src, Bcr-Abl;35;6457207166;<1;NA;http://www.selleckchem.com/products/AZD0530.html;"Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.";Angiogenesis;C27H32ClN5O5;Free Base;N/A;CN1CCN(CCOC2=CC(OC3CCOCC3)=C3C(NC4=C(Cl)C=CC5=C4OCO5)=NC=NC3=C2)CC1 |c:22,25,27,33,35,38,t:8,18|;3,814;7;1;8;1;c;1;L1200-01;c1;100;1;E01;2
98;S1067;SB431542;E02;1;E;2;NA;c1;L2100-01;38439;301836-41-9;TGF-beta/Smad;77;200317386;<1;NA;http://www.selleckchem.com/products/SB-431542.html;SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM, 100-fold more selective for ALK5 than p38 MAPK and other kinases.;Others;C22H16N4O3;Free Base;N/A;NC(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=NC=CC=C1)C1=CC2=C(OCO2)C=C1 |c:5,7,12,18,20,31,t:3,10,16,23,25|;3,447;5;2;4;9;c;1;L2100-01;c1;100;1;E02;2
99;S1020;PD184352 (CI-1040);E03;1;E;3;NA;c2;L1200-01;47867;212631-79-3;MEK;96;2005557064;<1;NA;http://www.selleckchem.com/products/CI-1040-(PD184352).html;PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.;MAPK;C17H14ClF2IN2O2;Free Base;N/A;FC1=CC=C(C(=O)NOCC2CC2)C(NC2=CC=C(I)C=C2Cl)=C1F |c:21,24,t:1,3,16,18|;4,907;2;2;6;1;c;2;L1200-01;c2;100;1;E03;2
100;S1459;Thiazovivin;E04;1;E;4;NA;c2;L2100-01;31136;1226056-71-8;ROCK;15;4817574512;<1;NA;http://www.selleckchem.com/products/Thiazovivin.html;Thiazovivin (Tzv) is a novel ROCK inhibitor with IC50 of 0.5 _M, promotes hESC survival after single-cell dissociation.;Cell Cycle;C15H13N5OS;Free Base;N/A;O=C(NCC1=CC=CC=C1)C1=CSC(NC2=CC=NC=N2)=N1 |c:6,8,18,20,22,t:4,11,16|;2,357;4;2;5;9;c;2;L2100-01;c2;100;1;E04;2
101;S1034;NVP-AEW541;E05;1;E;5;NA;c3;L1200-01;43955;475489-16-8;IGF-1R;88;2002047549;<1;NA;http://www.selleckchem.com/products/NVP-AEW541.html;NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity  for IGF-1R in a cell-based assay.;Protein Tyrosine Kinase;C27H29N5O;Free Base;AEW541;NC1=NC=NC2=C1C(=CN2[C@@H]1C[C@H](CN2CCC2)C1)C1=CC(OCC2=CC=CC=C2)=CC=C1 |r,c:3,5,8,30,32,34,36,t:1,23,28|;4,226;3;1;7;1;c;3;L1200-01;c3;100;1;E05;2
102;S1621;Theophylline;E06;1;E;6;NA;c3;L2100-01;180.16;58-55-9;TGF-beta/Smad;36;19982;<1;NA;http://selleckchem.com/products/Theophylline(Theo-Dur).html;Theophylline (Theo-Dur) is a methylxanthine agent and has bronchodilator properties and is used in the treatment of asthma and COAD.;TGF-beta/Smad;C7H8N4O2;Free Base;NA;CN1C2=C(NC=N2)C(=O)N(C)C1=O |c:5,t:2|;-0,306;3;1;0;9;c;3;L2100-01;c3;100;1;E06;2
103;S1048;VX-680 (Tozasertib, MK-0457);E07;1;E;7;NA;c4;L1200-01;46459;639089-54-6;Aurora Kinase;93;2001764997;<1;NA;http://www.selleckchem.com/products/VX-680(MK-0457).html;VX-680 (Tozasertib, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.;Endocrinology & Hormones;C23H28N8OS;Free Base;N/A;CN1CCN(CC1)C1=NC(SC2=CC=C(NC(=O)C3CC3)C=C2)=NC(NC2=NNC(C)=C2)=C1 |c:23,25,33,35,t:8,12,14,29|;4,445;4;3;7;1;c;4;L1200-01;c4;100;1;E07;2
104;S2219;CYT387;E08;1;E;8;NA;c4;L2100-01;41446;1056634-68-4;JAK;74;1785455774;<1;NA;http://www.selleckchem.com/products/Cyt387.html;CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 1/2.;JAK/STAT;C23H22N6O2;Free Base;CYT 11387;O=C(NCC#N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1 |c:8,10,19,21,30,32,t:6,13,17|;2,857;4;2;6;9;c;4;L2100-01;c4;100;1;E08;2
105;S1070;PHA-665752;E09;1;E;9;NA;c5;L1200-01;64161;477575-56-7;c-Met;128;1994981375;<1;NA;http://www.selleckchem.com/products/PHA-665752.html;PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays,  >50-fold selectivity for c-Met than RTKs or STKs.;Others;C32H34Cl2N4O4S;Free Base;N/A;CC1=C(C(=O)N2CCC[C@@H]2CN2CCCC2)C(C)=C(N1)\C=C1/C(=O)NC2=C1C=C(C=C2)S(=O)(=O)CC1=C(Cl)C=CC=C1Cl |r,c:1,19,28,31,33,40,43,45|;5,689;4;2;7;1;c;5;L1200-01;c5;100;1;E09;2
106;S2686;NVP-BSK805 2HCl;E10;1;E;10;NA;c5;L2100-01;56347;1092499-93-8 (free base);JAK;113;2005430635;3;5324152129;http://www.selleckchem.com/products/nvp-bsk805.html;NVP-BSK805 is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM,>20-fold selectivity towards JAK1, JAK3 and TYK2.;JAK/STAT;C27H30Cl2F2N6O;dihydrochloride;N/A;Cl.Cl.FC1=CC(=CC(F)=C1CN1CCOCC1)C1=C2N=C(C=NC2=CC=C1)C1=CN(N=C1)C1CCNCC1 |c:3,6,17,19,21,24,26,32,t:1,29|;3,92;4;1;5;9;c;5;L2100-01;c5;100;1;E10;2
107;S1089;Refametinib (RDEA119, Bay 86-9766);E11;1;E;11;NA;c6;L1200-01;57234;923032-37-5;MEK;100;1747213195;<1;NA;http://www.selleckchem.com/products/refametinib-rdea119-bay86-9766.html;Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.;Others;C19H20F3IN2O5S;Free Base;BAY 869766;COC1=C(NS(=O)(=O)C2(C[C@H](O)CO)CC2)C(NC2=CC=C(I)C=C2F)=C(F)C(F)=C1 |r,c:2,24,31,t:19,21,27|;2,827;3;4;9;1;c;6;L1200-01;c6;100;1;E11;2
108;S2777;PF-5274857;E12;1;E;12;NA;c6;L2100-01;436.96;1373615-35-0;Hedgehog/Smoothened;93;21283;93;2128341267;http://selleckchem.com/products/pf-5274857.html;PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the bloodÐbrain barrier.;Stem Cells &  Wnt;C20H25ClN4O3S;Free Base;N/A;CC1=CC(C)=C(N=C1)C1=CC(=NC=C1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O |c:4,6,11,13,t:1,9|;2,744;5;0;5;9;c;6;L2100-01;c6;100;1;E12;2
109;S1103;ZM 447439;E13;1;E;13;NA;c7;L1200-01;51359;331771-20-1;Aurora Kinase;103;2005490761;<1;NA;http://www.selleckchem.com/products/ZM-447439.html;ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.;Others;C29H31N5O4;Free Base;N/A;COC1=C(OCCCN2CCOCC2)C=C2N=CN=C(NC3=CC=C(NC(=O)C4=CC=CC=C4)C=C3)C2=C1 |c:2,17,31,33,36,40,t:15,19,22,24,29|;4,118;6;2;10;1;c;7;L1200-01;c7;100;1;E13;2
110;S2907;Pirfenidone;E14;1;E;14;NA;c7;L2100-01;18522;53179-13-8;TGF-beta/Smad;37;1997624447;<1;NA;http://www.selleckchem.com/products/pirfenidone.html;Pirfenidone is an inhibitor for TGF-_ production and TGF-_ stimulated collagen production, reduces production of TNF-_ and IL-1_, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.;TGF-beta/Smad;C12H11NO;Free Base;N/A;CC1=CN(C(=O)C=C1)C1=CC=CC=C1 |c:6,11,13,t:1,9|;1,905;1;0;1;9;c;7;L2100-01;c7;100;1;E14;2
111;S1114;JNJ-38877605;E15;1;E;15;NA;c8;L1200-01;37735;943540-75-8;c-Met;37;9805220617;<1;NA;http://www.selleckchem.com/products/JNJ-38877605.html;JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1.;Others;C19H13F2N7;Free Base;N/A;CN1C=C(C=N1)C1=NN2C(C=C1)=NN=C2C(F)(F)C1=CC2=C(C=C1)N=CC=C2 |c:2,4,11,13,15,23,25,28,30,t:7,21|;3,052;5;0;3;1;c;8;L1200-01;c8;100;1;E15;2
112;S7096;KY02111;E16;1;E;16;NA;c8;L2100-01;37686;1118807-13-8;Wnt/beta-catenin;75;199012896;<1;NA;https://www.selleckchem.com/products/ky02111.html;KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, may act downstream of APC and GSK3_.;Stem Cells &  Wnt;C18H17ClN2O3S;Free Base;N/A;COC1=CC=C(CCC(=O)NC2=NC3=CC=C(Cl)C=C3S2)C=C1OC |c:18,23,t:2,4,11,13,15|;4,362;4;1;6;9;c;8;L2100-01;c8;100;1;E16;2
113;S1143;AG-490 (Tyrphostin B42);E17;1;E;17;NA;c9;L1200-01;2943;133550-30-8;JAK, EGFR;59;2004757051;<1;NA;http://www.selleckchem.com/products/AG-490.html;AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 _M in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.;Others;C17H14N2O3;Free Base;N/A;OC1=C(O)C=C(\C=C(/C#N)C(=O)NCC2=CC=CC=C2)C=C1 |c:1,16,18,21,t:4,14|;2,444;1;3;4;1;c;9;L1200-01;c9;100;1;E17;2
114;S7208;GF109203X;E18;1;E;18;NA;c9;L2100-01;41248;133052-90-1;PKC;82;1987975175;<1;NA;http://www.selleckchem.com/products/gf109203x.html;GF109203X is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKC_, PKC_I, PKC_II, and PKC_, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.;TGF-beta/Smad;C25H24N4O2;Free Base;GO 6850;CN(C)CCCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CNC2=CC=CC=C12 |c:7,11,30,t:9,13,17,25,28,32|;3,557;2;2;6;9;c;9;L2100-01;c9;100;1;E18;2
115;S1169;TGX-221;E19;1;E;19;NA;c10;L1200-01;36444;663619-89-4;PI3K;12;3292723082;<1;NA;http://www.selleckchem.com/products/TGX-221.html;TGX-221 is a p110_-specific inhibitor with IC50 of 5 nM in a cell-free assay, 1000-fold more selective for p110_ than p110_.;PI3K/Akt/mTOR;C21H24N4O2;Free Base;N/A;CC(NC1=CC=CC=C1)C1=CC(C)=CN2C(=O)C=C(N=C12)N1CCOCC1 |c:5,7,13,18,t:3,10,20|;2,373;3;1;4;1;c;10;L1200-01;c10;100;1;E19;2
116;S7484;FH535;E20;1;E;20;NA;c10;L2100-01;3612;108409-83-2;Wnt/beta-catenin;72;1993355482;<1;NA;http://www.selleckchem.com/products/fh535.html;FH535 is a Wnt/_-catenin signaling inhibitor and also a dual PPAR_ and PPAR_ antagonist.;Stem Cells &  Wnt;C13H10Cl2N2O4S;Free Base;N/A;CC1=C(NS(=O)(=O)C2=C(Cl)C=CC(Cl)=C2)C=CC(=C1)[N+]([O-])=O |c:1,7,10,13,16,18|;4,027;2;1;4;9;c;10;L2100-01;c10;100;1;E20;2
117;S1194;CUDC-101;E21;1;E;21;NA;c11;L1200-01;43449;1012054-59-9;HDAC, EGFR, HER2;20;4603097885;<1;NA;http://www.selleckchem.com/products/CUDC-101.html;CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.;Epigenetics;C24H26N4O4;Free Base;N/A;COC1=CC2=C(C=C1OCCCCCCC(=O)NO)C(NC1=CC(=CC=C1)C#C)=NC=N2 |c:4,6,24,26,30,32,t:2,22|;5,376;5;2;11;1;c;11;L1200-01;c11;100;1;E21;2
118;S8004;ZM 39923 HCl;E22;1;E;22;NA;c11;L2100-01;36791;1021868-92-7;JAK;30;8154168139;<1;NA;http://www.selleckchem.com/products/zm-39923-hcl.html;"ZM 39923 is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.";JAK/STAT;C23H26ClNO;HCl;N/A;Cl.CC(C)N(CCC(=O)C1=CC=C2C=CC=CC2=C1)CC1=CC=CC=C1 |c:12,14,17,23,25,t:8,10,21|;5,424;1;0;7;9;c;11;L2100-01;c11;100;1;E22;2
119;NA;DMSO;E23;1;E;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;E23;2
120;NA;DMSO;E24;1;E;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;E24;2
121;S1249;JNJ-7706621;F01;1;F;1;NA;c1;L1200-02;39436;443797-96-4;CDK, Aurora Kinase;79;2003245765;<1;NA;http://www.selleckchem.com/products/JNJ-7706621.html;JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.;Cell Cycle;C15H12F2N6O3S;Free Base;N/A;NC1=NC(NC2=CC=C(C=C2)S(N)(=O)=O)=NN1C(=O)C1=C(F)C=CC=C1F |c:7,9,15,21,24,26,t:1,5|;2,226;5;3;4;2;c;1;L1200-02;c1;100;1;F01;2
122;S7541;Decernotinib (VX-509);F02;1;F;2;NA;c1;L1200-05;392.38;944842-54-0;JAK;78;19879;<1;NA;http://selleckchem.com/products/decernotinib-vx-509.html;Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.;JAK/STAT;C18H19F3N6O;Free Base;N/A;CC[C@@](C)(NC1=NC(=NC=C1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F |r,c:7,9,17,t:5,12,15,19|;2,747;4;3;7;5;c;1;L1200-05;c1;100;1;F02;2
123;S1352;TG100-115;F03;1;F;3;NA;c2;L1200-02;34634;677297-51-7;PI3K;9;2598602529;<1;NA;http://www.selleckchem.com/products/TG100-115.html;TG100-115 is a PI3K_/_ inhibitor with IC50 of 83 nM/235 nM, with little effect on PI3K_/_. Phase 1/2.;PI3K/Akt/mTOR;C18H14N6O2;Free Base;N/A;NC1=NC2=NC(C3=CC=CC(O)=C3)=C(N=C2C(N)=N1)C1=CC(O)=CC=C1 |c:8,11,13,15,19,25,27,t:1,3,6,22|;2,687;4;4;2;2;c;2;L1200-02;c2;100;1;F03;2
124;NA;DMSO;F04;1;F;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;F04;2
125;S1458;VX-745;F05;1;F;5;NA;c3;L1200-02;43626;209410-46-8;p38 MAPK;15;34383166;<1;NA;http://www.selleckchem.com/products/VX-745.html;VX-745 is a potent and selective inhibitor of p38_ with IC50 of 10 nM, 22-fold greater selectivity versus p38_ and no inhibition to p38_.;MAPK;C19H9Cl2F2N3OS;Free Base;N/A;FC1=CC(F)=C(SC2=NN3C=NC(=O)C(=C3C=C2)C2=C(Cl)C=CC=C2Cl)C=C1 |c:10,14,17,20,23,25,29,t:1,4,7|;5,342;3;0;3;2;c;3;L1200-02;c3;100;1;F05;2
126;S7722;Bikinin;F06;1;F;6;NA;c3;L1200-05;273.08;188011-69-0;GSK-3;54;1977442508;<1;NA;http://www.selleckchem.com/products/bikinin.html;Bikinin is an ATP-competitive Arabidopsis GSK-3 inhibitor, and acts as a strong activator of brassinosteroid (BR) signaling.;PI3K/Akt/mTOR;C9H9BrN2O3;Free Base;N/A;OC(=O)CCC(=O)NC1=NC=C(Br)C=C1 |c:13,t:8,10|;0,932;3;1;4;5;c;3;L1200-05;c3;100;1;F06;2
127;S1486;AEE788 (NVP-AEE788);F07;1;F;7;NA;c4;L1200-02;44058;497839-62-0;EGFR, Flt, VEGFR, HER2;88;1997367107;<1;NA;http://www.selleckchem.com/products/AEE788.html;AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKC_ and CDK1. Phase 1/2.;Protein Tyrosine Kinase;C27H32N6;Free Base;N/A;CCN1CCN(CC2=CC=C(C=C2)C2=CC3=C(N[C@H](C)C4=CC=CC=C4)N=CN=C3N2)CC1 |r,c:9,11,16,23,25,28,30,t:7,14,21|;5,042;2;2;7;2;c;4;L1200-02;c4;100;1;F07;2
128;NA;DMSO;F08;1;F;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;F08;2
129;S1530;BIX 02188;F09;1;F;9;NA;c5;L1200-02;41248;1094614-84-2;MEK;43;1042474787;<1;NA;http://www.selleckchem.com/products/BIX-02188.html;BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.;MAPK;C26H26N4O2;Free Base;N/A;CNC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC(CN(C)C)=CC=C2)C2=CC=CC=C2)=C1 |c:6,22,24,29,31,33,t:4,16,27|;3,102;2;3;6;2;c;5;L1200-02;c5;100;1;F09;2
130;S7886;CC-223;F10;1;F;10;NA;c5;L1200-05;397.47;1228013-30-6;mTOR;79;19876;<1;NA;http://selleckchem.com/products/cc-223.html;CC-223 is a potent, selective, and orally bioavailable mTOR inhibitor with IC50 of 16 nM, >200-fold selectivity over the related PI3K-_. Phase 1/2.;PI3K/Akt/mTOR;C21H27N5O3;Free Base;N/A;CO[C@H]1CC[C@@H](CC1)N1C(=O)CNC2=NC=C(N=C12)C1=CN=C(C=C1)C(C)(C)O |r,c:16,24,26,t:14,18,22|;1,66;5;1;4;5;c;5;L1200-05;c5;100;1;F10;2
131;S1558;AT7867;F11;1;F;11;NA;c6;L1200-02;33785;857531-00-1;Akt, S6 kinase;68;2012727542;<1;NA;http://www.selleckchem.com/products/AT7867.html;"AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; little activity outside the AGC kinase family.";PI3K/Akt/mTOR;C20H20ClN3;Free Base;N/A;ClC1=CC=C(C=C1)C1(CCNCC1)C1=CC=C(C=C1)C1=CNN=C1 |c:3,5,17,19,25,t:1,15,22|;3,85;1;2;3;2;c;6;L1200-02;c6;100;1;F11;2
132;NA;DMSO;F12;1;F;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;F12;2
133;S1582;H 89 2HCl;F13;1;F;13;NA;c7;L1200-02;51928;130964-39-5;S6 Kinase;104;200277307;6;11,55446002;http://www.selleckchem.com/products/H-89-dihydrochloride.html;H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II.;PI3K/Akt/mTOR;C20H22BrCl2N3O2S;2HCl;N/A;Cl.Cl.BrC1=CC=C(\C=C\CNCCNS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C=C1 |c:17,19,22,24,27,t:1,3,15|;3,665;3;2;8;2;c;7;L1200-02;c7;100;1;F13;2
134;S8015;CEP-32496;F14;1;F;14;NA;c7;L1200-05;51746;1188910-76-0;Raf;9;1739264871;<1;NA;http://www.selleckchem.com/products/cep-32496.html;"CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFR_ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2.";MAPK;C24H22F3N5O5;Free Base;N/A;COC1=CC2=NC=NC(OC3=CC(NC(=O)NC4=NOC(=C4)C(C)(C)C(F)(F)F)=CC=C3)=C2C=C1OC |c:6,20,29,31,33,36,t:2,4,10,17|;5,288;8;2;8;5;c;7;L1200-05;c7;100;1;F14;2
135;S2161;RAF265 (CHIR-265);F15;1;F;15;NA;c8;L1200-02;51841;927880-90-8;Raf, VEGFR;100;1928975136;<1;NA;http://www.selleckchem.com/products/RAF265(CHIR-265).html;RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM in cell-free assays. Phase 2.;MAPK;C24H16F6N6O;Free Base;N/A;CN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=C1C=CC(OC1=CC=NC(=C1)C1=NC=C(N1)C(F)(F)F)=C2 |c:6,8,14,16,19,25,27,32,39,t:4,23,30|;6,469;4;2;7;2;c;8;L1200-02;c8;100;1;F15;2
136;NA;DMSO;F16;1;F;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;F16;2
137;S2198;SGI-1776 free base;F17;1;F;17;NA;c9;L1200-02;40542;1025065-69-3;Pim;81;1997928075;<1;NA;http://www.selleckchem.com/products/SGI-1776.html;SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay, 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. Phase 1.;JAK/STAT;C20H22F3N5O;Free Base;N/A;CN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1 |c:11,13,15,20,27,t:7,18|;5,206;3;1;6;2;c;9;L1200-02;c9;100;1;F17;2
138;S8195;Oclacitinib;F18;1;F;18;NA;c9;L1200-05;453.51;1640292-55-2;JAK;90;19845;18;39,69041476;http://selleckchem.com/products/oclacitinib-maleate.html;Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.;JAK/STAT;C19H27N5O6S;Maleate;PF-03394197;OC(=O)\C=C/C(O)=O.CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(C)C1=C2C=CNC2=NC=N1 |r,c:22,24,28,30|;1,758;6;2;7;5;c;9;L1200-05;c9;100;1;F18;2
139;S2219;CYT387;F19;1;F;19;NA;c10;L1200-02;41446;1056634-68-4;JAK;74;1785455774;<1;NA;http://www.selleckchem.com/products/Cyt387.html;Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 3.;JAK/STAT;C23H22N6O2;Free Base;CYT 11387;O=C(NCC#N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1 |c:8,10,19,21,30,32,t:6,13,17|;2,857;4;2;6;2;c;10;L1200-02;c10;100;1;F19;2
140;NA;DMSO;F20;1;F;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;F20;2
141;S2243;Degrasyn (WP1130);F21;1;F;21;NA;c11;L1200-02;38427;856243-80-6;DUB, Bcr-Abl;77;2003799412;<1;NA;http://www.selleckchem.com/products/WP1130.html;Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).;Angiogenesis;C19H18BrN3O;Free Base;N/A;CCC[C@H](NC(=O)C(=C\C1=NC(Br)=CC=C1)\C#N)C1=CC=CC=C1 |r,c:12,14,21,23,t:9,19|;4,546;2;1;6;2;c;11;L1200-02;c11;100;1;F21;2
142;NA;DMSO;F22;1;F;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;F22;2
143;NA;DMSO;F23;1;F;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;F23;2
144;NA;DMSO;F24;1;F;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;F24;2
145;S1008;Selumetinib (AZD6244);G01;1;G;1;NA;d1;L1200-01;45768;606143-52-6;MEK;91;1988288761;<1;NA;http://www.selleckchem.com/products/AZD6244.html;Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38_, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.;MAPK;C17H15BrClFN4O3;Free Base;ARRY-142886;CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO |c:2,4,14,17,t:9,11,19|;3,234;3;3;6;1;d;1;L1200-01;d1;100;1;G01;2
146;S1075;SB216763;G02;1;G;2;NA;d1;L2100-01;37122;280744-09-4;GSK-3;23;6195786865;<1;NA;http://www.selleckchem.com/products/SB-216763.html;SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3_ and equally effective at inhibiting human GSK-3_.;Others;C19H12Cl2N2O2;Free Base;N/A;CN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)C1=CC=C(Cl)C=C1Cl |c:2,4,7,9,25,t:12,20,22|;4,391;2;1;2;9;d;1;L2100-01;d1;100;1;G02;2
147;S1021;Dasatinib;G03;1;G;3;NA;d2;L1200-01;48801;302962-49-8;Src, Bcr-Abl, c-Kit;98;2008155571;<1;NA;http://www.selleckchem.com/products/Dasatinib.html;Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.;Angiogenesis;C22H26ClN7O2S;Free Base;Sprycel;CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=CC(=N1)N1CCN(CCO)CC1 |c:7,14,17,19,22,24,t:1,5|;3,439;4;3;7;1;d;2;L1200-01;d2;100;1;G03;2
148;S1474;GSK429286A;G04;1;G;4;NA;d2;L2100-01;43237;864082-47-3;ROCK;87;2012165506;<1;NA;http://www.selleckchem.com/products/GSK429286A.html;GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.;Cell Cycle;C21H16F4N4O2;Free Base;N/A;CC1=C(C(CC(=O)N1)C1=CC=C(C=C1)C(F)(F)F)C(=O)NC1=C(F)C=C2NN=CC2=C1 |c:11,13,23,29,32,t:1,9,26|;3,033;3;3;4;9;d;2;L2100-01;d2;100;1;G04;2
149;S1035;Pazopanib HCl;G05;1;G;5;NA;d3;L1200-01;47398;635702-64-6;VEGFR, PDGFR, c-Kit;17;3586649226;<1;NA;http://www.selleckchem.com/products/Pazopanib-Hydrochloride.html;Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.;Protein Tyrosine Kinase;C21H24ClN7O2S;Hydrochloride;GW786034;Cl.CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1 |c:9,12,24,30,32,t:2,4,15,19,21|;4,123;5;2;5;1;d;3;L1200-01;d3;100;1;G05;2
150;S2151;LDE225 (NVP-LDE225,Erismodegib);G06;1;G;6;NA;d3;L2100-01;4855;956697-53-3;Smoothened;97;1997940268;<1;NA;http://www.selleckchem.com/products/LDE225(NVP-LDE225).html;LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3.;Stem Cells &  Wnt;C26H26F3N3O3;Free Base;N/A;C[C@H]1CN(C[C@@H](C)O1)C1=CC=C(NC(=O)C2=C(C)C(=CC=C2)C2=CC=C(OC(F)(F)F)C=C2)C=N1 |r,c:16,19,21,33,36,t:9,11,24,26|;6,732;4;1;6;9;d;3;L2100-01;d3;100;1;G06;2
151;S1049;Y-27632 2HCl;G07;1;G;7;NA;d4;L1200-01;32026;129830-38-2;ROCK;64;1998376319;14;43,71448198;http://www.selleckchem.com/products/Y-27632.html;Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.;Others;C14H23Cl2N3O;Dihydrochloric;N/A;Cl.Cl.C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)NC1=CC=NC=C1 |r,c:15,17,t:13|;1,871;2;2;3;1;d;4;L1200-01;d4;100;1;G07;2
152;S2230;LY2157299;G08;1;G;8;NA;d4;L2100-01;36942;700874-72-2;TGF-beta/Smad;74;2003140057;<1;NA;http://www.selleckchem.com/products/ly2157299.html;LY2157299 is a potent TGF_ receptor I (T_RI) inhibitor with IC50 of 56 nM. Phase 2.;TGF-beta/Smad;C22H19N5O;Free Base;N/A;CC1=CC=CC(=N1)C1=NN2CCCC2=C1C1=CC=NC2=C1C=C(C=C2)C(N)=O |c:3,5,15,20,22,25,27,t:1,8,18|;3,095;4;1;3;9;d;4;L2100-01;d4;100;1;G08;2
153;S1072;ZSTK474;G09;1;G;9;NA;d5;L1200-01;41741;475110-96-4;PI3K;21;5031024652;<1;NA;http://www.selleckchem.com/products/ZSTK474.html;ZSTK474 inhibits class I PI3K isoforms with IC50 of 37 nM in a cell-free assay, mostly PI3K_. Phase1/2.;Neuronal Signaling;C19H21F2N7O2;Free Base;N/A;FC(F)C1=NC2=C(C=CC=C2)N1C1=NC(=NC(=N1)N1CCOCC1)N1CCOCC1 |c:7,9,16,18,t:3,5,14|;3,366;6;0;4;1;d;5;L1200-01;d5;100;1;G09;2
154;S2692;TG101209;G10;1;G;10;NA;d5;L2100-01;50967;936091-14-4;Flt, JAK, c-RET;102;2001294956;<1;NA;http://www.selleckchem.com/products/tg101209.html;TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.;JAK/STAT;C26H35N7O2S;Free Base;N/A;CN1CCN(CC1)C1=CC=C(NC2=NC=C(C)C(NC3=CC(=CC=C3)S(=O)(=O)NC(C)(C)C)=N2)C=C1 |c:22,24,34,37,t:8,10,13,15,20|;4,659;4;3;8;9;d;5;L2100-01;d5;100;1;G10;2
155;S1091;OSI-906 (Linsitinib);G11;1;G;11;NA;d6;L1200-01;42149;867160-71-2;IGF-1R;84;1992929844;<1;NA;http://www.selleckchem.com/products/OSI-906.html;"OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.";Others;C26H23N5O;Free Base;N/A;C[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1 |r,c:9,13,15,23,25,28,33,35,t:7,19,21,31|;3,757;3;1;3;1;d;6;L1200-01;d6;100;1;G11;2
156;S2789;Tofacitinib (CP-690550,Tasocitinib);G12;1;G;12;NA;d6;L2100-01;31237;477600-75-2;JAK;62;1984825687;<1;NA;http://www.selleckchem.com/products/tofacitinib-cp-690550.html;Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.;JAK/STAT;C16H20N6O;Free Base;Tasocitinib;C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N |r,c:10,12,16,18|;1,512;3;1;3;9;d;6;L2100-01;d6;100;1;G12;2
157;S1104;GDC-0879;G13;1;G;13;NA;d7;L1200-01;33437;905281-76-7;Raf;66;1973861291;<1;NA;http://www.selleckchem.com/products/GDC-0879.html;"GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.";Others;C19H18N4O2;Free Base;N/A;OCCN1C=C(C(=N1)C1=CC=NC=C1)C1=CC=C2C(CC\C2=N/O)=C1 |c:4,6,11,13,18,26,t:9,16|;2,387;3;1;4;1;d;7;L1200-01;d7;100;1;G13;2
158;S2911;Go 6983;G14;1;G;14;NA;d7;L2100-01;44251;133053-19-7;PKC;59;1333303202;<1;NA;http://www.selleckchem.com/products/go-6983.html;"Go 6983 is a pan-PKC inhibitor against for PKC_, PKC_, PKC_ and PKC_ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKC_ and inactive to PKC_.";TGF-beta/Smad;C26H26N4O3;Free Base;N/A;COC1=CC=C2N(CCCN(C)C)C=C(C2=C1)C1=C(C(=O)NC1=O)C1=CNC2=C1C=CC=C2 |c:13,16,30,33,35,t:2,4,19,27|;3,54;3;2;7;9;d;7;L2100-01;d7;100;1;G14;2
159;S1117;Triciribine;G15;1;G;15;NA;d8;L1200-01;3203;35943-35-2;Akt;64;1998126756;<1;NA;http://www.selleckchem.com/products/Triciribine.html;"Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.";Others;C13H16N6O4;Free Base;N/A;CN1N=C(N)C2=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3 |r,c:18,24,t:2,5,22|;-1,119;4;4;2;1;d;8;L1200-01;d8;100;1;G15;2
160;S7138;BMS-833923;G16;1;G;16;NA;d8;L2100-01;47357;1059734-66-5;Hedgehog/Smoothened;95;2006039234;<1;NA;http://www.selleckchem.com/products/bms-833923.html;BMS-833923 is an orally bioavailable Smoothened antagonist. Phase 2.;GPCR & G Protein;C30H27N5O;Free Base;XL139;CNCC1=CC(NC(=O)C2=CC=C(NC3=NC4=CC=CC=C4C(=N3)C3=CC=CC=C3)C=C2)=C(C)C=C1 |c:18,20,23,28,30,33,38,t:3,9,11,14,16,26,35|;6,214;3;3;7;9;d;8;L2100-01;d8;100;1;G16;2
161;S1145;SNS-032 (BMS-387032);G17;1;G;17;NA;d9;L1200-01;38053;345627-80-7;CDK;76;1997214411;<1;NA;http://www.selleckchem.com/products/SNS-032.html;SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.;Others;C17H24N4O2S2;Free Base;BMS-387032;CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1 |t:4,6,10,12|;2,07;4;2;6;1;d;9;L1200-01;d9;100;1;G17;2
162;S7223;RepSox;G18;1;G;18;NA;d9;L2100-01;28732;446859-33-2;TGF-beta/Smad;57;1983850759;<1;NA;http://www.selleckchem.com/products/repsox.html;RepSox is a potent and selective inhibitor of the TGF_R-1/ALK5 with IC50 of 23 nM and 4 nM for ATP binding to ALK5 and ALK5 autophosphorylation, respectively.;TGF-beta/Smad;C17H13N5;Free Base;E-616452, SJN 2511;CC1=CC=CC(=N1)C1=NNC=C1C1=CC=C2N=CC=CC2=N1 |c:3,5,11,18,20,23,t:1,8,14,16|;3,192;4;1;2;9;d;9;L2100-01;d9;100;1;G18;2
163;S1170;WZ3146;G19;1;G;19;NA;d10;L1200-01;46495;1214265-56-1;EGFR;93;2000215077;<1;NA;http://www.selleckchem.com/products/WZ3146.html;"WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).";Protein Tyrosine Kinase;C24H25ClN6O2;Free Base;N/A;CN1CCN(CC1)C1=CC=C(NC2=NC=C(Cl)C(OC3=CC(NC(=O)C=C)=CC=C3)=N2)C=C1 |c:27,29,31,34,t:8,10,13,15,20|;4,823;4;2;7;1;d;10;L1200-01;d10;100;1;G19;2
164;S7490;WIKI4;G20;1;G;20;NA;d10;L2100-01;52159;838818-26-1;Wnt/beta-catenin;7;1342050269;<1;NA;http://www.selleckchem.com/products/wiki4.html;WIKI4 is a novel Tankyrase inhibitor with IC50 of 15 nM for TNKS2, and leads to inhibition of Wnt/beta-catenin signaling. ;Stem Cells &  Wnt;C29H23N5O3S;Free Base;N/A;COC1=CC=C(C=C1)N1C(SCCCN2C(=O)C3=CC=CC4=C3C(=CC=C4)C2=O)=NN=C1C1=CC=NC=C1 |c:4,6,20,25,27,32,34,39,41,t:2,18,37|;4,469;6;0;8;9;d;10;L2100-01;d10;100;1;G20;2
165;S1207;Tivozanib (AV-951);G21;1;G;21;NA;d11;L1200-01;45486;475108-18-0;VEGFR, c-Kit, PDGFR;20;4396957306;<1;NA;http://www.selleckchem.com/products/AV-951.html;Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.;Protein Tyrosine Kinase;C22H19ClN4O5;Free Base;N/A;COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)NC3=NOC(C)=C3)C(Cl)=C1)=CC=N2 |c:4,6,25,29,31,33,t:2,13,15,21|;4,039;7;2;6;1;d;11;L1200-01;d11;100;1;G21;2
166;S8057;Pacritinib (SB1518);G22;1;G;22;NA;d11;L2100-01;47258;937272-79-2;JAK;11;2327648229;<1;NA;http://www.selleckchem.com/products/pacritinib-sb1518.html;Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM, respectively.;JAK/STAT;C28H32N4O3;Free Base;N/A;C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\C=C\COCC1=C2)=CC=C3 |c:16,18,33,35,37,t:9,11,14,21,27|;4,547;5;1;4;9;d;11;L2100-01;d11;100;1;G22;2
167;NA;DMSO;G23;1;G;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;G23;2
168;NA;DMSO;G24;1;G;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;G24;2
169;S1263;CHIR-99021 (CT99021);H01;1;H;1;NA;d1;L1200-02;465.34;252917-06-9;GSK-3;78;1676193751;<1;NA;http://selleckchem.com/products/CHIR-99021.html;CHIR-99021 (CT99021) is a GSK-3_ and GSK-3_ inhibitor with IC50 of 10 nM and 6.7 nM, respectively.;PI3K/Akt/mTOR;C22H18Cl2N8;free base;CT99021;CC1=CNC(=N1)C1=CN=C(NCCNC2=NC=C(C=C2)C#N)N=C1C1=CC=C(Cl)C=C1Cl |c:4,17,19,24,32,t:1,7,9,15,27,29|;4,476;4;3;7;2;d;1;L1200-02;d1;100;1;H01;2
170;S7544;Vacquinol-1;H02;1;H;2;NA;d1;L1200-05;425.78;5428-80-8_free base_;JNK;70;16440;<1;NA;http://selleckchem.com/products/vacquinol-1.html;Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.;MAPK;C21H23Cl3N2O;dihydrochloride;NSC13316;Cl.Cl.OC(C1CCCCN1)C1=C2C=CC=CC2=NC(=C1)C1=CC=C(Cl)C=C1 |c:9,11,13,16,18,26,t:21,23|;5,364;1;2;3;5;d;1;L1200-05;d1;100;1;H02;2
171;S1361;MGCD-265;H03;1;H;3;NA;d2;L1200-02;5176;875337-44-3;c-Met, VEGFR, Tie-2;104;200927357;<1;NA;http://www.selleckchem.com/products/MGCD-265.html;"MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.";Protein Tyrosine Kinase;C26H20FN5O2S2;Free Base;N/A;CN1C=NC(=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)=C2S1 |c:2,4,11,28,30,33,36,t:7,9,15,17,26|;6,037;4;2;8;2;d;2;L1200-02;d2;100;1;H03;2
172;NA;DMSO;H04;1;H;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;H04;2
173;S1459;Thiazovivin;H05;1;H;5;NA;d3;L1200-02;31136;1226056-71-8;ROCK;15;4817574512;<1;NA;http://www.selleckchem.com/products/Thiazovivin.html;Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 _M in a cell-free assay, promotes hESC survival after single-cell dissociation.;Cell Cycle;C15H13N5OS;Free Base;N/A;O=C(NCC1=CC=CC=C1)C1=CSC(NC2=CC=NC=N2)=N1 |c:6,8,18,20,22,t:4,11,16|;2,357;4;2;5;2;d;3;L1200-02;d3;100;1;H05;2
174;S7725;BLZ945;H06;1;H;6;NA;d3;L1200-05;398.48;953769-46-5;CSF-1R;79;1982533628;<1;NA;http://www.selleckchem.com/products/blz945.html;BLZ945 is an orally active, potent and selective CSF-1R inhibitor with IC50 of 1 nM, >1000-fold selective against its closest receptor tyrosine kinase homologs.;Protein Tyrosine Kinase;C20H22N4O3S;Free Base;N/A;CNC(=O)C1=NC=CC(OC2=CC3=C(C=C2)N=C(N[C@@H]2CCCC[C@H]2O)S3)=C1 |r,c:6,12,14,29,t:4,10,17|;3,201;4;3;5;5;d;3;L1200-05;d3;100;1;H06;2
175;S1487;PHA-793887;H07;1;H;7;NA;d4;L1200-02;36148;718630-59-2;CDK;72;1991811442;<1;NA;http://www.selleckchem.com/products/PHA-793887.html;PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. Phase 1.;Cell Cycle;C19H31N5O2;Free Base;N/A;CC(C)CC(=O)NC1=NNC2=C1CN(C(=O)C1CCN(C)CC1)C2(C)C |c:10,t:7|;1,895;3;2;4;2;d;4;L1200-02;d4;100;1;H07;2
176;NA;DMSO;H08;1;H;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;H08;2
177;S1531;BIX 02189;H09;1;H;9;NA;d5;L1200-02;44054;1094614-85-3;MEK;60;1361964861;<1;NA;http://www.selleckchem.com/products/BIX-02189.html;BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.;MAPK;C27H28N4O2;Free Base;N/A;CN(C)CC1=CC=CC(N\C(C2=CC=CC=C2)=C2/C(=O)NC3=CC(=CC=C23)C(=O)N(C)C)=C1 |c:6,13,15,24,34,t:4,11,22,26|;3,308;2;2;6;2;d;5;L1200-02;d5;100;1;H09;2
178;S7898;GSK621;H10;1;H;10;NA;d5;L1200-05;489.91;1346607-05-3;AMPK;97;1979955502;<1;NA;http://www.selleckchem.com/products/gsk621.html;GSK621 is a specific and potent AMPK activator.;PI3K/Akt/mTOR;C26H20ClN3O5;Free Base;N/A;COC1=CC(=CC=C1)N1C(=O)NC2=C(N(C(Cl)=C2)C2=CC=C(C=C2)C2=C(O)C(OC)=CC=C2)C1=O |c:4,6,17,22,24,27,32,34,t:2,13,20|;5,217;4;2;5;5;d;5;L1200-05;d5;100;1;H10;2
179;S1561;BMS-777607;H11;1;H;11;NA;d6;L1200-02;51289;1025720-94-8;c-Met;47;9163758311;<1;NA;http://www.selleckchem.com/products/BMS-777607.html;BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. Phase 1/2.;Protein Tyrosine Kinase;C25H19ClF2N4O4;Free Base;N/A;CCOC1=C(C(=O)NC2=CC=C(OC3=CC=NC(N)=C3Cl)C(F)=C2)C(=O)N(C=C1)C1=CC=C(F)C=C1 |c:3,15,18,23,29,37,t:8,10,13,32,34|;3,517;5;2;7;2;d;6;L1200-02;d6;100;1;H11;2
180;NA;DMSO;H12;1;H;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;H12;2
181;S1590;TWS119;H13;1;H;13;NA;d7;L1200-02;31833;601514-19-6;GSK-3;64;2010492256;<1;NA;http://www.selleckchem.com/products/TWS119.html;"TWS119 is a GSK-3_ inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.";PI3K/Akt/mTOR;C18H14N4O2;Free Base;N/A;NC1=CC(=CC=C1)C1=CC2=C(N1)N=CN=C2OC1=CC=CC(O)=C1 |c:3,5,10,14,16,22,25,t:1,8,20|;3,464;3;3;3;2;d;7;L1200-02;d7;100;1;H13;2
182;S8019;AZD5363;H14;1;H;14;NA;d7;L1200-05;42892;1143532-39-1;Akt;86;2005035904;<1;NA;http://www.selleckchem.com/products/azd5363.html;AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.;PI3K/Akt/mTOR;C21H25ClN6O2;Free Base;N/A;NC1(CCN(CC1)C1=NC=NC2=C1C=CN2)C(=O)N[C@@H](CCO)C1=CC=C(Cl)C=C1 |r,c:10,12,15,31,t:8,26,28|;1,317;3;4;6;5;d;7;L1200-05;d7;100;1;H14;2
183;S2162;AZD1480;H15;1;H;15;NA;d8;L1200-02;34877;935666-88-9, 1260222-79-4 (TFA);JAK;69;1978381168;<1;NA;http://www.selleckchem.com/products/AZD1480.html;AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.;JAK/STAT;C14H14ClFN8;Free Base;N/A;C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1 |r,c:14,16,24,t:3,5,10,19,21|;2,645;5;3;5;2;d;8;L1200-02;d8;100;1;H15;2
184;NA;DMSO;H16;1;H;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;H16;2
185;S2201;BMS-794833;H17;1;H;17;NA;d9;L1200-02;46884;1174046-72-0;c-Met, VEGFR;94;2004948383;<1;NA;http://www.selleckchem.com/products/BMS-794833.html;"BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.";Protein Tyrosine Kinase;C23H15ClF2N4O3;Free Base;BMS794833;NC1=NC=CC(OC2=CC=C(NC(=O)C3=CNC=C(C3=O)C3=CC=C(F)C=C3)C=C2F)=C1Cl |c:3,17,27,30,33,t:1,7,9,14,22,24|;2,85;4;3;5;2;d;9;L1200-02;d9;100;1;H17;2
186;S8201;BI-78D3;H18;1;H;18;NA;d9;L1200-05;379.37;883065-90-5;JNK;100;26359;<1;NA;http://selleckchem.com/products/bi-78d3.html;BI-78D3 is a competitive JNK inhibitor with IC50 of 280nM that displays > 100 fold selectivity over p38_ and no activity at mTOR and PI-3K.;MAPK;C13H9N5O5S2;Free Base;N/A;OC1=NN=C(SC2=NC=C(S2)[N+]([O-])=O)N1C1=CC=C2OCCOC2=C1 |c:8,26,t:1,3,6,17,19|;2,738;5;1;4;5;d;9;L1200-05;d9;100;1;H18;2
187;S2220;SB590885;H19;1;H;19;NA;d10;L1200-02;45354;405554-55-4;Raf;5;1102438594;<1;NA;http://www.selleckchem.com/products/SB590885.html;SB590885 is a potent B-Raf inhibitor with Ki of 0.16 nM in a cell-free assay, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.;MAPK;C27H27N5O2;Free Base;GSK2118436;CN(C)CCOC1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=C2C(CC\C2=N/O)=C1)C1=CC=NC=C1 |c:8,10,15,21,29,34,36,t:6,13,19,32|;4,503;4;1;7;2;d;10;L1200-02;d10;100;1;H19;2
188;NA;DMSO;H20;1;H;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;H20;2
189;S2247;BKM120 (NVP-BKM120, Buparlisib);H21;1;H;21;NA;d11;L1200-02;41039;944396-07-0;PI3K;82;1998099369;<1;NA;http://www.selleckchem.com/products/BKM-120.html;BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110_/_/_/_ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4K_. Phase 2.;PI3K/Akt/mTOR;C18H21F3N6O2;Free Base;N/A;NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F |c:3,5,10,12,t:1,8|;2,342;5;1;4;2;d;11;L1200-02;d11;100;1;H21;2
190;NA;DMSO;H22;1;H;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;H22;2
191;NA;DMSO;H23;1;H;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;H23;2
192;NA;DMSO;H24;1;H;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;H24;2
193;S1010;Nintedanib (BIBF 1120)_uncertain;I01;1;I;1;NA;e1;L1200-01;53962;656247-17-5;VEGFR, PDGFR, FGFR;6;1111893555;<1;NA;http://www.selleckchem.com/products/BIBF1120.html;Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFR_/_ with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.;Protein Tyrosine Kinase;C31H33N5O4;Free Base;N/A;COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1 |c:6,18,20,38,40,42,t:4,16,36|;2,965;4;2;8;1;e;1;L1200-01;e1;100;1;I01;2
194;S1082;Vismodegib (GDC-0449);I02;1;I;2;NA;e1;L2100-01;4213;879085-55-9;Hedgehog, P-gp;84;1993828626;<1;NA;http://www.selleckchem.com/products/GDC-0449.html;Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 _M.;Neuronal Signaling;C19H14Cl2N2O3S;Free Base;N/A;CS(=O)(=O)C1=CC=C(C(=O)NC2=CC(=C(Cl)C=C2)C2=NC=CC=C2)C(Cl)=C1 |c:16,21,23,27,t:4,6,11,13,19|;4,265;4;1;4;9;e;1;L2100-01;e1;100;1;I02;2
195;S1022;Ridaforolimus (Deforolimus, MK-8669);I03;1;I;3;NA;e2;L1200-01;990.21;572924-54-0;mTOR;198;19996;<1;NA;http://selleckchem.com/products/Deforolimus.html;"Ridaforolimus (Deforolimus, MK-8669) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. Phase 3.";PI3K/Akt/mTOR;C53H84NO14P;Free Base;AP23573, MK-8669;[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@H](CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H](OP(C)(C)=O)[C@@H](C1)OC |r,c:31,50,t:46,48|;6,303;12;1;8;1;e;2;L1200-01;e2;100;1;I03;2
196;S1476;SB525334;I04;1;I;4;NA;e2;L2100-01;34342;356559-20-1;TGF-beta/Smad;68;1980082698;<1;NA;http://www.selleckchem.com/products/SB-525334.html;SB525334 is a potent and selective inhibitor of TGF_ receptor I (ALK5) with IC50 of 14.3 nM, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.;TGF-beta/Smad;C21H21N5;Free Base;N/A;CC1=NC(=CC=C1)C1=C(NC(=N1)C(C)(C)C)C1=CC=C2N=CC=NC2=C1 |c:3,5,11,22,24,27,t:1,8,18,20|;4,305;4;1;3;9;e;2;L2100-01;e2;100;1;I04;2
197;S1036;PD0325901;I05;1;I;5;NA;e3;L1200-01;48219;391210-10-9;MEK;96;1990916444;<1;NA;http://www.selleckchem.com/products/PD-0325901.html;PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.;DNA Damage;C16H14F3IN2O4;Free Base;N/A;OC[C@@H](O)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1 |r,c:9,17,25,t:12,14,22|;2,578;2;4;7;1;e;3;L1200-01;e3;100;1;I05;2
198;S2157;Taladegib (LY2940680);I06;1;I;6;NA;e3;L2100-01;512.5;1258861-20-9;Hedgehog,Hedgehog/Smoothened;NA;1000;NA;NA;http://selleckchem.com/products/ly2940680.html;Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.;Stem Cells &  Wnt;C26H24F4N6O;Free Base;N/A;CN(C1CCN(CC1)C1=NN=C(C2=CC=NN2C)C2=C1C=CC=C2)C(=O)C1=C(C=C(F)C=C1)C(F)(F)F |c:15,20,23,25,35,t:9,11,13,30,32|;NA;NA;NA;NA;9;e;3;L2100-01;e3;100;1;I06;2
199;S1055;Enzastaurin (LY317615);I07;1;I;7;NA;e4;L1200-01;51561;170364-57-5;PKC;30;5818351079;<1;NA;http://www.selleckchem.com/products/Enzastaurin.html;Enzastaurin (LY317615) is a potent PKC_ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKC_, PKC_ and PKC_. Phase 3.;Neuronal Signaling;C32H29N5O2;Free Base;N/A;CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=NC=CC=C3)CC2)C2=CC=CC=C12 |c:2,6,30,32,40,t:4,8,12,20,28,38,42|;4,32;3;1;5;1;e;4;L1200-01;e4;100;1;I07;2
200;S2308;Hesperetin;I08;1;I;8;NA;e4;L2100-01;30227;520-33-2;Histamine Receptor;60;1984980316;<1;NA;http://www.selleckchem.com/products/Hesperetin.html;Hesperetin is a bioflavonoid and, to be more specific, a flavanone.;TGF-beta/Smad;C16H14O6;Free Base;N/A;COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1 |r,c:4,6,14,20,t:2,17|;2,357;3;3;2;9;e;4;L2100-01;e4;100;1;I08;2
201;S1075;SB216763;I09;1;I;9;NA;e5;L1200-01;37122;280744-09-4;GSK-3;23;6195786865;<1;NA;http://www.selleckchem.com/products/SB-216763.html;SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3_ and equally effective at inhibiting human GSK-3_.;Others;C19H12Cl2N2O2;Free Base;N/A;CN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)C1=CC=C(Cl)C=C1Cl |c:2,4,7,9,25,t:12,20,22|;4,391;2;1;2;1;e;5;L1200-01;e5;100;1;I09;2
202;S2711;YO-01027;I10;1;I;10;NA;e5;L2100-01;46348;209984-56-5;Gamma-secretase;92;1984983171;<1;NA;http://www.selleckchem.com/products/yo-01027.html;YO-01027 (Dibenzazepine, DBZ) is a dipeptidic _-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.;Proteases;C26H23F2N3O3;Free Base;N/A;C[C@H](NC(=O)CC1=CC(F)=CC(F)=C1)C(=O)N[C@H]1C2=C(C=CC=C2)C2=C(C=CC=C2)N(C)C1=O |r,c:9,12,21,23,28,30,t:6,19,26|;3,277;3;2;5;9;e;5;L2100-01;e5;100;1;I10;2
203;S1092;KU-55933 (ATM Kinase Inhibitor);I11;1;I;11;NA;e6;L1200-01;39549;587871-26-9;ATM;33;8344079496;<1;NA;http://www.selleckchem.com/products/KU-55933.html;KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.;Others;C21H17NO3S2;Free Base;N/A;O=C1C=C(OC(=C1)C1=CC=CC2=C1SC1=CC=CC=C1S2)N1CCOCC1 |c:2,5,10,12,18,20,t:8,16|;4,393;3;0;2;1;e;6;L1200-01;e6;100;1;I11;2
204;S2791;Sotrastaurin;I12;1;I;12;NA;e6;L2100-01;43848;425637-18-9;PKC;87;1984126984;<1;NA;http://www.selleckchem.com/products/sotrastaurin-aeb071.html;"Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKC_ with Ki of 0.22 nM; inactive to PKC_. Phase 1/2.";TGF-beta/Smad;C25H22N6O2;Free Base;N/A;CN1CCN(CC1)C1=NC(C2=C(C(=O)NC2=O)C2=CNC3=C2C=CC=C3)=C2C=CC=CC2=N1 |c:22,25,27,31,33,36,t:8,11,19,29|;3,483;4;2;3;9;e;6;L2100-01;e6;100;1;I12;2
205;S1105;LY294002;I13;1;I;13;NA;e7;L1200-01;30734;154447-36-6;PI3K;36;1171341186;<1;NA;http://www.selleckchem.com/products/LY294002.html;"LY294002 is the first synthetic molecule known to inhibit PI3K_/_/_ with IC50 of 0.5 _M/0.57 _M/0.97 _M in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.";Others;C19H17NO3;Free Base;N/A;O=C1C=C(OC2=C(C=CC=C12)C1=CC=CC=C1)N1CCOCC1 |c:2,7,15,17,t:5,9,13|;3,342;3;0;2;1;e;7;L1200-01;e7;100;1;I13;2
206;S2924;CHIR-99021 (CT99021) HCl;I14;1;I;14;NA;e7;L2100-01;5018;252917-06-9 (free base);PI3K/Akt/mTOR;93;1853328019;<1;NA;http://www.selleckchem.com/products/chir-99021-ct99021-hcl.html;"CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3_/_ inhibitor with IC50 of 10 nM/6.7 nM; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.";PI3K/Akt/mTOR;C22H19Cl3N8;HCl;N/A;Cl.CC1=CNC(=N1)C1=CN=C(NCCNC2=NC=C(C=C2)C#N)N=C1C1=CC=C(Cl)C=C1Cl |c:4,17,19,24,32,t:1,7,9,15,27,29|;4,858;4;3;7;9;e;7;L2100-01;e7;100;1;I14;2
207;S1119;Cabozantinib (XL184, BMS-907351);I15;1;I;15;NA;e8;L1200-01;50151;849217-68-1;VEGFR, c-Met, Flt, Tie-2, c-Kit;100;1993978186;<1;NA;http://www.selleckchem.com/products/XL184.html;Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.;Others;C28H24FN3O5;Free Base;BMS-907351;COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2 |c:4,6,32,35,37,39,t:2,13,15,27,29|;4,342;6;2;8;1;e;8;L1200-01;e8;100;1;I15;2
208;S7143;LGK-974;I16;1;I;16;NA;e8;L2100-01;39644;1243244-14-5;Wnt/beta-catenin;79;1992735345;<1;NA;http://www.selleckchem.com/products/lgk-974.html;LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM. Phase 1.;Stem Cells &  Wnt;C23H20N6O;Free Base;N/A;CC1=CC(=CC=N1)C1=C(C)C=C(CC(=O)NC2=CC=C(C=N2)C2=CN=CC=N2)C=N1 |c:3,5,8,19,21,26,28,31,t:1,11,17,24|;2,098;6;1;5;9;e;8;L2100-01;e8;100;1;I16;2
209;S1147;Barasertib (AZD1152-HQPA);I17;1;I;17;NA;e9;L1200-01;50756;722544-51-6;Aurora Kinase;102;2009614627;<1;NA;http://www.selleckchem.com/products/AZD1152-HQPA.html;Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.;Others;C26H30FN7O3;Free Base;AZD1152;CCN(CCO)CCCOC1=CC=C2C(NC3=CC(CC(=O)NC4=CC=CC(F)=C4)=NN3)=NC=NC2=C1 |c:25,28,30,33,35,38,t:10,12,16,23|;3,493;5;4;13;1;e;9;L1200-01;e9;100;1;I17;2
210;S7253;AZD2858;I18;1;I;18;NA;e9;L2100-01;45352;486424-20-8;GSK-3;7;1543482096;<1;NA;http://www.selleckchem.com/products/azd2858.html;AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.;PI3K/Akt/mTOR;C21H23N7O3S;Free Base;N/A;CN1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CN=C(N)C(=N1)C(=O)NC1=CN=CC=C1 |c:13,15,23,31,33,t:11,18,20,29|;0,405;6;2;5;9;e;9;L2100-01;e9;100;1;I18;2
211;S1171;CYC116;I19;1;I;19;NA;e10;L1200-01;36846;693228-63-6;Aurora Kinase, VEGFR;24;6513597134;<1;NA;http://www.selleckchem.com/products/CYC116.html;CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3_/_, CK2, Plk1 and SAPK2A. Phase 1.;Cell Cycle;C18H20N6OS;Free Base;N/A;CC1=C(SC(N)=N1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1 |c:5,14,16,25,27,t:1,8,12|;2,743;4;2;4;1;e;10;L1200-01;e10;100;1;I19;2
212;S7501;HO-3867;I20;1;I;20;NA;e10;L2100-01;46455;1172133-28-6;STAT;13;2798407061;<1;NA;http://www.selleckchem.com/products/ho-3867.html;HO-3867, an analog of curcumin, is a selective STAT3 inhibitor.;JAK/STAT;C28H30F2N2O2;Free Base;N/A;[H]ON1C(C)(C)C=C(CN2C\C(=C/C3=CC=C(F)C=C3)C(=O)\C(C2)=C\C2=CC=C(F)C=C2)C1(C)C |c:18,32,t:6,13,15,27,29|;5,209;1;0;4;9;e;10;L2100-01;e10;100;1;I20;2
213;S1219;YM201636;I21;1;I;21;NA;e11;L1200-01;46748;371942-69-7;PI3K;35;7486951313;<1;NA;http://www.selleckchem.com/products/ym201636.html;YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110_ and insensitive to Fabl (yeast orthologue).;PI3K/Akt/mTOR;C25H21N7O3;Free Base;N/A;NC1=CC=C(C=N1)C(=O)NC1=CC=CC(=C1)C1=NC(N2CCOCC2)=C2OC3=NC=CC=C3C2=N1 |c:3,5,13,15,32,34,38,t:1,11,18,27,30|;2,467;7;2;4;1;e;11;L1200-01;e11;100;1;I21;2
214;S8178;Wnt agonist 1;I22;1;I;22;NA;e11;L2100-01;386.83;853220-52-7(free-base);Wnt/beta-catenin;77;19905;<1;NA;http://selleckchem.com/products/wnt-agonist-1.html;Wnt agonist 1 is a cell permeable Wnt signaling pathway activator, which induces _-catenin- and TCF-dependent transcriptional activity with EC50 of 0.7 _M.;Stem Cells &  Wnt;C19H19ClN4O3;Salt;N/A;Cl.COC1=CC(=CC=C1)C1=NC(N)=NC(NCC2=CC=C3OCOC3=C2)=C1 |c:4,6,12,25,27,t:2,9,17,19|;3,837;5;2;5;9;e;11;L2100-01;e11;100;1;I22;2
215;NA;DMSO;I23;1;I;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;I23;2
216;NA;DMSO;I24;1;I;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;I24;2
217;S1264;PD173074;J01;1;J;1;NA;e1;L1200-02;52367;219580-11-7;FGFR, VEGFR;100;1909599557;<1;NA;http://www.selleckchem.com/products/PD-173074.html;PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.;Angiogenesis;C28H41N7O3;Free Base;N/A;CCN(CC)CCCCNC1=NC=C2C=C(C(NC(=O)NC(C)(C)C)=NC2=N1)C1=CC(OC)=CC(OC)=C1 |c:14,24,27,34,38,t:10,12,30|;4,313;6;3;13;2;e;1;L1200-02;e1;100;1;J01;2
218;S7545;G-749;J02;1;J;2;NA;e1;L1200-05;521.41;1457983-28-6;FLT3;24;4602903665;<1;NA;http://www.selleckchem.com/products/g-749.html;G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y), and Mer, respectively, showing lower potency against other tyrosine kinases.;Angiogenesis;C25H25BrN6O2;Free Base;N/A;CN1CCC(CC1)NC1=NC2=C(C(=O)NC=C2Br)C(NC2=CC=C(OC3=CC=CC=C3)C=C2)=N1 |c:16,29,31,34,36,t:9,11,22,24,27|;3,919;4;3;6;5;e;1;L1200-05;e1;100;1;J02;2
219;S1362;Rigosertib (ON-01910);J03;1;J;3;NA;e2;L1200-02;47347;1225497-78-8;PLK;95;2006462923;95;200,6462923;http://www.selleckchem.com/products/ON-01910.html;Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.;Cell Cycle;C21H24NNaO8S;Sodium Salt;ON-01910;[Na+].COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(NCC([O-])=O)=C2)C(OC)=C1 |c:25,30,t:2,6,14,16|;0,632;6;1;11;2;e;2;L1200-02;e2;100;1;J03;2
220;NA;DMSO;J04;1;J;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;J04;2
221;S1460;SP600125;J05;1;J;5;NA;e3;L1200-02;22023;129-56-6;JNK;44;1997911275;<1;NA;http://www.selleckchem.com/products/SP600125.html;"SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKC_, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc.";MAPK;C14H8N2O;Free Base;N/A;O=C1C2=C3C(NN=C3C3=C1C=CC=C3)=CC=C2 |c:6,9,12,14,16,18,t:2|;2,994;2;1;0;2;e;3;L1200-02;e3;100;1;J05;2
222;S7734;LFM-A13;J06;1;J;6;NA;e3;L1200-05;360;244240-24-2;BTK;72;200;<1;NA;http://www.selleckchem.com/products/lfm-a13.html;LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 _M, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.;Angiogenesis;C11H8Br2N2O2;Free Base;N/A;C\C(O)=C(/C#N)C(=O)NC1=C(Br)C=CC(Br)=C1 |c:9,12,15|;2,645;1;2;2;5;e;3;L1200-05;e3;100;1;J06;2
223;S1489;PIK-93;J07;1;J;7;NA;e4;L1200-02;38988;593960-11-3;PI3K, VEGFR;78;2000615574;<1;NA;http://www.selleckchem.com/products/PIK-93.html;"PIK-93 is the first potent, synthetic PI4K (PI4KIII_) inhibitor with IC50 of 19 nM; shown to inhibit PI3K_ with IC50 of 39 nM.";PI3K/Akt/mTOR;C14H16ClN3O4S2;Free Base;N/A;CC(=O)NC1=NC(C)=C(S1)C1=CC(=C(Cl)C=C1)S(=O)(=O)NCCO |c:7,16,t:4,11,13|;1,076;4;3;6;2;e;4;L1200-02;e4;100;1;J07;2
224;NA;DMSO;J08;1;J;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;J08;2
225;S1532;AZD7762;J09;1;J;9;NA;e5;L1200-02;36242;860352-01-8;Chk;50;1379614812;<1;NA;http://www.selleckchem.com/products/AZD7762.html;AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.;Cell Cycle;C17H19FN4O2S;Free Base;N/A;NC(=O)NC1=C(SC(=C1)C1=CC(F)=CC=C1)C(=O)N[C@H]1CCCNC1 |r,c:7,13,15,t:4,10|;2,009;2;4;4;2;e;5;L1200-02;e5;100;1;J09;2
226;S7928;DASA-58;J10;1;J;10;NA;e5;L1200-05;453.53;1203494-49-8;PKM2;91;2006482482;<1;NA;http://www.selleckchem.com/products/dasa-58.html;DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.;Others;C19H23N3O6S2;Free Base;N/A;NC1=CC(=CC=C1)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)C1=CC2=C(OCCO2)C=C1 |c:3,5,31,t:1,22,24|;0,632;6;1;4;5;e;5;L1200-05;e5;100;1;J10;2
227;S1568;PD318088;J11;1;J;11;NA;e6;L1200-02;56109;391210-00-7;MEK;112;1996114705;<1;NA;http://www.selleckchem.com/products/PD318088.html;PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.;MAPK;C16H13BrF3IN2O4;Free Base;N/A;OCC(O)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C(Br)=C1 |c:9,17,26,t:12,14,22|;3,327;2;4;7;2;e;6;L1200-02;e6;100;1;J11;2
228;NA;DMSO;J12;1;J;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;J12;2
229;S1802;Acadesine;J13;1;J;13;NA;e7;L1200-02;25823;2627-69-2;AMPK;51;1974983542;<1;NA;http://www.selleckchem.com/products/Acadesine.html;AICAR (Acadesine) results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.;PI3K/Akt/mTOR;C9H14N4O5;Free Base;AICAR, AICA-riboside;NC(=O)C1=C(N)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O |r,c:3,7|;-2,913;3;5;3;2;e;7;L1200-02;e7;100;1;J13;2
230;S8023;TCS 359;J14;1;J;14;NA;e7;L1200-05;36043;301305-73-7;FLT3;15;4161695752;<1;NA;http://www.selleckchem.com/products/tcs-359.html;TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM.;Angiogenesis;C18H20N2O4S;Free Base;N/A;COC1=CC=C(C=C1OC)C(=O)NC1=C(C(N)=O)C2=C(CCCC2)S1 |c:4,6,14,t:2,19|;2,753;4;2;5;5;e;7;L1200-05;e7;100;1;J14;2
231;S2163;PF-4708671;J15;1;J;15;NA;e8;L1200-02;39041;1255517-76-0;S6 Kinase;30;76842294;<1;NA;http://www.selleckchem.com/products/pf-4708671.html;PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.;PI3K/Akt/mTOR;C19H21F3N6;Free Base;PF-04708671;CCC1=CN=CN=C1N1CCN(CC2=NC3=C(N2)C=CC(=C3)C(F)(F)F)CC1 |c:4,6,16,20,22,t:2,14|;3,886;3;1;5;2;e;8;L1200-02;e8;100;1;J15;2
232;NA;DMSO;J16;1;J;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;J16;2
233;S2202;NVP-BHG712;J17;1;J;17;NA;e9;L1200-02;50348;940310-85-0;VEGFR, Src, Raf, Bcr-Abl;101;2006037976;<1;NA;http://www.selleckchem.com/products/NVP-BHG712.html;"NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 _M, 1.266 _M and 1.667 _M, respectively.";Protein Tyrosine Kinase;C26H20F3N7O;Free Base;N/A;CN1N=CC2=C1N=C(N=C2NC1=CC(=CC=C1C)C(=O)NC1=CC=CC(=C1)C(F)(F)F)C1=CC=CN=C1 |c:2,4,7,9,15,17,26,28,37,39,t:13,24,35|;4,871;5;2;6;2;e;9;L1200-02;e9;100;1;J17;2
234;S8294;Olmutinib (HM61713, BI 1482694);J18;1;J;18;NA;e9;L1200-05;486.59;1353550-13-6;EGFR;97;19935;<1;NA;http://selleckchem.com/products/olmutinib-hm61713-bi-1482694.html;Olmutinib is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.;Protein Tyrosine Kinase;C26H26N6O2S;Free Base;BI 1482694, HM61713, HM71224;CN1CCN(CC1)C1=CC=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3SC=CC3=N2)C=C1 |c:19,26,31,34,37,t:8,10,13,17,28|;5,449;4;2;7;5;e;9;L1200-05;e9;100;1;J18;2
235;S2221;Apatinib;J19;1;J;19;NA;e10;L1200-02;49358;811803-05-1;VEGFR;22;4457230844;<1;NA;http://www.selleckchem.com/products/Apatinib-YN968D1.html;Apatinib is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.;Protein Tyrosine Kinase;C25H27N5O4S;Mesylate;YN968D1;CS(O)(=O)=O.O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1 |c:9,11,24,26,33,35,t:7,22,31|;3,164;3;2;6;2;e;10;L1200-02;e10;100;1;J19;2
236;NA;DMSO;J20;1;J;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;J20;2
237;S2266;Asiatic Acid;J21;1;J;21;NA;e11;L1200-02;4887;464-92-6;p38 MAPK;97;1984857786;<1;NA;http://www.selleckchem.com/products/Asiatic-acid.html;Asiatic acid is the aglycone of asiaticoside isolated from the plant Centella asiatica, commonly used in wound healing.;MAPK;C30H48O5;Free Base;N/A;[H][C@@]12[C@@H](C)[C@H](C)CC[C@@]1(CC[C@]1(C)C2=CC[C@]2([H])[C@@]3(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@]3([H])CC[C@@]12C)C(O)=O |r,t:15|;4,435;1;3;2;2;e;11;L1200-02;e11;100;1;J21;2
238;NA;DMSO;J22;1;J;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;J22;2
239;NA;DMSO;J23;1;J;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;J23;2
240;NA;DMSO;J24;1;J;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;J24;2
241;S1011;Afatinib (BIBW2992)_uncertain;K01;1;K;1;NA;f1;L1200-01;48594;439081-18-2;EGFR;97;199613121;<1;NA;http://www.selleckchem.com/products/BIBW2992.html;"Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.";Protein Tyrosine Kinase;C24H25ClFN5O3;Free Base;N/A;CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@H]1CCOC1 |r,c:11,20,23,25,28,t:9,14,16|;3,917;5;2;8;1;f;1;L1200-01;f1;100;1;K01;2
242;S1134;AT9283;K02;1;K;2;NA;f1;L2100-01;38143;896466-04-9;Bcr-Abl, JAK, Aurora Kinase;76;1992501901;<1;NA;http://www.selleckchem.com/products/AT9283.html;"AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM; also potent to Aurora A/B, Abl(T315I). Phase 1/2.";Others;C19H23N7O2;Free Base;N/A;O=C(NC1CC1)NC1=CNN=C1C1=NC2=CC(CN3CCOCC3)=CC=C2N1 |c:11,26,28,t:8,14,16|;1,51;4;4;5;9;f;1;L2100-01;f1;100;1;K02;2
243;S1025;Gefitinib (ZD1839);K03;1;K;3;NA;f2;L1200-01;4469;184475-35-2;EGFR;89;1991496979;<1;NA;http://www.selleckchem.com/products/Gefitinib.html;Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.;Protein Tyrosine Kinase;C22H24ClFN4O3;Free Base;ZD-1839;COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC=C(F)C(Cl)=C3)=NC=NC2=C1 |c:2,25,27,29,32,t:15,19,21|;4,203;5;1;8;1;f;2;L1200-01;f2;100;1;K03;2
244;S1528;LY2811376;K04;1;K;4;NA;f2;L2100-01;32036;1194044-20-6;5-alpha Reductase;16;4994381321;<1;NA;http://www.selleckchem.com/products/LY2811376.html;LY2811376 is the first orally available non-peptidic _-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease A_ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.;Proteases;C15H14F2N4S;Free Base;LY 2811376;C[C@]1(CCSC(N)=N1)C1=CC(=C(F)C=C1F)C1=CN=CN=C1 |r,c:6,14,20,22,t:9,11,18|;2,478;3;1;2;9;f;2;L2100-01;f2;100;1;K04;2
245;S1038;PI-103;K05;1;K;5;NA;f3;L1200-01;34836;371935-74-9;DNA-PK, PI3K, mTOR;24;6889424733;<1;NA;http://www.selleckchem.com/products/PI-103.html;PI-103 is a multi-targeted PI3K inhibitor for p110_/_/_/_ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.;Neuronal Signaling;C19H16N4O3;Free Base;N/A;OC1=CC(=CC=C1)C1=NC2=C(OC3=C2C=CC=N3)C(=N1)N1CCOCC1 |c:3,5,13,16,18,21,t:1,8,10|;2,798;5;1;2;1;f;3;L1200-01;f3;100;1;K05;2
246;S2162;AZD1480;K06;1;K;6;NA;f3;L2100-01;34877;935666-88-9, 1260222-79-4 (TFA);JAK;69;1978381168;<1;NA;http://www.selleckchem.com/products/AZD1480.html;AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.;JAK/STAT;C14H14ClFN8;Free Base;N/A;C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1 |r,c:14,16,24,t:3,5,10,19,21|;2,645;5;3;5;9;f;3;L2100-01;f3;100;1;K06;2
247;S1056;AC480 (BMS-599626);K07;1;K;7;NA;f4;L1200-01;56701;714971-09-2;HER2;113;1992910178;<1;NA;http://www.selleckchem.com/products/BMS-599626.html;AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1.;Neuronal Signaling;C27H27FN8O3;Free Base;N/A;CC1=C2N(C=C1NC(=O)OC[C@@H]1COCCN1)N=CN=C2NC1=CC2=C(C=C1)N(CC1=CC=CC(F)=C1)N=C2 |r,c:4,19,21,27,29,36,39,42,t:1,25,34|;3,726;6;3;8;1;f;4;L1200-01;f4;100;1;K07;2
248;S2386;Indirubin;K08;1;K;8;NA;f4;L2100-01;26226;479-41-4;GSK-3;53;2020895295;<1;NA;http://www.selleckchem.com/products/Indirubin.html;"Indirubin is a potent cyclin-dependent kinases and GSK-3_ inhibitor with IC50 of about 5 &mu;M and 0.6 &mu;M.";PI3K/Akt/mTOR;C16H10N2O2;Free Base;N/A;O=C1NC2=CC=CC=C2\C1=C1/NC2=C(C=CC=C2)C1=O |c:5,7,16,18,t:3,14|;1,876;2;2;0;9;f;4;L2100-01;f4;100;1;K08;2
249;S1076;SB203580;K09;1;K;9;NA;f5;L1200-01;37743;152121-47-6;p38 MAPK;43;1139284106;<1;NA;http://www.selleckchem.com/products/SB-203580.html;SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 _M in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 _M.;Transmembrane Transporters;C21H16FN3OS;Free Base;N/A;CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1 |c:5,7,12,18,20,28,t:3,10,16,23,25|;3,883;3;1;4;1;f;5;L1200-01;f5;100;1;K09;2
250;S2714;LY411575;K10;1;K;10;NA;f5;L2100-01;47948;209984-57-6;Gamma-secretase;95;1981313089;<1;NA;http://www.selleckchem.com/products/ly-411575.html;LY411575 is a potent _-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM.;Proteases;C26H23F2N3O4;Free Base;N/A;C[C@H](NC(=O)[C@@H](O)C1=CC(F)=CC(F)=C1)C(=O)N[C@H]1C2=C(C=CC=C2)C2=C(C=CC=C2)N(C)C1=O |r,c:10,13,22,24,29,31,t:7,20,27|;2,625;3;3;5;9;f;5;L2100-01;f5;100;1;K10;2
251;S1093;GSK1904529A;K11;1;K;11;NA;f6;L1200-01;85196;1089283-49-7;IGF-1R;124;1455467393;<1;NA;http://www.selleckchem.com/products/GSK1904529A.html;GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.;Others;C44H47F2N9O5S;Free Base;N/A;CCC1=CC(NC2=NC(=CC=N2)C2=C(N=C3C=CC=CN23)C2=CC(C(=O)NC3=C(F)C=CC=C3F)=C(OC)C=C2)=C(OC)C=C1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O |c:8,10,17,19,30,33,35,42,48,t:2,6,13,15,24,38,44|;6,571;8;2;12;1;f;6;L1200-01;f6;100;1;K11;2
252;S2796;WP1066;K12;1;K;12;NA;f6;L2100-01;35622;857064-38-1;JAK;71;19931503;<1;NA;http://www.selleckchem.com/products/wp1066.html;"WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 _M and 2.43 _M in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3.";JAK/STAT;C17H14BrN3O;Free Base;N/A;C[C@H](NC(=O)C(=C\C1=NC(Br)=CC=C1)\C#N)C1=CC=CC=C1 |r,c:10,12,19,21,t:7,17|;3,566;2;1;4;9;f;6;L2100-01;f6;100;1;K12;2
253;S1106;OSU-03012 (AR-12);K13;1;K;13;NA;f7;L1200-01;46045;742112-33-0;PDK-1;11;2388967315;<1;NA;http://www.selleckchem.com/products/OSU-03012.html;OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 _M in a cell-free assay and 2-fold increase in potency over OSU-02067.;Others;C26H19F3N4O;Free Base;AR-12;NCC(=O)NC1=CC=C(C=C1)N1N=C(C=C1C1=CC2=C(C=C1)C1=C(C=CC=C1)C=C2)C(F)(F)F |c:7,9,13,15,20,22,27,29,32,t:5,18,25|;5,212;2;2;5;1;f;7;L1200-01;f7;100;1;K13;2
254;S5001;Tofacitinib (CP-690550) Citrate;K14;1;K;14;NA;f7;L2100-01;50449;540737-29-9;JAK;100;1982199845;<1;NA;http://www.selleckchem.com/products/CP-690550.html;Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.;JAK/STAT;C22H28N6O8;Citrate;N/A;OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N |r,c:22,24,28,30|;0,193;6;1;8;9;f;7;L2100-01;f7;100;1;K14;2
255;S1120;Everolimus (RAD001);K15;1;K;15;NA;f8;L1200-01;95822;159351-69-6;mTOR;30;3130805034;<1;NA;http://www.selleckchem.com/products/Everolimus(RAD001).html;Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.;Others;C53H83NO14;Free Base;Certican, Zortress, Afinitor;CO[C@@H]1C[C@H](C[C@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |r,c:14,33,t:29,31|;6,164;11;2;9;1;f;8;L1200-01;f8;100;1;K15;2
256;S7145;AZD1080;K16;1;K;16;NA;f8;L2100-01;33437;612487-72-6;GSK-3;52;1555163442;<1;NA;http://www.selleckchem.com/products/azd1080.html;AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3_ and GSK3_ with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.;PI3K/Akt/mTOR;C19H18N4O2;Free Base;N/A;OC1=C(C2=CC(=CC=C2N1)C#N)C1=CC=C(CN2CCOCC2)C=N1 |c:5,7,26,t:1,3,14,16|;2,442;2;2;3;9;f;8;L2100-01;f8;100;1;K16;2
257;S1152;PLX-4720;K17;1;K;17;NA;f9;L1200-01;41383;918505-84-7;Raf;83;2005654496;<1;NA;http://www.selleckchem.com/products/PLX-4720.html;PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.;Others;C17H14ClF2N3O3S;Free Base;N/A;CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(Cl)C=C23)=C1F |c:26,t:7,9,15,18,20,23|;3,435;4;2;6;1;f;9;L1200-01;f9;100;1;K17;2
258;S7269;PD173955;K18;1;K;18;NA;f9;L2100-01;44335;260415-63-2;Bcr-Abl;15;3383331454;<1;NA;http://www.selleckchem.com/products/pd173955.html;PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.;Angiogenesis;C21H18Cl2N4OS;Free Base;N/A;CSC1=CC(NC2=NC3C(C=N2)C=C(C(=O)N3C)C2=C(Cl)C=CC=C2Cl)=CC=C1 |c:10,13,20,23,25,28,30,t:2,6|;4,854;3;1;4;9;f;9;L2100-01;f9;100;1;K18;2
259;S1173;WZ4002;K19;1;K;19;NA;f10;L1200-01;49418;1213269-23-8;EGFR;13;2630620422;<1;NA;http://www.selleckchem.com/products/WZ4002.html;"WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I).";Protein Tyrosine Kinase;C25H27ClN6O3;Free Base;N/A;COC1=C(NC2=NC=C(Cl)C(OC3=CC(NC(=O)C=C)=CC=C3)=N2)C=CC(=C1)N1CCN(C)CC1 |c:2,19,21,23,26,28,t:5,7,12|;4,807;5;2;8;1;f;10;L1200-01;f10;100;1;K19;2
260;S7526;GNF-5;K20;1;K;20;NA;f10;L2100-01;41837;778277-15-9;Bcr-Abl;83;1983889858;<1;NA;http://www.selleckchem.com/products/gnf-5.html;GNF-5 is a selective and allosteric Bcr-Abl inhibitor with IC50 of 220 nM.;Angiogenesis;C20H17F3N4O3;Free Base;N/A;OCCNC(=O)C1=CC=CC(=C1)C1=CC(NC2=CC=C(OC(F)(F)F)C=C2)=NC=N1 |c:8,10,26,28,30,t:6,13,17,19|;4,876;4;3;8;9;f;10;L2100-01;f10;100;1;K20;2
261;S1220;OSI-930;K21;1;K;21;NA;f11;L1200-01;44344;728033-96-3;c-Kit, VEGFR;89;2007035901;<1;NA;http://www.selleckchem.com/products/OSI-930.html;"OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFR_/_, Flt-3 and Abl. Phase 1.";Protein Tyrosine Kinase;C22H16F3N3O2S;Free Base;N/A;FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=CC=CC=C34)C=CS2)C=C1 |c:12,18,22,28,32,t:5,7,16,20,24|;6,266;3;2;7;1;f;11;L1200-01;f11;100;1;K21;2
262;S8195;Oclacitinib;K22;1;K;22;NA;f11;L2100-01;453.51;1640292-55-2;JAK;90;19845;18;3969041476;http://selleckchem.com/products/oclacitinib-maleate.html;Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.;JAK/STAT;C19H27N5O6S;Maleate;PF-03394197;OC(=O)\C=C/C(O)=O.CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(C)C1=C2C=CNC2=NC=N1 |r,c:22,24,28,30|;1,758;6;2;7;9;f;11;L2100-01;f11;100;1;K22;2
263;NA;DMSO;K23;1;K;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;K23;2
264;NA;DMSO;K24;1;K;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;K24;2
265;S1266;WYE-354;L01;1;L;1;NA;f1;L1200-02;49553;1062169-56-5;mTOR;99;1997860876;<1;NA;http://www.selleckchem.com/products/WYE-354.html;WYE-354 is a potent, specific and ATP-competitive inhibitor of mTOR with IC50 of 5 nM, blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) not P-AKT(T308), selective for mTOR than PI3K_ (>100-fold) and PI3K_ (>500-fold).;PI3K/Akt/mTOR;C24H29N7O5;Free Base;N/A;COC(=O)NC1=CC=C(C=C1)C1=NC2=C(C=NN2C2CCN(CC2)C(=O)OC)C(=N1)N1CCOCC1 |c:7,9,16,31,t:5,12,14|;1,886;8;1;6;2;f;1;L1200-02;f1;100;1;L01;2
266;S7563;AT13148;L02;1;L;2;NA;f1;L1200-05;313.78;1056901-62-2;Akt;62;1975906686;<1;NA;http://www.selleckchem.com/products/at13148.html;AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.;PI3K/Akt/mTOR;C17H16ClN3O;Free Base;N/A;NC[C@@](O)(C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)C1=CNN=C1 |r,c:9,14,16,22,t:4,6,12,19|;2,491;1;2;4;5;f;1;L1200-05;f1;100;1;L02;2
267;S1363;Ki8751;L03;1;L;3;NA;f2;L1200-02;46941;228559-41-9;VEGFR, c-Kit, PDGFR;47;1001256897;<1;NA;http://www.selleckchem.com/products/Ki8751.html;Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFR_ and FGFR-2, little activity to EGFR, HGFR and InsR.;Protein Tyrosine Kinase;C24H18F3N3O4;Free Base;N/A;COC1=CC2=NC=CC(OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(F)=C3)=C2C=C1OC |c:6,23,28,30,33,t:2,4,10,12,18,20|;4,853;5;2;6;2;f;2;L1200-02;f2;100;1;L03;2
268;NA;DMSO;L04;1;L;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;L04;2
269;S1462;AZD6482;L05;1;L;5;NA;f3;L1200-02;40845;1173900-33-8;PI3K;82;2007589668;<1;NA;http://www.selleckchem.com/products/azd6482.html;AZD6482 is a PI3K_ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3K_ than PI3K_, PI3K_ and PI3K_ in cell-free assays. Phase 1.;PI3K/Akt/mTOR;C22H24N4O4;Free Base;N/A;C[C@@H](NC1=CC=CC=C1C(O)=O)C1=CC(C)=CN2C(=O)C=C(N=C12)N1CCOCC1 |r,c:5,7,16,21,t:3,13,23|;2,003;4;1;5;2;f;3;L1200-02;f3;100;1;L05;2
270;S7741;SB239063;L06;1;L;6;NA;f3;L1200-05;368.4;193551-21-2;p38 MAPK;60;1628664495;<1;NA;http://www.selleckchem.com/products/sb239063.html;SB239063 is a potent and selective p38 MAPK_/_ inhibitor with IC50 of 44 nM, showing no activity against the _- and _-kinase isoforms.;MAPK;C20H21FN4O2;Free Base;N/A;COC1=NC=CC(=N1)C1=C(N=CN1[C@H]1CC[C@H](O)CC1)C1=CC=C(F)C=C1 |r,c:4,6,11,28,t:2,9,23,25|;3,661;4;1;4;5;f;3;L1200-05;f3;100;1;L06;2
271;S1490;Ponatinib (AP24534);L07;1;L;7;NA;f4;L1200-02;53256;943319-70-8;Bcr-Abl, VEGFR, FGFR, PDGFR, Flt;30;5633168094;<1;NA;http://www.selleckchem.com/products/AP24534.html;Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFR_, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.;Angiogenesis;C29H27F3N6O;Free Base;N/A;CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2)C(F)(F)F)CC1 |c:22,24,31,34,t:6,8,13,18,20,28|;4,884;3;1;7;2;f;4;L1200-02;f4;100;1;L07;2
272;NA;DMSO;L08;1;L;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;L08;2
273;S1533;R406 (free base);L09;1;L;9;NA;f5;L1200-02;47045;841290-80-0;Syk;21;4463811245;<1;NA;http://www.selleckchem.com/products/R406(free-base).html;R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.;Angiogenesis;C22H23FN6O5;Free Base;N/A;COC1=CC(NC2=NC(NC3=NC4=C(OC(C)(C)C(=O)N4)C=C3)=C(F)C=N2)=CC(OC)=C1OC |c:22,27,29,33,t:2,6,10,12,24|;3,881;8;3;7;2;f;5;L1200-02;f5;100;1;L09;2
274;S7938;GSK2292767;L10;1;L;10;NA;f5;L1200-05;512.58;1254036-66-2;PI3K;100;19509;<1;NA;http://selleckchem.com/products/gsk2292767.html;GSK2292767 is a potent and selective PI3K_ inhibitor.;PI3K/Akt/mTOR;C24H28N6O5S;Free Base;N/A;COC1=C(NS(C)(=O)=O)C=C(C=N1)C1=CC2=C(C=NN2)C(=C1)C1=NC=C(CN2C[C@H](C)O[C@H](C)C2)O1 |r,c:2,9,11,18,22,t:14,16,25,27|;1,692;8;2;7;5;f;5;L1200-05;f5;100;1;L10;2
275;S1570;KU-60019;L11;1;L;11;NA;f6;L1200-02;54767;925701-49-1;ATM;18;328665072;<1;NA;http://www.selleckchem.com/products/KU-60019.html;KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.;DNA Damage;C30H33N3O5S;Free Base;N/A;C[C@H]1CN(CC(=O)NC2=CC3=C(SC4=C(C3)C=CC=C4C3=CC(=O)C=C(O3)N3CCOCC3)C=C2)C[C@@H](C)O1 |r,c:13,17,19,26,37,t:8,10,22|;3,818;5;1;5;2;f;6;L1200-02;f6;100;1;L11;2
276;NA;DMSO;L12;1;L;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;L12;2
277;S2013;PF-573228;L13;1;L;13;NA;f7;L1200-02;49149;869288-64-2;FAK;26;529003642;<1;NA;http://www.selleckchem.com/products/pf-573228.html;PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3_.;Angiogenesis;C22H20F3N5O3S;Free Base;N/A;CS(=O)(=O)C1=CC(CNC2=NC(NC3=CC4=C(NC(=O)CC4)C=C3)=NC=C2C(F)(F)F)=CC=C1 |c:23,25,27,33,35,t:4,9,13,15|;3,967;5;3;7;2;f;7;L1200-02;f7;100;1;L13;2
278;S8024;Tyrphostin AG 1296;L14;1;L;14;NA;f7;L1200-05;26629;146535-11-7;PDGFR;6;225318262;<1;NA;http://www.selleckchem.com/products/tyrphostin-ag-1296-ag-1296.html;Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 _M, no activity to EGFR.;Protein Tyrosine Kinase;C16H14N2O2;Free Base;N/A;COC1=CC2=NC=C(N=C2C=C1OC)C1=CC=CC=C1 |c:6,8,11,18,20,t:2,4,16|;3,208;4;0;3;5;f;7;L1200-05;f7;100;1;L14;2
279;S2179;LY2784544;L15;1;L;15;NA;f8;L1200-02;46994;1229236-86-5;JAK;94;2000255352;<1;NA;http://www.selleckchem.com/products/LY2784544.html;Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.;JAK/STAT;C23H25ClFN7O;Free Base;N/A;CC1=NNC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN3CCOCC3)=C2)=C1 |c:16,22,33,35,t:1,6,11,13,19|;3,938;4;2;6;2;f;8;L1200-02;f8;100;1;L15;2
280;NA;DMSO;L16;1;L;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;L16;2
281;S2205;OSI-420;L17;1;L;17;NA;f9;L1200-02;41587;183320-51-6;EGFR;83;1995816;<1;NA;http://www.selleckchem.com/products/OSI-420-Desmethyl-Erlotinib,CP-473420.html;OSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).;Protein Tyrosine Kinase;C21H22ClN3O4;Hydrochloride;CP-473420;Cl.COCCOC1=CC2=C(C=C1OCCO)C(NC1=CC=CC(=C1)C#C)=NC=N2 |c:7,9,20,22,26,28,t:5,18|;4,283;5;2;9;2;f;9;L1200-02;f9;100;1;L17;2
282;S8319;7,8-Dihydroxyflavone;L18;1;L;18;NA;f9;L1200-05;254.24;38183-03-8;Trk receptor;50;19666;<1;NA;http://selleckchem.com/products/7-8-dihydroxyflavone.html;7,8-Dihydroxyflavone acts as a potent and selective small-molecule agonist of the TrkB receptor (Kd Å 320 nM), the main signaling receptor of brain-derived neurotrophic factor (BDNF).;Protein Tyrosine Kinase;C15H10O4;Free Base;7,8-DHF;OC1=CC=C2C(=O)C=C(OC2=C1O)C1=CC=CC=C1 |c:7,11,17,19,t:1,3,15|;2,652;2;2;1;5;f;9;L1200-05;f9;100;1;L18;2
283;S2226;CAL-101 (Idelalisib, GS-1101);L19;1;L;19;NA;f10;L1200-02;41542;870281-82-6;PI3K;83;199797795;<1;NA;http://www.selleckchem.com/products/CAL-101.html;"CAL-101 (Idelalisib, GS-1101) is a selective p110_ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110_ than p110_/_/_, and 400- to 4000-fold more selectivity to p110_ than C2_, hVPS34, DNA-PK and mTOR.";PI3K/Akt/mTOR;C22H18FN7O;Free Base;CAL101;CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 |r,c:4,6,10,12,19,22,31,33,t:15,17,29|;3,624;5;2;5;2;f;10;L1200-02;f10;100;1;L19;2
284;NA;DMSO;L20;1;L;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;L20;2
285;S2310;Honokiol;L21;1;L;21;NA;f11;L1200-02;266334;35354-74-6;Akt, MEK;53;1989982503;<1;NA;http://www.selleckchem.com/products/Honokiol.html;Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.;PI3K/Akt/mTOR;C18H18O2;Free Base;N/A;OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=C(O)C=C1 |c:8,19,t:1,3,11,16|;4,88;0;2;5;2;f;11;L1200-02;f11;100;1;L21;2
286;NA;DMSO;L22;1;L;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;L22;2
287;NA;DMSO;L23;1;L;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;L23;2
288;NA;DMSO;L24;1;L;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;L24;2
289;S1012;BMS-536924;M01;1;M;1;NA;g1;L1200-01;47996;468740-43-4;IGF-1R;96;2000166681;<1;NA;http://www.selleckchem.com/products/BMS-536924.html;BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.;Protein Tyrosine Kinase;C25H26ClN5O3;Free Base;N/A;CC1=C2N=C(NC2=CC(=C1)N1CCOCC1)C1=C(NC[C@@H](O)C2=CC=CC(Cl)=C2)C=CNC1=O |r,c:1,3,7,9,19,27,30,33,t:25|;2,385;3;4;6;1;g;1;L1200-01;g1;100;1;M01;2
290;S1143;AG-490 (Tyrphostin B42);M02;1;M;2;NA;g1;L2100-01;2943;133550-30-8;JAK, EGFR;59;2004757051;<1;NA;http://www.selleckchem.com/products/AG-490.html;AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 _M, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.;Others;C17H14N2O3;Free Base;N/A;OC1=C(O)C=C(\C=C(/C#N)C(=O)NCC2=CC=CC=C2)C=C1 |c:1,16,18,21,t:4,14|;2,444;1;3;4;9;g;1;L2100-01;g1;100;1;M02;2
291;S1026;Imatinib Mesylate (STI571);M03;1;M;3;NA;g2;L1200-01;58971;220127-57-1;PDGFR, c-Kit, Bcr-Abl;118;2000983534;118;200,0983534;http://www.selleckchem.com/products/Imatinib-Mesylate.html;Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 _M, 0.1 _M and 0.1 _M in cell-free or cell-based assays, respectively.;Protein Tyrosine Kinase;C30H35N7O4S;Mesylate;Glivec, CGP-57148B, STI-571;CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CC=CN=C3)=C2)CC1 |c:12,14,29,31,36,38,40,t:10,20,22,27,34|;3,806;4;2;7;1;g;2;L1200-01;g2;100;1;M03;2
292;S1573;Fasudil (HA-1077) HCl;M04;1;M;4;NA;g2;L2100-01;32783;105628-07-7;ROCK;5;1525180734;65;1982734954;http://www.selleckchem.com/products/Fasudil-HCl(HA-1077).html;Fasudil (HA-1077) is a potent inhibitor of ROCK-II, PKA,  PKG,  PKC, and MLCK with Ki of 0.33 _M, 1.6 _M, 1.6 _M, 3.3 _M and 36 _M, respectively.;Cell Cycle;C14H18ClN3O2S;Hydrochloride;AT-877;Cl.O=S(=O)(N1CCCNCC1)C1=C2C=CN=CC2=CC=C1 |c:11,13,15,18,20|;0,57;3;1;2;9;g;2;L2100-01;g2;100;1;M04;2
293;S1039;Rapamycin (Sirolimus);M05;1;M;5;NA;g3;L1200-01;91418;53123-88-9;mTOR;20;2187752959;<1;NA;http://www.selleckchem.com/products/Rapamycin.html;Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.;DNA Damage;C51H79NO13;Free Base;N/A;CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |r,c:14,33,t:29,31|;6,295;10;2;6;1;g;3;L1200-01;g3;100;1;M05;2
294;S2179;LY2784544;M06;1;M;6;NA;g3;L2100-01;46994;1229236-86-5;JAK;94;2000255352;<1;NA;http://www.selleckchem.com/products/LY2784544.html;LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.;JAK/STAT;C23H25ClFN7O;Free Base;N/A;CC1=NNC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN3CCOCC3)=C2)=C1 |c:16,22,33,35,t:1,6,11,13,19|;3,938;4;2;6;9;g;3;L2100-01;g3;100;1;M06;2
295;S1064;Masitinib (AB1010);M07;1;M;7;NA;g4;L1200-01;49864;790299-79-5;c-Kit, PDGFR, FGFR, FAK;100;2005454837;<1;NA;http://www.selleckchem.com/products/Masitinib-(AB1010).html;Masitinib is a novel inhibitor for Kit and PDGFR_/_ with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.;Others;C28H30N6OS;Free Base;N/A;CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC(=CS3)C3=CC=CN=C3)=C(C)C=C2)CC1 |c:8,10,22,28,30,35,t:6,16,20,26,32|;4,475;3;2;7;1;g;4;L1200-01;g4;100;1;M07;2
296;S2391;Quercetin;M08;1;M;8;NA;g4;L2100-01;30224;117-39-5;PI3K, PKC, Src, Sirtuin;61;2018263632;<1;NA;http://www.selleckchem.com/products/Quercetin(Sophoretin).html;"Quercetin is a natural flavonoid present in vegetables, fruit and wine and is a PI3K inhibitor with IC50 of 2.4 Ð 5.4 &mu;M.";Epigenetics;C15H10O7;Free Base;Meletin, Quercetine;OC1=CC(O)=C2C(=O)C(O)=C(OC2=C1)C1=CC=C(O)C(O)=C1 |c:9,13,22,t:1,4,16,18|;1,63;2;5;1;9;g;4;L2100-01;g4;100;1;M08;2
297;S1077;SB202190 (FHPI);M09;1;M;9;NA;g5;L1200-01;33134;152121-30-7;p38 MAPK;66;1991911632;<1;NA;http://www.selleckchem.com/products/SB-202190.html;SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38_/_ with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.;PI3K/Akt/mTOR;C20H14FN3O;Free Base;N/A;OC1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1 |c:3,5,10,16,18,26,t:1,8,14,21,23|;4,211;2;2;3;1;g;5;L1200-01;g5;100;1;M09;2
298;S2729;SB415286;M10;1;M;10;NA;g5;L2100-01;35972;264218-23-7;GSK-3;72;2001556766;<1;NA;http://www.selleckchem.com/products/sb-415286.html;SB415286 is a potent GSK3_ inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3_.;PI3K/Akt/mTOR;C16H10ClN3O5;Free Base;N/A;OC1=C(Cl)C=C(NC2=C(C(=O)NC2=O)C2=C(C=CC=C2)[N+]([O-])=O)C=C1 |c:1,17,19,25,t:4,7,15|;2,49;2;3;4;9;g;5;L2100-01;g5;100;1;M10;2
299;S1094;PF-04217903;M11;1;M;11;NA;g6;L1200-01;37238;956905-27-4;c-Met;5;1342714431;<1;NA;http://www.selleckchem.com/products/PF-04217903.html;PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.;Others;C19H16N8O;Free Base;N/A;OCCN1C=C(C=N1)C1=NC2=C(N=NN2CC2=CC3=CC=CN=C3C=C2)N=C1 |c:4,6,13,22,24,27,30,t:9,11,18,20|;1,561;6;1;5;1;g;6;L1200-01;g6;100;1;M11;2
300;S2806;CEP-33779;M12;1;M;12;NA;g6;L2100-01;46257;1257704-57-6;JAK;93;2010506518;<1;NA;http://www.selleckchem.com/products/cep33779.html;CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.;JAK/STAT;C24H26N6O2S;Free Base;N/A;CN1CCN(CC1)C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C2=CC=C(C=C2)S(C)(=O)=O)=C1 |c:10,17,19,22,27,29,35,t:8,14,25|;3,86;4;1;5;9;g;6;L2100-01;g6;100;1;M12;2
301;S1107;Danusertib (PHA-739358);M13;1;M;13;NA;g7;L1200-01;47455;827318-97-8;Aurora Kinase, FGFR, Bcr-Abl, c-RET, Src;95;2001896534;<1;NA;http://www.selleckchem.com/products/PHA-739358(Danusertib).html;Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.;Others;C26H30N6O3;Free Base;N/A;CO[C@@H](C(=O)N1CC2=C(C1)C(NC(=O)C1=CC=C(C=C1)N1CCN(C)CC1)=NN2)C1=CC=CC=C1 |r,c:7,17,19,29,35,37,t:15,33|;2,337;4;2;6;1;g;7;L1200-01;g7;100;1;M13;2
302;S7036;XL019;M14;1;M;14;NA;g7;L2100-01;44453;945755-56-6;JAK;16;3599307133;<1;NA;http://www.selleckchem.com/products/xl019.html;XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.;JAK/STAT;C25H28N6O2;Free Base;N/A;O=C(NC1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1)[C@@H]1CCCN1 |r,c:5,7,12,18,20,29,t:3,10,16|;3,106;4;3;6;9;g;7;L2100-01;g7;100;1;M14;2
303;S1124;BMS-754807;M15;1;M;15;NA;g8;L1200-01;46149;1001350-96-4;IGF-1R;92;1993542655;<1;NA;http://www.selleckchem.com/products/BMS-754807.html;BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.;Others;C23H24FN9O;Free Base;N/A;C[C@]1(CCCN1C1=NN2C=CC=C2C(NC2=NNC(=C2)C2CC2)=N1)C(=O)NC1=CC=C(F)N=C1 |r,c:10,12,20,26,37,t:7,17,32,34|;4,069;5;3;6;1;g;8;L1200-01;g8;100;1;M15;2
304;S7193;1-Azakenpaullone;M16;1;M;16;NA;g8;L2100-01;32816;676596-65-9;GSK-3;66;2011214042;<1;NA;http://www.selleckchem.com/products/1-azakenpaullone.html;1-Azakenpaullone is a potent and selective GSK-3_ inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.;PI3K/Akt/mTOR;C15H10BrN3O;Free Base;N/A;BrC1=CC2=C(NC3=C2CC(=O)NC2=C3N=CC=C2)C=C1 |c:6,13,16,18,21,t:1,3|;2,949;2;2;0;9;g;8;L2100-01;g8;100;1;M16;2
305;S1153;Roscovitine (Seliciclib,CYC202);M17;1;M;17;NA;g9;L1200-01;35445;186692-46-6;CDK;71;20031034;<1;NA;http://www.selleckchem.com/products/Roscovitine.html;Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 _M, 0.7 _M and 0.16 _M in cell-free assays. It shows little effect on CDK4/6. Phase 2.;Others;C19H26N6O;Free Base;N/A;CC[C@H](CO)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1 |r,c:13,15,19,26,t:6,11,17|;3,32;3;3;8;1;g;9;L1200-01;g9;100;1;M17;2
306;S7301;IWP-L6;M18;1;M;18;NA;g9;L2100-01;47258;1427782-89-5;Wnt/beta-catenin;25;5290109611;<1;NA;http://www.selleckchem.com/products/iwp-l6.html;IWP-L6 is a highly potent Porcn inhibitor with EC50 of 0.5 nM.;Stem Cells &  Wnt;C25H20N4O2S2;Free Base;Porcn Inhibitor III;O=C(CSC1=NC2=C(SCC2)C(=O)N1C1=CC=CC=C1)NC1=NC=C(C=C1)C1=CC=CC=C1 |c:18,20,26,28,33,35,t:4,6,16,24,31|;4,072;4;1;6;9;g;9;L2100-01;g9;100;1;M18;2
307;S1177;PD98059;M19;1;M;19;NA;g10;L1200-01;26728;167869-21-8;MEK;14;5237952709;<1;NA;http://www.selleckchem.com/products/PD-98059.html;"PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 _M in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.";MAPK;C16H13NO3;Free Base;N/A;COC1=C(N)C(=CC=C1)C1=CC(=O)C2=CC=CC=C2O1 |c:2,5,7,16,18,t:10,14|;2,373;3;1;2;1;g;10;L1200-01;g10;100;1;M19;2
308;S7541;Decernotinib (VX-509);M20;1;M;20;NA;g10;L2100-01;392.38;944842-54-0;JAK;78;19879;<1;NA;http://selleckchem.com/products/decernotinib-vx-509.html;Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.;JAK/STAT;C18H19F3N6O;Free Base;N/A;CC[C@@](C)(NC1=NC(=NC=C1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F |r,c:7,9,17,t:5,12,15,19|;2,747;4;3;7;9;g;10;L2100-01;g10;100;1;M20;2
309;S1226;KU-0063794;M21;1;M;21;NA;g11;L1200-01;46554;938440-64-3;mTOR;16;3436869012;<1;NA;http://www.selleckchem.com/products/KU-0063794.html;"KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.";PI3K/Akt/mTOR;C25H31N5O4;Free Base;N/A;COC1=C(CO)C=C(C=C1)C1=NC2=NC(=NC(N3CCOCC3)=C2C=C1)N1C[C@H](C)O[C@H](C)C1 |r,c:2,6,8,15,24,27,t:11,13|;3,274;6;1;5;1;g;11;L1200-01;g11;100;1;M21;2
310;S8262;PRI-724;M22;1;M;22;NA;g11;L2100-01;548.63;847591-62-2;Wnt/beta-catenin;100;18227;<1;NA;http://selleckchem.com/products/pri-724.html;PRI-724 is a potent, specific inhibitor of the canonical Wnt signaling pathway in cancer stem cells with potential antineoplastic activity. PRI-724 specifically inhibits the recruiting of beta-catenin with its coactivator CBP.;Stem Cells &  Wnt;C33H32N4O4;Free Base;N/A;[H][C@]12CN(CC3=CC=CC4=C3C=CC=C4)C(=O)[C@H](CC3=CC=C(O)C=C3)N1C(=O)CCN2C(=O)NCC1=CC=CC=C1 |r,c:7,9,12,14,26,43,45,t:5,21,23,41|;4,065;3;2;6;9;g;11;L2100-01;g11;100;1;M22;2
311;NA;DMSO;M23;1;M;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;M23;2
312;NA;DMSO;M24;1;M;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;M24;2
313;S1267;Vemurafenib (PLX4032, RG7204);N01;1;N;1;NA;g1;L1200-02;48992;918504-65-1;Raf;97;1979915088;<1;NA;http://www.selleckchem.com/products/PLX-4032.html;Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay.;MAPK;C23H18ClF2N3O3S;Free Base;RG7204;CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F |c:20,31,33,t:7,9,15,18,22,26,28|;4,953;4;2;7;2;g;1;L1200-02;g1;100;1;N01;2
314;S7565;WH-4-023;N02;1;N;2;NA;g1;L1200-05;56867;837422-57-8;Src;12;2110186927;<1;NA;http://www.selleckchem.com/products/wh-4-023.html;WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.;Angiogenesis;C32H36N6O4;Free Base;KIN001-112;COC1=CC=C(N(C(=O)OC2=C(C)C=CC=C2C)C2=CC=NC(NC3=CC=C(C=C3)N3CCN(C)CC3)=N2)C(OC)=C1 |c:10,13,15,21,27,29,39,44,t:2,4,19,25|;6,843;6;1;9;5;g;1;L1200-05;g1;100;1;N02;2
315;S1378;Ruxolitinib (INCB018424);N03;1;N;3;NA;g2;L1200-02;30637;941678-49-5;JAK;61;1991056566;<1;NA;http://www.selleckchem.com/products/INCB18424.html;Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3.;JAK/STAT;C17H18N6;Free Base;N/A;N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |r,c:11,13,18,20,23,t:16|;2,88;3;1;4;2;g;2;L1200-02;g2;100;1;N03;2
316;NA;DMSO;N04;1;N;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;N04;2
317;S1470;TSU-68 (SU6668, Orantinib);N05;1;N;5;NA;g3;L1200-02;31035;252916-29-3;VEGFR, PDGFR , FGFR;62;1997744482;<1;NA;http://www.selleckchem.com/products/TSU-68(SU6668).html;"TSU-68 (SU6668, Orantinib) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3.";Protein Tyrosine Kinase;C18H18N2O3;Free Base;SU6668;CC1=C(CCC(O)=O)C(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12 |c:1,9,20,t:18,22|;2,868;2;2;4;2;g;3;L1200-02;g3;100;1;N05;2
318;S7745;ANA-12;N06;1;N;6;NA;g3;L1200-05;407.49;219766-25-3;Trk receptor;37;9079977423;<1;NA;http://www.selleckchem.com/products/ana-12.html;ANA-12 is a selective TrkB antagonist with Kd of 10 nM and 12 _M for the high and low affinity sites, respectively.;Protein Tyrosine Kinase;C22H21N3O3S;Free Base;N/A;O=C(NC1=CC=CC=C1C(=O)NC1CCCCNC1=O)C1=CC2=C(S1)C=CC=C2 |c:5,7,24,28,30,t:3,22|;3,088;3;3;4;5;g;3;L1200-05;g3;100;1;N06;2
319;S1523;SAR245409 (XL765);N07;1;N;7;NA;g4;L1200-02;59966;1349796-36-6;PI3K, mTOR;12;2001133976;<1;NA;http://www.selleckchem.com/products/XL765(SAR245409).html#;"Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110_ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.";PI3K/Akt/mTOR;C31H29N5O6S;Free Base;N/A;COC1=CC(NC2=NC3=CC=CC=C3N=C2NS(=O)(=O)C2=CC=C(NC(=O)C3=CC=C(C)C(OC)=C3)C=C2)=CC(OC)=C1 |c:10,12,15,36,39,41,45,t:2,6,8,22,24,29,31|;5,631;8;3;10;2;g;4;L1200-02;g4;100;1;N07;2
320;NA;DMSO;N08;1;N;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;N08;2
321;S1536;CP-673451;N09;1;N;9;NA;g5;L1200-02;4175;343787-29-1;PDGFR;28;6706586826;<1;NA;http://www.selleckchem.com/products/CP-673451.html;CP-673451 is a selective inhibitor of PDGFR_/_ with IC50 of 10 nM/1 nM in cell-free assays, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.;Protein Tyrosine Kinase;C24H27N5O2;Free Base;CP673451;COCCOC1=CC=C2N(C=NC2=C1)C1=NC2=C(C=CC=C2C=C1)N1CCC(N)CC1 |c:10,13,20,22,25,t:5,7,16,18|;3,011;4;1;6;2;g;5;L1200-02;g5;100;1;N09;2
322;S7951;STA-21;N10;1;N;10;NA;g5;L1200-05;306.31;111540-00-2;STAT;61;19914;NA;NA;http://selleckchem.com/products/sta-21.html;STA-21 is a selective STAT3 inhibitor.;JAK/STAT;C19H14O4;Free Base;N/A;CC1CC(=O)C2=C(C1)C=CC1=C2C(=O)C2=C(C(O)=CC=C2)C1=O |c:5,9,11,19,21,t:16|;3,339;3;1;0;5;g;5;L1200-05;g5;100;1;N10;2
323;S1572;BS-181 HCl;N11;1;N;11;NA;g6;L1200-02;41699;1397219-81-6;CDK;83;1990455407;3;7,194417132;http://www.selleckchem.com/products/BS-181.html;BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.;Cell Cycle;C22H33ClN6;Hydrochloride;N/A;Cl.CC(C)C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1 |c:3,21,23,28,t:5,15,19|;4,684;2;3;11;2;g;6;L1200-02;g6;100;1;N11;2
324;NA;DMSO;N12;1;N;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;N12;2
325;S2014;BMS-265246;N13;1;N;13;NA;g7;L1200-02;34534;582315-72-8;CDK;20;5791393989;<1;NA;http://www.selleckchem.com/products/bms-265246.html;BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM in a cell-free assay. It is 25-fold more selective for CDK1/2 than CDK4.;Cell Cycle;C18H17F2N3O2;Free Base;N/A;CCCCOC1=C2C=NNC2=NC=C1C(=O)C1=C(F)C=C(C)C=C1F |c:5,7,11,13,18,24,t:21|;4,135;4;1;6;2;g;7;L1200-02;g7;100;1;N13;2
326;S8031;NSC 23766;N14;1;N;14;NA;g7;L1200-05;53096;1177865-17-6;Rac;100;1883381046;100;188,3381046;http://www.selleckchem.com/products/nsc-23766.html;"NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 _M in a cell-free assay; does not inhibit the closely related  targets, Cdc42 or RhoA.";Cell Cycle;C24H38Cl3N7;trihydrochloride;N/A;Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(C)=CC(NC2=CC3=C(N)C=C(C)N=C3C=C2)=N1 |c:14,20,26,29,31,t:11,18,23|;5,477;3;3;10;5;g;7;L1200-05;g7;100;1;N14;2
327;S2185;AST-1306;N15;1;N;15;NA;g8;L1200-02;62108;1050500-29-2;EGFR;124;1996522187;<1;NA;http://www.selleckchem.com/products/ast-1306.html;AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.;Protein Tyrosine Kinase;C31H26ClFN4O5S;4-methylbenzenesulfonate;N/A;CC1=CC=C(C=C1)S(O)(=O)=O.FC1=CC(COC2=CC=C(NC3=C4C=C(NC(=O)C=C)C=CC4=NC=N3)C=C2Cl)=CC=C1 |c:3,5,22,31,34,36,39,42,44,t:1,12,17,19,24|;7,381;4;2;8;2;g;8;L1200-02;g8;100;1;N15;2
328;NA;DMSO;N16;1;N;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;N16;2
329;S2207;PIK-293;N17;1;N;17;NA;g9;L1200-02;39743;900185-01-5;PI3K;80;2012933095;<1;NA;http://www.selleckchem.com/products/PIK-293.html;PIK-293 is a PI3K inhibitor, mostly for PI3K_ with IC50 of 0.24 _M, 500-, 100- and 50-fold less potent to PI3K_/_/_, respectively.;PI3K/Akt/mTOR;C22H19N7O;Free Base;N/A;CC1=CC=CC2=C1C(=O)N(C(CN1N=CC3=C1N=CN=C3N)=N2)C1=C(C)C=CC=C1 |c:3,5,14,16,19,21,24,27,30,32,t:1|;3,162;5;1;3;2;g;9;L1200-02;g9;100;1;N17;2
330;S8322;LY3023414;N18;1;N;18;NA;g9;L1200-05;406.48;1386874-06-1;Akt;47;11563;<1;NA;http://selleckchem.com/products/ly3023414.html;LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.;PI3K/Akt/mTOR;C23H26N4O3;Free Base;GTPL8918;CO[C@@H](C)CN1C(=O)N(C)C2=C1C1=CC(=CC=C1N=C2)C1=CC(=CN=C1)C(C)(C)O |r,c:10,15,17,20,25,27,t:13,23|;1,883;4;0;5;5;g;9;L1200-05;g9;100;1;N18;2
331;S2227;PIK-294;N19;1;N;19;NA;g10;L1200-02;48953;900185-02-6;PI3K;98;2001920209;<1;NA;http://www.selleckchem.com/products/PIK-294.html;PIK-294 is a highly selective p110_ inhibitor with IC50 of 10 nM, 1000-, 49- and 16-fold less potent to PI3K_/_/_, respectively.;PI3K/Akt/mTOR;C28H23N7O2;Free Base;N/A;CC1=CC=CC2=C1C(=O)N(C(CN1N=C(C3=C(N)N=CN=C13)C1=CC(O)=CC=C1)=N2)C1=C(C)C=CC=C1 |c:3,5,14,16,19,28,30,32,35,38,40,t:1,21,25|;4,867;5;2;4;2;g;10;L1200-02;g10;100;1;N19;2
332;NA;DMSO;N20;1;N;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;N20;2
333;S2386;Indirubin;N21;1;N;21;NA;g11;L1200-02;26226;479-41-4;GSK-3;53;2020895295;<1;NA;http://www.selleckchem.com/products/Indirubin.html;Indirubin is a potent cyclin-dependent kinases and GSK-3_ inhibitor with IC50 of about 5 _M and 0.6 _M.;PI3K/Akt/mTOR;C16H10N2O2;Free Base;N/A;O=C1NC2=CC=CC=C2\C1=C1/NC2=C(C=CC=C2)C1=O |c:5,7,16,18,t:3,14|;1,876;2;2;0;2;g;11;L1200-02;g11;100;1;N21;2
334;NA;DMSO;N22;1;N;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;N22;2
335;NA;DMSO;N23;1;N;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;N23;2
336;NA;DMSO;N24;1;N;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;N24;2
337;S1014;Bosutinib (SKI-606);O01;1;O;1;NA;h1;L1200-01;53045;380843-75-4;Src;100;1885191818;<1;NA;http://www.selleckchem.com/products/Bosutinib.html;Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.;Angiogenesis;C26H29Cl2N5O3;Free Base;N/A;COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1 |c:2,12,37,t:5,10,14,28,32|;4,883;4;1;9;1;h;1;L1200-01;h1;100;1;O01;2
338;S1180;XAV-939;O02;1;O;2;NA;h1;L2100-01;31231;284028-89-3;Wnt/beta-catenin;12;384233614;<1;NA;http://www.selleckchem.com/products/XAV-939.html;XAV-939 selectively inhibits Wnt/_-catenin-mediated transcription through tankyrase1/2 inhibition with IC50 of 11 nM/4 nM, regulates axin levels and does not affect CRE, NF-_B or TGF-_.;Stem Cells &  Wnt;C14H11F3N2OS;Free Base;N/A;OC1=C2CSCCC2=NC(=N1)C1=CC=C(C=C1)C(F)(F)F |c:1,8,10,15,17,t:13|;3,676;2;1;2;9;h;1;L2100-01;h1;100;1;O02;2
339;S1028;Lapatinib (GW-572016) Ditosylate;O03;1;O;3;NA;h2;L1200-01;92546;388082-77-7;EGFR, HER2;100;108054373;<1;NA;http://www.selleckchem.com/products/Lapatinib-Ditosylate.html;Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.;Protein Tyrosine Kinase;C43H42ClFN4O10S3;Ditosylat;GW-57201;CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1 |c:3,5,14,16,32,40,53,56,60,64,t:1,12,30,36,38,42,45,47,51|;9,339;6;2;13;1;h;2;L1200-01;h2;100;1;O03;2
340;S1575;RO4929097;O04;1;O;4;NA;h2;L2100-01;4694;847925-91-1;Y-Secretase;94;2002556455;<1;NA;http://www.selleckchem.com/products/RO4929097.html;RO4929097 is a _ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of A_40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.;Proteases;C22H20F5N3O3;Free Base;RO-4929097;CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C2=C(NC1=O)C=CC=C2 |r,c:20,22,25,31,33,t:18|;3,184;3;3;6;9;h;2;L2100-01;h2;100;1;O04;2
341;S1040;Sorafenib Tosylate;O05;1;O;5;NA;h3;L1200-01;63703;475207-59-1;VEGFR, PDGFR, Raf;127;1993626674;0.01;0,015697848;http://www.selleckchem.com/products/Sorafenib-Tosylate.html;Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.;Neuronal Signaling;C28H24ClF3N4O6S;Tosylate;Bay 43-9006;CC1=CC=C(C=C1)S(O)(=O)=O.CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 |c:3,5,32,39,41,43,t:1,15,19,21,27,29|;5,824;4;3;7;1;h;3;L1200-01;h3;100;1;O05;2
342;S2186;SB505124;O06;1;O;6;NA;h3;L2100-01;3354;694433-59-5;TGF-beta/Smad;67;1997614788;<1;NA;http://www.selleckchem.com/products/sb-505124.html;SB505124 is a selective inhibitor of TGF_R for ALK4, ALK5 with IC50 of 129 nM and 47 nM, respectively, also inhibits ALK7, but does not inhibit ALK1, 2, 3, or 6.;TGF-beta/Smad;C20H21N3O2;Free Base;N/A;CC1=CC=CC(=N1)C1=C(N=C(N1)C(C)(C)C)C1=CC2=C(OCO2)C=C1 |c:3,5,10,26,t:1,8,18,20|;4,609;4;1;3;9;h;3;L2100-01;h3;100;1;O06;2
343;S1065;GDC-0941;O07;1;O;7;NA;h4;L1200-01;51364;957054-30-7;PI3K;44;8566311035;<1;NA;http://www.selleckchem.com/products/GDC-0941.html;Pictilisib (GDC-0941) is a potent inhibitor of PI3K_/_ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110_ (11-fold) and p110_ (25-fold). Phase 2.;Metabolism;C23H27N7O3S2;Free Base;N/A;CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C2=CC=CC3=C2C=NN3)CC1 |c:13,22,29,31,34,t:9,11,27|;2,153;6;1;5;1;h;4;L1200-01;h4;100;1;O07;2
344;S2415;Astragaloside A;O08;1;O;8;NA;h4;L2100-01;78497;83207-58-3;others;100;1273934036;<1;NA;http://www.selleckchem.com/products/astragaloside-a.html;Astragaloside A (Astragaloside IV) is the primary pure saponin isolated from Astragalus membranaceus, which has been widely used for the treatment of cardiovascular diseases.;TGF-beta/Smad;C41H68O14;Free Base;Cyclosiversioside F;[H][C@@]1([C@@H](O)C[C@@]2(C)[C@]3([H])C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@]4([H])[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C)[C@]1(C)CC[C@@H](O1)C(C)(C)O |r|;-0,348;5;8;7;9;h;4;L2100-01;h4;100;1;O08;2
345;S1078;MK-2206 2HCl;O09;1;O;9;NA;h5;L1200-01;48039;1032350-13-2;Akt;14;2914298799;<1;NA;http://www.selleckchem.com/products/MK-2206.html;"MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.";Others;C25H23Cl2N5O;Dihydrochloride;N/A;Cl.Cl.NC1(CCC1)C1=CC=C(C=C1)C1=C(C=C2C3=NNC(=O)N3C=CC2=N1)C1=CC=CC=C1 |c:8,10,24,27,32,34,t:6,13,15,17,30|;4,183;3;2;3;1;h;5;L1200-01;h5;100;1;O09;2
346;S2736;TG101348 (SAR302503);O10;1;O;10;NA;h5;L2100-01;52468;936091-26-8;JAK;100;1905923611;<1;NA;http://www.selleckchem.com/products/tg-101348.html;TG-101348 (SAR302503) is a selective inhibitor of JAK2 with IC50 of 3 nM, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 1/2.;JAK/STAT;C27H36N6O3S;Free Base;N/A;CC1=C(NC2=CC=CC(=C2)S(=O)(=O)NC(C)(C)C)N=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1 |c:1,6,8,35,38,t:4,19,22,24|;5,123;5;3;11;9;h;5;L2100-01;h5;100;1;O10;2
347;S1100;MLN8054;O11;1;O;11;NA;h6;L1200-01;47686;869363-13-3;Aurora Kinase;95;1992198968;<1;NA;http://www.selleckchem.com/products/MLN8054.html;MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.;Others;C25H15ClF2N4O2;Free Base;N/A;OC(=O)C1=CC=C(NC2=NC3=C(CN=C(C4=CC(Cl)=CC=C34)C3=C(F)C=CC=C3F)C=N2)C=C1 |c:13,18,24,27,29,33,36,t:3,5,8,10,15,20|;6,192;4;1;4;1;h;6;L1200-01;h6;100;1;O11;2
348;S2851;Baricitinib (LY3009104, INCB028050);O12;1;O;12;NA;h6;L2100-01;37142;1187594-09-7;JAK;74;199235367;<1;NA;http://www.selleckchem.com/products/baricitinib-ly3009104.html;Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3.;Epigenetics;C16H17N7O2S;Free Base;INCB 28050;CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |c:14,16,21,23,26,t:19|;0,36;5;1;5;9;h;6;L2100-01;h6;100;1;O12;2
349;S1109;BI 2536;O13;1;O;13;NA;h7;L1200-01;52166;755038-02-9;PLK;21;4025610551;<1;NA;http://www.selleckchem.com/products/BI-2536.html;BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.;Others;C28H39N7O3;Free Base;N/A;CC[C@H]1N(C2CCCC2)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC3CCN(C)CC3)=NC=C2N(C)C1=O |r,c:16,18,33,35,t:10,14|;3,548;5;2;7;1;h;7;L1200-01;h7;100;1;O13;2
350;S7037;Wnt-C59 (C59);O14;1;O;14;NA;h7;L2100-01;37945;1243243-89-1;Wnt/beta-catenin;76;2002898933;<1;NA;http://www.selleckchem.com/products/wnt-c59-c59.html;Wnt-C59 (C59) is a PORCN inhibitor for Wnt3A-mediated activation of a multimerized TCF-binding site driving luciferase with IC50 of 74 pM.;Stem Cells &  Wnt;C25H21N3O;Free Base;N/A;CC1=NC=CC(=C1)C1=CC=C(CC(=O)NC2=CC=C(C=C2)C2=CC=CN=C2)C=C1 |c:3,5,18,20,25,27,30,t:1,8,10,16,23|;3,667;3;1;5;9;h;7;L2100-01;h7;100;1;O14;2
351;S1133;Alisertib (MLN8237);O15;1;O;15;NA;h8;L1200-01;51892;1028486-01-2;Aurora Kinase;27;520311416;<1;NA;http://www.selleckchem.com/products/MLN8237.html;Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.;Others;C27H20ClFN4O4;Free Base;Alisertib;COC1=C(C=CC(NC2=NC3=C(CN=C(C4=C3C=CC(Cl)=C4)C3=C(OC)C=CC=C3F)C=N2)=C1)C(O)=O |c:4,13,15,18,21,24,28,30,34,36,t:2,8,10|;5,954;6;1;6;1;h;8;L1200-01;h8;100;1;O15;2
352;S7195;RKI-1447;O16;1;O;16;NA;h8;L2100-01;32637;1342278-01-6;ROCK;65;1991604621;<1;NA;http://www.selleckchem.com/products/rki-1447.html;RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.;Cell Cycle;C16H14N4O2S;Free Base;N/A;OC1=CC(CNC(=O)NC2=NC(=CS2)C2=CC=NC=C2)=CC=C1 |c:11,17,19,21,23,t:1,9,15|;2,081;3;3;4;9;h;8;L2100-01;h8;100;1;O16;2
353;S1154;SNS-314 Mesylate;O17;1;O;17;NA;h9;L1200-01;52704;1146618-41-8;Aurora Kinase;105;1992258652;6;11,38433515;http://www.selleckchem.com/products/SNS-314.html;SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.;Others;C19H19ClN6O4S3;Mesylate;N/A;CS(O)(=O)=O.ClC1=CC=CC(NC(=O)NC2=NC=C(CCNC3=NC=NC4=C3SC=C4)S2)=C1 |c:7,23,25,29,33,t:5,14,16,21|;3,539;4;3;6;1;h;9;L1200-01;h9;100;1;O17;2
354;S7337;SH-4-54;O18;1;O;18;NA;h9;L2100-01;61059;1456632-40-8;STAT;100;1637760199;<1;NA;http://www.selleckchem.com/products/sh-4-54.html;SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively.;JAK/STAT;C29H27F5N2O5S;Free Base;N/A;CN(CC(=O)N(CC1=CC=C(C=C1)C1CCCCC1)C1=CC=C(C=C1)C(O)=O)S(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F |c:9,11,23,25,34,42,t:7,21,38|;6,221;4;0;9;9;h;9;L2100-01;h9;100;1;O18;2
355;S1178;Regorafenib (BAY 73-4506);O19;1;O;19;NA;h10;L1200-01;48282;755037-03-7;c-Kit, Raf, VEGFR;97;200903028;<1;NA;http://www.selleckchem.com/products/BAY-73-4506.html;Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFR_, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.;Protein Tyrosine Kinase;C21H15ClF4N4O3;Free Base;BAY 73-4506;CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 |c:22,29,31,33,t:4,8,11,17,19|;4,381;4;3;6;1;h;10;L1200-01;h10;100;1;O19;2
356;S7566;IM-12;O20;1;O;20;NA;h10;L2100-01;37741;1129669-05-1;GSK-3;75;1987228743;<1;NA;http://www.selleckchem.com/products/im-12.html;IM-12 is a selective GSK-3_ inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling. ;PI3K/Akt/mTOR;C22H20FN3O2;Free Base;N/A;CN1C(=O)C(NCCC2=CC=C(F)C=C2)=C(C1=O)C1=C(C)NC2=C1C=CC=C2 |c:13,15,20,24,27,29,t:8,10|;3,074;2;2;5;9;h;10;L2100-01;h10;100;1;O20;2
357;S1230;Flavopiridol (Alvocidib);O21;1;O;21;NA;h11;L1200-01;401.84;146426-40-6;CDK;15;3732828987;<1;NA;http://selleckchem.com/products/Flavopiridol.html;Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.;Cell Cycle;C21H20ClNO5;free base;Alvocidib;[H][C@@]1(CCN(C)C[C@H]1O)C1=C2OC(=CC(=O)C2=C(O)C=C1O)C1=C(Cl)C=CC=C1 |r,c:10,13,21,25,28,30,t:18|;3,108;2;3;2;1;h;11;L1200-01;h11;100;1;O21;2
358;NA;DMSO;O22;1;O;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;O22;2
359;NA;DMSO;O23;1;O;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;1;NA;NA;DMSO-source;1;100;1;O23;2
360;NA;DMSO;O24;1;O;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;1;O24;2
361;S1274;BX-795;P01;1;P;1;NA;h1;L1200-02;59147;702675-74-9;PDK-1, IKK;100;1690702825;<1;NA;http://www.selleckchem.com/products/bx-795.html;BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3_ more than 100-fold selectivity observed for PDK1.;PI3K/Akt/mTOR;C23H26IN7O2S;Free Base;N/A;IC1=CN=C(NC2=CC(NC(=O)N3CCCC3)=CC=C2)N=C1NCCCNC(=O)C1=CC=CS1 |c:17,19,22,34,t:1,3,6,32|;3,704;4;4;9;2;h;1;L1200-02;h1;100;1;P01;2
362;S7566;IM-12;P02;1;P;2;NA;h1;L1200-05;37741;1129669-05-1;GSK-3;75;1987228743;<1;NA;http://www.selleckchem.com/products/im-12.html;IM-12 is a selective GSK-3_ inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.;PI3K/Akt/mTOR;C22H20FN3O2;Free Base;N/A;CN1C(=O)C(NCCC2=CC=C(F)C=C2)=C(C1=O)C1=C(C)NC2=C1C=CC=C2 |c:13,15,20,24,27,29,t:8,10|;3,074;2;2;5;5;h;1;L1200-05;h1;100;1;P02;2
363;S1392;Pelitinib (EKB-569);P03;1;P;3;NA;h2;L1200-02;46792;257933-82-7;EGFR;13;2778252693;<1;NA;http://www.selleckchem.com/products/Pelitinib.html;Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Phase2.;Protein Tyrosine Kinase;C24H23ClFN5O2;Free Base;WAY-EKB 569;CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC(Cl)=C(F)C=C1 |c:3,14,16,19,23,33,t:27,30|;4,455;3;2;8;2;h;2;L1200-02;h2;100;1;P03;2
364;NA;DMSO;P04;1;P;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;P04;2
365;S1474;GSK429286A;P05;1;P;5;NA;h3;L1200-02;43237;864082-47-3;ROCK;87;2012165506;<1;NA;http://www.selleckchem.com/products/GSK429286A.html;GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.;Cell Cycle;C21H16F4N4O2;Free Base;N/A;CC1=C(C(CC(=O)N1)C1=CC=C(C=C1)C(F)(F)F)C(=O)NC1=C(F)C=C2NN=CC2=C1 |c:11,13,23,29,32,t:1,9,26|;3,033;3;3;4;2;h;3;L1200-02;h3;100;1;P05;2
366;S7747;Ro-3306;P06;1;P;6;NA;h3;L1200-05;351.45;872573-93-8;CDK;13;3698961445;<1;NA;http://www.selleckchem.com/products/ro-3306.html;RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.;Cell Cycle;C18H13N3OS2;Free Base;N/A;O=C1N=C(NCC2=CC=CS2)S\C1=C/C1=CC=C2N=CC=CC2=C1 |c:8,20,22,25,t:2,6,16,18|;3,712;3;1;4;5;h;3;L1200-05;h3;100;1;P06;2
367;S1524;AT7519;P07;1;P;7;NA;h4;L1200-02;38224;844442-38-2;CDK;10;2616157388;<1;NA;http://www.selleckchem.com/products/AT7519.html;AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. Phase 2.;Cell Cycle;C16H17Cl2N5O2;Free Base;N/A;ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 |c:3,6,15,t:1,12|;1,599;3;4;4;2;h;4;L1200-02;h4;100;1;P07;2
368;NA;DMSO;P08;1;P;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;P08;2
369;S1555;AZD8055;P09;1;P;9;NA;h5;L1200-02;46554;1009298-09-2;mTOR;50;1074021566;<1;NA;http://www.selleckchem.com/products/AZD8055.html;AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (_1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.;PI3K/Akt/mTOR;C25H31N5O4;Free Base;N/A;COC1=C(CO)C=C(C=C1)C1=NC2=C(C=C1)C(=NC(=N2)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C |r,c:2,6,8,13,15,18,20,t:11|;3,274;6;1;5;2;h;5;L1200-02;h5;100;1;P09;2
370;S7953;ETC-1002;P10;1;P;10;NA;h5;L1200-05;34449;738606-46-7;AMPK;68;14928;<1;NA;http://selleckchem.com/products/etc-1002.html;ETC-1002,also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).;PI3K/Akt/mTOR;C19H36O5;Free Base;Bempedoic acid|ESP-55016;CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O;5,18;2;1;14;5;h;5;L1200-05;h5;100;1;P10;2
371;S1573;Fasudil (HA-1077) HCl;P11;1;P;11;NA;h6;L1200-02;32783;105628-07-7;ROCK;5;1525180734;65;198,2734954;http://www.selleckchem.com/products/Fasudil-HCl(HA-1077).html;Fasudil (HA-1077) HCl is a potent inhibitor of ROCK-II, PKA,  PKG,  PKC, and MLCK with Ki of 0.33 _M, 1.6 _M, 1.6 _M, 3.3 _M and 36 _M in cell-free assays, respectively.;Cell Cycle;C14H18ClN3O2S;Hydrochloride;AT-877;Cl.O=S(=O)(N1CCCNCC1)C1=C2C=CN=CC2=CC=C1 |c:11,13,15,18,20|;0,57;3;1;2;2;h;6;L1200-02;h6;100;1;P11;2
372;NA;DMSO;P12;1;P;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;P12;2
373;S2111;Lapatinib;P13;1;P;13;NA;h7;L1200-02;58106;231277-92-2;EGFR, HER2;100;1720992669;<1;NA;http://www.selleckchem.com/products/lapatinib.html;Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.;Protein Tyrosine Kinase;C29H26ClFN4O4S;Free Base;N/A;CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1 |c:10,18,31,34,38,42,t:8,14,16,20,23,25,29|;6,041;6;2;11;2;h;7;L1200-02;h7;100;1;P13;2
374;S8032;PRT062607 (P505-15, BIIB057) HCl;P14;1;P;14;NA;h7;L1200-05;42991;1370261-97-4,1370261-96-3(free base);Syk;86;2000418692;86;200,0418692;https://www.selleckchem.com/products/prt062607-p505-15-hcl.html;PRT062607 (P505-15, BIIB057) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.;Angiogenesis;C19H24ClN9O;HCl;N/A;Cl.N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC2=CC(=CC=C2)N2N=CC=N2)=N1 |r,c:20,22,26,28,30,t:9,11,18|;2,033;5;4;6;5;h;7;L1200-05;h7;100;1;P14;2
375;S2192;AZD8931 (Sapitinib);P15;1;P;15;NA;h8;L1200-02;47393;848942-61-0;EGFR, HER2;40;8440064989;<1;NA;http://www.selleckchem.com/products/AZD8931.html;AZD8931 (Sapitinib) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.;Protein Tyrosine Kinase;C23H25ClFN5O3;Free Base;N/A;CNC(=O)CN1CCC(CC1)OC1=C(OC)C=C2N=CN=C(NC3=C(F)C(Cl)=CC=C3)C2=C1 |c:13,19,24,28,30,34,t:17,21|;3,485;5;2;7;2;h;8;L1200-02;h8;100;1;P15;2
376;NA;DMSO;P16;1;P;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;P16;2
377;S2214;AZ 960;P17;1;P;17;NA;h9;L1200-02;35436;905586-69-8;JAK;71;2003612146;<1;NA;http://www.selleckchem.com/products/AZ-960.html;AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.;JAK/STAT;C18H16F2N6;Free Base;N/A;C[C@H](NC1=NC(NC2=NNC(C)=C2)=C(F)C=C1C#N)C1=CC=C(F)C=C1 |r,c:11,16,26,t:3,7,13,21,23|;4,495;2;3;5;2;h;9;L1200-02;h9;100;1;P17;2
378;NA;DMSO;P18;1;P;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;P18;2
379;S2231;Telatinib;P19;1;P;19;NA;h10;L1200-02;40983;332012-40-5;VEGFR, PDGFR, c-Kit;82;2000829612;<1;NA;http://www.selleckchem.com/products/Telatinib-BAY-57-9352.html;Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFR_ with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. Phase 2.;Protein Tyrosine Kinase;C20H16ClN5O3;Free Base;N/A;CNC(=O)C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C3=C2OC=C3)=C1 |c:6,21,24,28,30,t:4,11,13,16,18|;3,861;6;2;6;2;h;10;L1200-02;h10;100;1;P19;2
380;NA;DMSO;P20;1;P;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;P20;2
381;S2391;Quercetin;P21;1;P;21;NA;h11;L1200-02;30224;117-39-5;PI3K, PKC, Src, Sirtuin;61;2018263632;<1;NA;http://www.selleckchem.com/products/Quercetin(Sophoretin).html;Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 _M. Phase 4.;Epigenetics;C15H10O7;Free Base;Meletin, Quercetine;OC1=CC(O)=C2C(=O)C(O)=C(OC2=C1)C1=CC=C(O)C(O)=C1 |c:9,13,22,t:1,4,16,18|;1,63;2;5;1;2;h;11;L1200-02;h11;100;1;P21;2
382;NA;DMSO;P22;1;P;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;1;P22;2
383;NA;DMSO;P23;1;P;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;2;NA;NA;DMSO-source;1;100;1;P23;2
384;NA;DMSO;P24;1;P;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;1;P24;2
385;S2406;Chrysophanic Acid;A01;2;A;1;NA;a1;L1200-03;25424;481-74-3;EGFR, mTOR;5;1966645689;<1;NA;http://www.selleckchem.com/products/Chrysophanic-acid-Chrysophanol.html;Chrysophanic acid (Chrysophanol), a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor.;Protein Tyrosine Kinase;C15H10O4;Free Base;Chrysophanol, NSC 37132, NSC 646567;CC1=CC2=C(C(O)=C1)C(=O)C1=C(O)C=CC=C1C2=O |c:3,6,11,14,16,t:1|;2,81;2;2;0;3;a;1;L1200-03;a1;100;2;A01;3
386;S7582;Anacardic Acid;A02;2;A;2;NA;a2;L1200-05;348.52;16611-84-0;Histone Acetyltransferase;69;1979800298;<1;NA;http://www.selleckchem.com/products/anacardic-acid.html;Anacardic Acid is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases, which also has antibacterial activity, antimicrobial activity,  prostaglandin synthase inhibition, and tyrosinase and lipoxygenase inhibition.;Epigenetics;C22H36O3;Free Base;6-pentadecylsalicylic Acid;CCCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O |c:17,20,t:15|;8,09;1;1;15;5;a;2;L1200-05;a2;100;2;A02;3
387;S2626;LY2603618;A03;2;A;3;NA;a2;L1200-03;4363;911222-45-2;Chk;13;2979601192;<1;NA;http://www.selleckchem.com/products/LY2603618-IC-83.html;LY2603618 is a selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. Phase 2.;Cell Cycle;C18H22BrN5O3;Free Base;N/A;CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1 |r,c:9,24,27,t:1,3,20|;1,58;5;3;5;3;a;2;L1200-03;a2;100;2;A03;3
388;NA;DMSO;A04;2;A;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;A04;3
389;S2672;PF-00562271;A05;2;A;5;NA;a3;L1200-03;66566;939791-38-5;FAK;14;2103175795;<1;NA;http://www.selleckchem.com/products/pf-00562271.html;PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.;Angiogenesis;C27H26F3N7O6S2;Besylate;N/A;OS(=O)(=O)C1=CC=CC=C1.CN(C1=C(CNC2=C(C=NC(NC3=CC=C4NC(=O)CC4=C3)=N2)C(F)(F)F)C=CC=N1)S(C)(=O)=O |c:6,8,12,18,31,33,40,42,t:4,16,22,24|;3,653;6;3;9;3;a;3;L1200-03;a3;100;2;A05;3
390;S7752;SC1;A06;2;A;6;NA;a4;L1200-05;550.53;839707-37-8;ERK;100;18164;<1;NA;http://selleckchem.com/products/pluripotin-sc1.html;Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal.;MAPK;C27H25F3N8O2;Free Base;N/A;CN1N=C(C)C=C1NC1=NC=C2CN(C(=O)N(C)C2=N1)C1=CC(NC(=O)C2=CC=CC(=C2)C(F)(F)F)=CC=C1C |c:5,20,31,33,39,41,t:2,9,11,23,29|;4,789;5;2;6;5;a;4;L1200-05;a4;100;2;A06;3
391;S2688;R547;A07;2;A;7;NA;a4;L1200-03;44145;741713-40-6;CDK;60;1359157322;<1;NA;http://www.selleckchem.com/products/r547.html;R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3_/_, while inactive to other kinases. Phase 1.;Cell Cycle;C18H21F2N5O4S;Free Base;N/A;COC1=CC=C(F)C(F)=C1C(=O)C1=C(N)N=C(NC2CCN(CC2)S(C)(=O)=O)N=C1 |c:8,13,30,t:2,4,16|;1,133;6;2;6;3;a;4;L1200-03;a4;100;2;A07;3
392;NA;DMSO;A08;2;A;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;A08;3
393;S2718;TAK-901;A09;2;A;9;NA;a5;L1200-03;50464;934541-31-8;Aurora Kinase;101;200142676;<1;NA;http://www.selleckchem.com/products/tak-901.html;TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1.;Cell Cycle;C28H32N4O3S;Free Base;N/A;CCS(=O)(=O)C1=CC=CC(=C1)C1=CC(C(=O)NC2CCN(C)CC2)=C(C)C2=C1C1=C(N2)N=CC(C)=C1 |c:7,9,28,31,35,38,t:5,12,25|;4,056;4;2;5;3;a;5;L1200-03;a5;100;2;A09;3
394;S7964;PLX7904;A10;2;A;10;NA;a6;L1200-05;512.53;1393465-84-3;Raf;100;19511;<1;NA;http://selleckchem.com/products/plx7904.html;PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. It is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells.;MAPK;C24H22F2N6O3S;Free Base;PB04;CCN(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CN=C(N=C2)C2CC2)=C1F |c:21,29,31,37,t:8,10,16,19,23,27|;2,291;6;2;8;5;a;6;L1200-05;a6;100;2;A10;3
395;S2736;TG101348 (SAR302503);A11;2;A;11;NA;a6;L1200-03;52468;936091-26-8;JAK;100;1905923611;<1;NA;http://www.selleckchem.com/products/tg-101348.html;Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.;JAK/STAT;C27H36N6O3S;Free Base;N/A;CC1=C(NC2=CC=CC(=C2)S(=O)(=O)NC(C)(C)C)N=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1 |c:1,6,8,35,38,t:4,19,22,24|;5,123;5;3;11;3;a;6;L1200-03;a6;100;2;A11;3
396;NA;DMSO;A12;2;A;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;A12;3
397;S2753;Tivantinib (ARQ 197);A13;2;A;13;NA;a7;L1200-03;369.42;905854-02-6;c-Met;73;1976070597;<1;NA;http://www.selleckchem.com/products/arq-197.html;Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 _M in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFR_ or FGFR1/4. Phase 3.;Protein Tyrosine Kinase;C23H19N3O2;Free Base;N/A;[H][C@]1(C(=O)NC(=O)[C@@]1([H])C1=CN2CCCC3=CC=CC1=C23)C1=CNC2=C1C=CC=C2 |r,c:18,21,28,31,33,t:10,16,25|;3,52;2;2;2;3;a;7;L1200-03;a7;100;2;A13;3
398;S8036;Butein;A14;2;A;14;NA;a8;L1200-05;27225;487-52-5;EGFR;55;202020202;<1;NA;https://www.selleckchem.com/products/butein.html;Butein, a plant polyphenol isolated from <i>Rhus verniciflua</i>, is able to inhibit the activation of protein tyrosine kinase, NF-_B and STAT3, also inhibits EGFR.;Protein Tyrosine Kinase;C15H12O5;Free Base;N/A;OC1=CC(O)=C(C=C1)C(=O)\C=C\C1=CC(O)=C(O)C=C1 |c:4,6,19,t:1,13,16|;2,734;1;4;3;5;a;8;L1200-05;a8;100;2;A14;3
399;S2774;MK-2461;A15;2;A;15;NA;a8;L1200-03;49555;917879-39-1;c-Met, FGFR, PDGFR;99;1997780244;<1;NA;http://www.selleckchem.com/products/mk-2461.html;"MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFR_, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2. .";Protein Tyrosine Kinase;C24H25N5O5S;Free Base;N/A;CN(C[C@@H]1COCCO1)S(=O)(=O)NC1=CC2=C(C=C1)C=CC1=C(C=C(C=N1)C1=CN(C)N=C1)C2=O |r,c:16,18,21,25,27,34,t:14,23,30|;0,924;7;1;6;3;a;8;L1200-03;a8;100;2;A15;3
400;NA;DMSO;A16;2;A;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;A16;3
401;S2807;Dabrafenib (GSK2118436);A17;2;A;17;NA;a9;L1200-03;51956;1195765-45-7;Raf;30;577411656;<1;NA;http://www.selleckchem.com/products/dabrafenib-gsk2118436a.html;Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.;MAPK;C23H20F3N5O2S2;Free Base;N/A;CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1 |c:6,13,15,18,26,29,31,34,36,t:4,10|;5,377;5;2;6;3;a;9;L1200-03;a9;100;2;A17;3
402;NA;DMSO;A18;2;A;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;A18;3
403;S2824;TPCA-1;A19;2;A;19;NA;a10;L1200-03;27929;507475-17-4;IKK;56;2005084321;<1;NA;http://www.selleckchem.com/products/tpca-1.html;TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-_B pathway, exhibits 22-fold selectivity over IKK-1.;NF-_B;C12H10FN3O2S;Free Base;N/A;NC(=O)NC1=C(C=C(S1)C1=CC=C(F)C=C1)C(N)=O |c:6,15,t:4,10,12|;1,544;2;3;3;3;a;10;L1200-03;a10;100;2;A19;3
404;NA;DMSO;A20;2;A;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;A20;3
405;S2882;IKK-16 (IKK Inhibitor VII);A21;2;A;21;NA;a11;L1200-03;48363;873225-46-8;IKK;97;2005665488;<1;NA;http://www.selleckchem.com/products/ikk-16.html;IKK-16 (IKK Inhibitor VII) is a selective I_B kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM in cell-free assays, respectively.;NF-_B;C28H29N5OS;Free Base;N/A;O=C(N1CCC(CC1)N1CCCC1)C1=CC=C(NC2=NC=CC(=N2)C2=CC3=CC=CC=C3S2)C=C1 |c:22,24,31,33,38,t:15,17,20,27,29|;5,208;3;1;5;3;a;11;L1200-03;a11;100;2;A21;3
406;NA;DMSO;A22;2;A;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;A22;3
407;NA;DMSO;A23;2;A;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;A23;3
408;NA;DMSO;A24;2;A;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;A24;3
409;S2904;PF-477736;B01;2;B;1;NA;a1;L1200-04;41948;952021-60-2;Chk;6;1430342329;<1;NA;http://www.selleckchem.com/products/pf-477736.html;PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with Ki of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.;Cell Cycle;C22H25N7O2;Free Base;PF-00477736;CN1C=C(C=N1)C1=C2C=NNC(=O)C3=C2C(N1)=CC(NC(=O)[C@H](N)C1CCCCC1)=C3 |r,c:2,4,7,9,14,19,33|;2,089;4;4;4;4;a;1;L1200-04;a1;100;2;B01;3
410;S1049;Y-27632 2HCl;B02;2;B;2;NA;a1;L2100-01;32026;129830-38-2;ROCK;64;1998376319;14;4371448198;http://www.selleckchem.com/products/Y-27632.html;Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.;Others;C14H23Cl2N3O;Dihydrochloric;N/A;Cl.Cl.C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)NC1=CC=NC=C1 |r,c:15,17,t:13|;1,871;2;2;3;9;a;1;L2100-01;a1;100;2;B02;3
411;S3026;Piceatannol;B03;2;B;3;NA;a2;L1200-04;24424;10083-24-6;Syk;48;1965280052;<1;NA;http://www.selleckchem.com/products/piceatannol.html;Piceatannol, a natural stilbene, is a selective Syk inhibitor and ~10-fold selectivity versus Lyn.;Angiogenesis;C14H12O4;Free Base;N/A;OC1=CC(O)=CC(\C=C\C2=CC=C(O)C(O)=C2)=C1 |c:4,15,17,t:1,9,11|;2,848;0;4;2;4;a;2;L1200-04;a2;100;2;B03;3
412;S1262;Avagacestat (BMS-708163);B04;2;B;4;NA;a2;L2100-01;52088;1146699-66-2;Gamma-secretase;104;1996621103;<1;NA;http://www.selleckchem.com/products/BMS-708163.html;Avagacestat (BMS-708163) is a potent, selective, orally bioavailable _-secretase inhibitor of A_40 and A_42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2.;Proteases;C20H17ClF4N4O4S;Free Base;N/A;NC(=O)[C@@H](CCC(F)(F)F)N(CC1=C(F)C=C(C=C1)C1=NOC=N1)S(=O)(=O)C1=CC=C(Cl)C=C1 |r,c:12,15,17,23,34,t:20,29,31|;3,364;6;1;10;9;a;2;L2100-01;a2;100;2;B04;3
413;S7000;AP26113;B05;2;B;5;NA;a3;L1200-04;52901;1197958-12-5;ALK;45;8506455455;<1;NA;http://www.selleckchem.com/products/ap26113.html;AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.;Protein Tyrosine Kinase;C26H34ClN6O2P;Free Base;N/A;COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N(C)C |c:4,6,19,21,27,t:2,10,12,17|;5,126;6;2;8;4;a;3;L1200-04;a3;100;2;B05;3
414;S1590;TWS119;B06;2;B;6;NA;a3;L2100-01;31833;601514-19-6;GSK-3;64;2010492256;<1;NA;http://www.selleckchem.com/products/TWS119.html;"TWS119 is a GSK-3_ inhibitor with IC50 of 30 nM; capable of inducing neuronal differentiation and may be useful to stem cell biology.";PI3K/Akt/mTOR;C18H14N4O2;Free Base;N/A;NC1=CC(=CC=C1)C1=CC2=C(N1)N=CN=C2OC1=CC=CC(O)=C1 |c:3,5,10,14,16,22,25,t:1,8,20|;3,464;3;3;3;9;a;3;L2100-01;a3;100;2;B06;3
415;S7039;PD168393;B07;2;B;7;NA;a4;L1200-04;36922;194423-15-9;EGFR;74;2004225123;<1;NA;https://www.selleckchem.com/products/pd168393.html;"PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773; inactive against insulin, PDGFR, FGFR and PKC.";Protein Tyrosine Kinase;C17H13BrN4O;Free Base;N/A;BrC1=CC(NC2=NC=NC3=CC=C(NC(=O)C=C)C=C23)=CC=C1 |c:7,21,23,t:1,5,9,11,18|;4,043;3;2;4;4;a;4;L1200-04;a4;100;2;B07;3
416;S2214;AZ 960;B08;2;B;8;NA;a4;L2100-01;35436;905586-69-8;JAK;71;2003612146;<1;NA;http://www.selleckchem.com/products/AZ-960.html;AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.;JAK/STAT;C18H16F2N6;Free Base;N/A;C[C@H](NC1=NC(NC2=NNC(C)=C2)=C(F)C=C1C#N)C1=CC=C(F)C=C1 |r,c:11,16,26,t:3,7,13,21,23|;4,495;2;3;5;9;a;4;L2100-01;a4;100;2;B08;3
417;S7080;RN486;B09;2;B;9;NA;a5;L1200-04;606.69;1242156-23-5;BTK;62;1021938717;<1;NA;http://www.selleckchem.com/products/rn486.html;RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.;Angiogenesis;C35H35FN6O3;Free Base;N/A;CN1CCN(CC1)C1=CN=C(NC2=CC(=CN(C)C2=O)C2=CC=CC(N3C=CC4=CC(=CC(F)=C4C3=O)C3CC3)=C2CO)C=C1 |c:15,24,28,32,35,44,49,t:8,10,13,22,30|;3,061;3;2;7;4;a;5;L1200-04;a5;100;2;B09;3
418;S2660;MK-0752;B10;2;B;10;NA;a5;L2100-01;4429;471905-41-6;Gamma-secretase;89;2009482953;<1;NA;http://www.selleckchem.com/products/mk-0752.html;MK-0752 is a moderately potent _-secretase inhibitor, which reduces A_40 production with IC50 of 5 nM. Phase 1/2.;Proteases;C21H21ClF2O4S;Free Base;N/A;OC(=O)CC[C@H]1CC[C@@](CC1)(C1=C(F)C=CC(F)=C1)S(=O)(=O)C1=CC=C(Cl)C=C1 |r,c:12,15,18,29,t:24,26|;5,615;3;0;6;9;a;5;L2100-01;a5;100;2;B10;3
419;S7106;AZD3463;B11;2;B;11;NA;a6;L1200-04;44895;1356962-20-3;ALK;24;5345806883;<1;NA;http://www.selleckchem.com/products/azd3463.html;AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.;Protein Tyrosine Kinase;C24H25ClN6O;Free Base;N/A;COC1=C(NC2=NC(C3=CNC4=C3C=CC=C4)=C(Cl)C=N2)C=CC(=C1)N1CCC(N)CC1 |c:2,11,14,16,21,24,26,t:5,8,18|;4,316;3;3;5;4;a;6;L1200-04;a6;100;2;B11;3
420;S2745;CHIR-98014;B12;2;B;12;NA;a6;L2100-01;486.31;252935-94-7;GSK-3;8;1645041229;<1;NA;http://www.selleckchem.com/products/chir-98014.html;CHIR-98014 is a potent <b>GSK-3_/_</b> inhibitor with <b>IC50</b> of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.;PI3K/Akt/mTOR;C20H17Cl2N9O2;Free Base;N/A;NC1=NC(NCCNC2=NC=C(N3C=CN=C3)C(=N2)C2=CC=C(Cl)C=C2Cl)=CC=C1[N+]([O-])=O |c:13,15,18,26,29,31,t:1,8,10,21,23|;3,859;4;3;8;9;a;6;L2100-01;a6;100;2;B12;3
421;S7167;SSR128129E;B13;2;B;13;NA;a7;L1200-04;34631;848318-25-2;FGFR;69;1992434524;1;2,887586267;http://www.selleckchem.com/products/ssr128129e.html;SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 _M, while not affecting other related RTKs.;Angiogenesis;C18H15N2NaO4;Free Base;SSR;COC1=C2C=CC=CN2C(C(=O)C2=CC=C(N)C(=C2)C(=O)O[Na])=C1C |c:2,4,6,18,24,t:13,15|;2,802;4;1;5;4;a;7;L1200-04;a7;100;2;B13;3
422;S2867;WHI-P154;B14;2;B;14;NA;a7;L2100-01;3762;211555-04-3;JAK, EGFR;75;1993620415;<1;NA;http://www.selleckchem.com/products/whi-p154.html;WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 _M, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.;JAK/STAT;C16H14BrN3O3;Free Base;N/A;COC1=CC2=NC=NC(NC3=CC=C(O)C(Br)=C3)=C2C=C1OC |c:6,16,18,21,t:2,4,10,12|;3,95;4;2;4;9;a;7;L2100-01;a7;100;2;B14;3
423;S7208;GF109203X;B15;2;B;15;NA;a8;L1200-04;41248;133052-90-1;PKC;82;1987975175;<1;NA;http://www.selleckchem.com/products/gf109203x.html;GF109203X is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKC_, PKC_I, PKC_II, and PKC_ in cell-free assays, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.;TGF-beta/Smad;C25H24N4O2;Free Base;GO 6850;CN(C)CCCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CNC2=CC=CC=C12 |c:7,11,30,t:9,13,17,25,28,32|;3,557;2;2;6;4;a;8;L1200-04;a8;100;2;B15;3
424;S7086;IWR-1-endo;B16;2;B;16;NA;a8;L2100-01;40944;1127442-82-3;Wnt/beta-catenin;30;7327080891;<1;NA;http://www.selleckchem.com/products/iwr-1-endo.html;IWR-1 (endo-IWR 1) is a Wnt pathway inhibitor with IC50 of 180 nM, induces Axin2 protein levels and promotes _-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.;Stem Cells &  Wnt;C26H21N3O3;Free Base;IWR-1;[H][C@@]12[C@H]3C[C@H](C=C3)[C@]1(C)C(=O)N(C2=O)C1=CC=C(C=C1)C(=O)NC1=CC=CC2=C1N=CC=C2 |r,c:5,19,21,29,31,34,36,t:17,27|;3,075;4;1;3;9;a;8;L2100-01;a8;100;2;B16;3
425;S7271;FRAX597;B17;2;B;17;NA;a9;L1200-04;558.1;1286739-19-2;PAK;14;250851102;<1;NA;http://www.selleckchem.com/products/frax597.html;FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.;Cytoskeletal Signaling;C29H28ClN7OS;Free Base;N/A;CCN1C(=O)C(=CC2=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C12)C1=CC=C(C=C1Cl)C1=CN=CS1 |c:5,14,16,33,35,41,t:7,9,12,27,31,39|;5,166;4;1;6;4;a;9;L1200-04;a9;100;2;B17;3
426;S7198;BIO;B18;2;B;18;NA;a9;L2100-01;35617;667463-62-9;GSK-3;71;1993430104;<1;NA;http://www.selleckchem.com/products/bio.html;BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3_/_, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.;PI3K/Akt/mTOR;C16H10BrN3O2;Free Base;GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime;O\N=C1C2=CC=CC=C2NC/1=C1\C(=O)NC2=C1C=CC(Br)=C2 |c:5,7,17,20,23,t:3|;2,692;2;2;0;9;a;9;L2100-01;a9;100;2;B18;3
427;S7320;TG003;B19;2;B;19;NA;a10;L1200-04;24933;300801-52-9;CDK;6;2406449284;<1;NA;http://www.selleckchem.com/products/tg003.html;TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.;Cell Cycle;C13H15NO2S;Free Base;N/A;CCN1\C(SC2=C1C=C(OC)C=C2)=C\C(C)=O |c:5,12,t:8|;3,024;2;0;3;4;a;10;L1200-04;a10;100;2;B19;3
428;S7359;K02288;B20;2;B;20;NA;a10;L2100-01;35238;1431985-92-0;TGF-beta/Smad;70;1986491855;<1;NA;http://www.selleckchem.com/products/k02288.html;K02288 is a potent, and selective type I BMP receptor inhibitor with IC50 of 1.1, 1.8, 6.4 nM for ALK2, ALK1 and ALK6, showing weaker inhibition on other ALKs (3, 4, 5) and ActRIIA.;TGF-beta/Smad;C20H20N2O4;Free Base;N/A;COC1=CC(=CC(OC)=C1OC)C1=C(N)N=CC(=C1)C1=CC=CC(O)=C1 |c:4,8,13,16,18,23,26,t:2,21|;3,217;4;2;5;9;a;10;L2100-01;a10;100;2;B20;3
429;S7422;KN-62;B21;2;B;21;NA;a11;L1200-04;72184;127191-97-3;Ca2+/calmodulin-dependent protein kinase II (CaMKII);100;1385348554;<1;NA;http://www.selleckchem.com/products/kn-62.html;KN-62 is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.9 _M.;Others;C38H35N5O6S2;Free Base;N/A;CN([C@@H](CC1=CC=C(OS(=O)(=O)C2=C3C=CN=CC3=CC=C2)C=C1)C(=O)N1CCN(CC1)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC2=C1C=CN=C2 |r,c:12,14,16,19,21,24,38,40,48,50,53,55,t:4,6,36,46|;4,532;6;0;10;4;a;11;L1200-04;a11;100;2;B21;3
430;S7605;Filgotinib (GLPG0634);B22;2;B;22;NA;a11;L2100-01;4255;1206161-97-8;JAK;85;1997649824;<1;NA;http://www.selleckchem.com/products/filgotinib.html;Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.;JAK/STAT;C21H23N5O3S;Free Base;N/A;O=C(NC1=NN2C(C=CC=C2C2=CC=C(CN3CCS(=O)(=O)CC3)C=C2)=N1)C1CC1 |c:7,9,26,28,t:3,12,14|;2,461;5;1;5;9;a;11;L2100-01;a11;100;2;B22;3
431;NA;DMSO;B23;2;B;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;B23;3
432;NA;DMSO;B24;2;B;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;B24;3
433;S2542;Phenformin HCl;C01;2;C;1;NA;b1;L1200-03;24172;834-28-6;AMPK;48;1985768658;48;198,5768658;http://www.selleckchem.com/products/Phenformin-hydrochloride.html;Phenformin HCl is a hydrochloride salt of phenformin that is an anti-diabetic drug from the biguanide class.;PI3K/Akt/mTOR;C10H16ClN5;Hydrochloride;N/A;Cl.NC(=N)NC(=N)NCCC1=CC=CC=C1 |c:11,13,t:9|;1,339;0;3;6;3;b;1;L1200-03;b1;100;2;C01;3
434;S7605;Filgotinib (GLPG0634);C02;2;C;2;NA;b2;L1200-05;4255;1206161-97-8;JAK;85;1997649824;<1;NA;http://www.selleckchem.com/products/filgotinib.html;Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.;JAK/STAT;C21H23N5O3S;Free Base;N/A;O=C(NC1=NN2C(C=CC=C2C2=CC=C(CN3CCS(=O)(=O)CC3)C=C2)=N1)C1CC1 |c:7,9,26,28,t:3,12,14|;2,461;5;1;5;5;b;2;L1200-05;b2;100;2;C02;3
435;S2634;DCC-2036 (Rebastinib);C03;2;C;3;NA;b2;L1200-03;55359;1020172-07-9;Bcr-Abl;111;2005094023;<1;NA;http://www.selleckchem.com/products/dcc-2036.html;DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.;Angiogenesis;C30H28FN7O3;Free Base;N/A;CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C3=CC4=C(C=C3)N=CC=C4)C(C)(C)C)C=C2)=C1 |c:6,21,27,29,32,34,41,43,t:4,10,13,19,25|;5,14;6;3;7;3;b;2;L1200-03;b2;100;2;C03;3
436;NA;DMSO;C04;2;C;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;C04;3
437;S2673;Trametinib (GSK1120212);C05;2;C;5;NA;b3;L1200-03;61539;871700-17-3;MEK;22;3574968719;<1;NA;http://www.selleckchem.com/products/gsk1120212-(jtp-74057).html;Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.;MAPK;C26H23FIN5O4;Free Base;GSK212;CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1 |c:18,27,37,39,t:5,22,24,31|;3,176;4;2;5;3;b;3;L1200-03;b3;100;2;C05;3
438;S7774;SU6656;C06;2;C;6;NA;b4;L1200-05;371.45;330161-87-0;Src;74;1992192758;<1;NA;http://www.selleckchem.com/products/su6656.html;SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.;Angiogenesis;C19H21N3O3S;Free Base;N/A;CN(C)S(=O)(=O)C1=CC=C2NC(=O)\C(=C/C3=CC4=C(CCCC4)N3)C2=C1 |c:27,t:6,8,15,17|;2,616;3;2;3;5;b;4;L1200-05;b4;100;2;C06;3
439;S2689;WAY-600;C07;2;C;7;NA;b4;L1200-03;49459;1062159-35-6;mTOR;22;4448128753;<1;NA;http://www.selleckchem.com/products/way-600.html;"WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3K_ (>100-fold) and PI3K_ (>500-fold).";PI3K/Akt/mTOR;C28H30N8O;Free Base;N/A;C(N1CCC(CC1)N1N=CC2=C1N=C(N=C2N1CCOCC1)C1=CC2=C(NC=C2)C=C1)C1=CC=CN=C1 |c:9,11,14,16,31,34,39,41,t:26,28,37|;2,946;5;1;5;3;b;4;L1200-03;b4;100;2;C07;3
440;NA;DMSO;C08;2;C;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;C08;3
441;S2719;AMG-900;C09;2;C;9;NA;b5;L1200-03;50358;945595-80-2;Aurora Kinase;100;1985781802;<1;NA;http://www.selleckchem.com/products/amg-900.html;AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases than p38_, Tyk2, JNK2, Met and Tie2. Phase 1.;Cell Cycle;C28H21N7OS;Free Base;N/A;CC1=CSC(=C1)C1=NN=C(NC2=CC=C(OC3=C(C=CC=N3)C3=NC(N)=NC=C3)C=C2)C2=C1C=CC=C2 |c:4,19,21,27,29,32,35,38,40,t:1,7,9,12,14,17,24|;6,487;6;2;6;3;b;5;L1200-03;b5;100;2;C09;3
442;S7971;AZD3759;C10;2;C;10;NA;b6;L1200-05;459.9;1626387-80-1;EGFR;92;20004;<1;NA;http://selleckchem.com/products/azd3759.html;AZD3759 is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.;Protein Tyrosine Kinase;C22H23ClFN5O3;Free Base;N/A;COC1=C(OC(=O)N2CCN(C)C[C@H]2C)C=C2C(NC3=CC=CC(Cl)=C3F)=NC=NC2=C1 |r,c:2,22,25,28,30,33,t:16,20|;4,635;5;1;5;5;b;6;L1200-05;b6;100;2;C10;3
443;S2742;PHA-767491;C11;2;C;11;NA;b6;L1200-03;2497;942425-68-5;CDK;24;9611;<1;NA;http://www.selleckchem.com/products/pha-767491.html;PHA-767491 is a potent ATP-competitive dualÊCdc7/CDK9Êinhibitor withÊIC50Êof 10 nM and 34 nM in cell-free assays, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-_, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2.;Cell Cycle;C12H11N3O.HCl;hydrochloride;CAY10572;Cl.O=C1NCCC2=C1C=C(N2)C1=CC=NC=C1;1,252;2;2;1;3;b;6;L1200-03;b6;100;2;C11;3
444;NA;DMSO;C12;2;C;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;C12;3
445;S2755;Varlitinib;C13;2;C;13;NA;b7;L1200-03;46694;845272-21-1;EGFR;6;1284961665;<1;NA;http://www.selleckchem.com/products/arry334543.html;Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2.;Protein Tyrosine Kinase;C22H19ClN6O2S;Free Base;N/A;C[C@@H]1COC(NC2=CC3=C(C=C2)N=CN=C3NC2=CC(Cl)=C(OCC3=NC=CS3)C=C2)=N1 |r,c:8,10,13,15,28,32,34,t:6,19,22,26|;4,577;6;2;7;3;b;7;L1200-03;b7;100;2;C13;3
446;S8040;GDC-0349;C14;2;C;14;NA;b8;L1200-05;45255;1207360-89-1;mTOR;91;2010827533;<1;NA;https://www.selleckchem.com/products/gdc-0349.html;GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3K_ and other 266 kinases. Phase 1.;PI3K/Akt/mTOR;C24H32N6O3;Free Base;RG7603;CCNC(=O)NC1=CC=C(C=C1)C1=NC(N2CCOC[C@@H]2C)=C2CCN(CC2=N1)C1COC1 |r,c:8,10,30,t:6,13,23|;1,982;5;2;5;5;b;8;L1200-05;b8;100;2;C14;3
447;S2783;AZD2014;C15;2;C;15;NA;b8;L1200-03;46254;1009298-59-2;mTOR;38;8215505686;<1;NA;http://www.selleckchem.com/products/azd2014.html;"AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (_/_/_/_). Phase 2.";PI3K/Akt/mTOR;C25H30N6O3;Free Base;N/A;CNC(=O)C1=CC=CC(=C1)C1=CC=C2C(N=C(N=C2N2CCOC[C@@H]2C)N2CCOC[C@@H]2C)=N1 |r,c:6,8,13,16,18,36,t:4,11|;3,103;6;1;4;3;b;8;L1200-03;b8;100;2;C15;3
448;NA;DMSO;C16;2;C;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;C16;3
449;S2808;GDC-0068;C17;2;C;17;NA;b9;L1200-03;458;1001264-89-6;Akt;92;2008733624;<1;NA;http://www.selleckchem.com/products/gdc-0068.html;Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.;PI3K/Akt/mTOR;C24H32ClN5O2;Free Base;N/A;CC(C)NC[C@@H](C(=O)N1CCN(CC1)C1=C2[C@H](C)C[C@@H](O)C2=NC=N1)C1=CC=C(Cl)C=C1 |r,c:15,23,25,33,t:28,30|;3,102;3;2;6;3;b;9;L1200-03;b9;100;2;C17;3
450;NA;DMSO;C18;2;C;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;C18;3
451;S2842;SAR131675;C19;2;C;19;NA;b10;L1200-03;358.39;1433953-83-3;VEGFR;30;8371;<1;NA;http://selleckchem.com/products/sar131675.html;SAR131675 is a VEGFR3 inhibitor with IC50/Ki of 23 nM/12 nM in cell-free assays, about 50- and 10-fold more selective for VEGFR3 than VEGFR1/2, little activity against Akt1, CDKs, PLK1, EGFR, IGF-1R, c-Met, Flt2 etc.;Protein Tyrosine Kinase;C18H22N4O4;Free Base;N/A;CCN1C(N)=C(C(=O)NC)C(=O)C2=CC=C(N=C12)C#C[C@@](C)(O)COC |r,c:14,t:4,12,16|;0,769;4;2;6;3;b;10;L1200-03;b10;100;2;C19;3
452;NA;DMSO;C20;2;C;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;C20;3
453;S2890;PF-562271;C21;2;C;21;NA;b11;L1200-03;50749;717907-75-0;FAK;100;1970482177;<1;NA;http://www.selleckchem.com/products/pf-562271.html;PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.;Angiogenesis;C21H20F3N7O3S;Free Base;N/A;CN(C1=C(CNC2=C(C=NC(NC3=CC=C4NC(=O)CC4=C3)=N2)C(F)(F)F)C=CC=N1)S(C)(=O)=O |c:2,8,21,23,30,32,t:6,12,14|;2,491;6;3;8;3;b;11;L1200-03;b11;100;2;C21;3
454;NA;DMSO;C22;2;C;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;C22;3
455;NA;DMSO;C23;2;C;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;C23;3
456;NA;DMSO;C24;2;C;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;C24;3
457;S2911;Go 6983;D01;2;D;1;NA;b1;L1200-04;44251;133053-19-7;PKC;59;1333303202;<1;NA;http://www.selleckchem.com/products/go-6983.html;"Go 6983 is a pan-PKC inhibitor against for PKC_, PKC_, PKC_ and PKC_ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKC_ and inactive to PKC_.";TGF-beta/Smad;C26H26N4O3;Free Base;N/A;COC1=CC=C2N(CCCN(C)C)C=C(C2=C1)C1=C(C(=O)NC1=O)C1=CNC2=C1C=CC=C2 |c:13,16,30,33,35,t:2,4,19,27|;3,54;3;2;7;4;b;1;L1200-04;b1;100;2;D01;3
458;S1055;Enzastaurin (LY317615);D02;2;D;2;NA;b1;L2100-01;51561;170364-57-5;PKC;30;5818351079;<1;NA;http://www.selleckchem.com/products/Enzastaurin.html;Enzastaurin (LY317615) is a potent PKC_ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKC_, PKC_ and PKC_. Phase 3.;Neuronal Signaling;C32H29N5O2;Free Base;N/A;CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=NC=CC=C3)CC2)C2=CC=CC=C12 |c:2,6,30,32,40,t:4,8,12,20,28,38,42|;4,32;3;1;5;9;b;1;L2100-01;b1;100;2;D02;3
459;S3600;Schisandrin B (Sch B);D03;2;D;3;NA;b2;L1200-04;400.46;61281-37-6;ATM/ATR;80;19977;<1;NA;http://selleckchem.com/products/schisandrin-b.html;Schisandrin B is the most abundant dibenzocyclooctadiene lignan present in the traditional Chinese medicinal herb Schisandra chinensis (Turcz.) Baill.;PI3K/Akt/mTOR;C23H28O6;Free Base;N/A;COC1=CC2=C(C(OC)=C1OC)C1=C(C[C@@H](C)[C@@H](C)C2)C=C2OCOC2=C1OC |r,c:4,8,13,28,t:2,22|;5,067;6;0;4;4;b;2;L1200-04;b2;100;2;D03;3
460;S1378;Ruxolitinib (INCB018424);D04;2;D;4;NA;b2;L2100-01;30637;941678-49-5;JAK;61;1991056566;<1;NA;http://www.selleckchem.com/products/INCB18424.html;INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.;JAK/STAT;C17H18N6;Free Base;N/A;N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |r,c:11,13,18,20,23,t:16|;2,88;3;1;4;9;b;2;L2100-01;b2;100;2;D04;3
461;S7003;AZD2932;D05;2;D;5;NA;b3;L1200-04;447.49;883986-34-3;PDGFR;89;198887126;<1;NA;http://www.selleckchem.com/products/azd2932.html;AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFR_, Flt-3, and c-Kit, respectively.;Protein Tyrosine Kinase;C24H25N5O4;Free Base;N/A;COC1=C(OC)C=C2C(OC3=CC=C(CC(=O)NC4=CN(N=C4)C(C)C)C=C3)=NC=NC2=C1 |c:2,21,27,29,31,34,t:6,10,12,18|;3,65;7;1;8;4;b;3;L1200-04;b3;100;2;D05;3
462;S1594;Semagacestat (LY450139);D06;2;D;6;NA;b3;L2100-01;36144;425386-60-3;Gamma-secretase;72;1992031873;<1;NA;http://www.selleckchem.com/products/Semagacestat(LY450139).html;Semagacestat (LY450139) is a _-secretase blocker for A_42, A_40 and A_38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM. Phase 3.;Proteases;C19H27N3O4;Free Base;LY-450139, LY450139;CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=C(CCN(C)C1=O)C=CC=C2 |r,c:14,23,25|;0,632;3;3;5;9;b;3;L2100-01;b3;100;2;D06;3
463;S7041;CX-6258 HCl;D07;2;D;7;NA;b4;L1200-04;4984;1353859-00-3;Pim;57;1143659711;89;178,5714286;http://www.selleckchem.com/products/CX-6258.html;CX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3, respectively.;JAK/STAT;C26H25Cl2N3O3;hydrochloride;N/A;Cl.CN1CCCN(CC1)C(=O)C1=CC=CC(=C1)C1=CC=C(O1)\C=C1\C(=O)NC2=C1C=C(Cl)C=C2 |c:13,15,20,29,35,t:11,18,32|;4,416;3;1;3;4;b;4;L1200-04;b4;100;2;D07;3
464;S2215;DAPT (GSI-IX);D08;2;D;8;NA;b4;L2100-01;43246;208255-80-5;Gamma-secretase, Beta Amyloid;86;1988623225;<1;NA;http://www.selleckchem.com/products/DAPT-GSI-IX.html;DAPT (GSI-IX) is a novel _-secretase inhibitor, which inhibits A_ production with IC50 of 20 nM in HEK 293 cells.;Proteases;C23H26F2N2O4;Free Base;GSI-IX;C[C@H](NC(=O)CC1=CC(F)=CC(F)=C1)C(=O)N[C@H](C(=O)OC(C)(C)C)C1=CC=CC=C1 |r,c:9,12,28,30,t:6,26|;3,385;4;2;9;9;b;4;L2100-01;b4;100;2;D08;3
465;S7083;LDK378;D09;2;D;9;NA;b5;L1200-04;55814;1032900-25-6;ALK;20;3583330347;<1;NA;http://www.selleckchem.com/products/ldk378.html;Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.;Protein Tyrosine Kinase;C28H36ClN5O3S;Free Base;N/A;CC(C)OC1=C(NC2=NC(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC1 |c:4,13,15,26,32,t:7,11,23,29|;6,479;5;3;9;4;b;5;L1200-04;b5;100;2;D09;3
466;S2662;ICG-001;D10;2;D;10;NA;b5;L2100-01;54863;780757-88-2;Wnt/beta-catenin;100;1822722053;<1;NA;http://www.selleckchem.com/products/icg-001.html;ICG-001 antagonizes Wnt/_-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC50 of 3 _M, but is not the related transcriptional coactivator p300.;Stem Cells &  Wnt;C33H32N4O4;Free Base;N/A;[H][C@]12CN(CC3=CC=CC4=C3C=CC=C4)C(=O)[C@H](CC3=CC=C(O)C=C3)N1C(=O)CCN2C(=O)NCC1=CC=CC=C1 |r,c:7,9,12,14,26,43,45,t:5,21,23,41|;4,065;3;2;6;9;b;5;L2100-01;b5;100;2;D10;3
467;S7114;NU6027;D11;2;D;11;NA;b6;L1200-04;25128;220036-08-8;CDK;50;1989812162;<1;NA;http://www.selleckchem.com/products/nu6027.html;NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 _M/1.3 _M, 0.4 _M and 2.2 _M, enter cells more readily than the 6-aminopurine-based inhibitors.;Cell Cycle;C11H17N5O2;Free Base;N/A;NC1=NC(N)=C(N=O)C(OCC2CCCCC2)=N1 |c:17,t:1,4|;2,576;4;2;4;4;b;6;L1200-04;b6;100;2;D11;3
468;S2750;GW788388;D12;2;D;12;NA;b6;L2100-01;42548;452342-67-5;TGF-beta/Smad;15;3525430102;<1;NA;http://www.selleckchem.com/products/gw788388.html;GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, also inhibits TGF-_ type II receptor and activin type II receptor activities, but does not inhibit BMP type II receptor.;TGF-beta/Smad;C25H23N5O2;Free Base;N/A;O=C(NC1CCOCC1)C1=CC=C(C=C1)C1=NC=CC(=C1)C1=CNN=C1C1=NC=CC=C1 |c:12,14,19,21,27,32,34,t:10,17,24,30|;2,862;5;2;5;9;b;6;L2100-01;b6;100;2;D12;3
469;S7173;AVL-292;D13;2;D;13;NA;b7;L1200-04;42344;1202757-89-8;BTK;85;2007368222;<1;NA;http://www.selleckchem.com/products/avl-292.html;CC-292 (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.;Angiogenesis;C22H22FN5O3;Free Base;CC-292;COCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC(NC(=O)C=C)=CC=C3)=N2)C=C1 |c:24,26,28,31,t:5,7,10,12,17|;4,087;5;3;10;4;b;7;L1200-04;b7;100;2;D13;3
470;S2902;S-Ruxolitinib (INCB018424);D14;2;D;14;NA;b7;L2100-01;30637;941685-37-6;JAK;61;1991056566;5;1632013578;http://www.selleckchem.com/products/s-ruxolitinib.html;S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.;JAK/STAT;C17H18N6;Free Base;N/A;N#CC[C@@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |r,c:11,13,18,20,23,t:16|;2,88;3;1;4;9;b;7;L2100-01;b7;100;2;D14;3
471;S7209;GSK650394;D15;2;D;15;NA;b8;L1200-04;38245;890842-28-1;SGK;76;1987187868;<1;NA;http://www.selleckchem.com/products/gsk650394.html;GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively.;Others;C25H22N2O2;Free Base;N/A;OC(=O)C1=C(C=C(C=C1)C1=CNC2=NC=C(C=C12)C1=CC=CC=C1)C1CCCC1 |c:5,7,15,23,25,t:3,10,13,17,21|;5,573;2;1;4;4;b;8;L1200-04;b8;100;2;D15;3
472;S7092;SANT-1;D16;2;D;16;NA;b8;L2100-01;37349;304909-07-7;Smoothened;21;5622640499;<1;NA;http://www.selleckchem.com/products/sant-1.html;SANT-1 directly binds to Smoothened (Smo) receptor with Kd of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.;Stem Cells &  Wnt;C23H27N5;Free Base;N/A;CC1=NN(C(C)=C1\C=N\N1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1 |c:5,17,19,27,29,t:1,15,25|;3,759;2;0;5;9;b;8;L2100-01;b8;100;2;D16;3
473;S7284;CO-1686 (AVL-301);D17;2;D;17;NA;b9;L1200-04;55555;1374640-70-6;EGFR;100;1800018;<1;NA;http://www.selleckchem.com/products/co-1686.html;Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.;Protein Tyrosine Kinase;C27H28F3N7O3;Free Base;CNX-419, AVL-301;COC1=C(NC2=NC=C(C(NC3=CC=CC(NC(=O)C=C)=C3)=N2)C(F)(F)F)C=CC(=C1)N1CCN(CC1)C(C)=O |c:2,7,13,20,22,29,31,t:5,11|;4,334;5;3;9;4;b;9;L1200-04;b9;100;2;D17;3
474;S7207;Ro 31-8220 Mesylate;D18;2;D;18;NA;b9;L2100-01;553.65;138489-18-6;PKC;100;18062;<1;NA;http://selleckchem.com/products/ro-31-8220-mesylate.html;Ro 31-8220 is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-_, PKC-_I, PKC-_II, PKC-_, and PKC-_, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3_ and S6K1.;TGF-beta/Smad;C26H27N5O5S2;Mesylate;Bisindolylmaleimide IX Mesylate;CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(CCCSC(N)=N)C2=CC=CC=C12 |c:6,10,36,t:8,12,16,24,34,38|;3,452;2;2;7;9;b;9;L2100-01;b9;100;2;D18;3
475;S7334;ERK5-IN-1;D19;2;D;19;NA;b10;L1200-04;638.81;1435488-37-1;ERK;100;1565410685;<1;NA;http://www.selleckchem.com/products/erk5-in-1.html;ERK5-IN-1 is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.;MAPK;C36H46N8O3;Free Base;N/A;CCOC1=C(NC2=NC=C3N(C)C(=O)C4=C(C=CC=C4)N(C4CCCC4)C3=N2)C=CC(=C1)C(=O)N1CCC(CC1)N1CCN(C)CC1 |c:3,16,18,29,32,34,t:6,8,14|;4,794;5;1;7;4;b;10;L1200-04;b10;100;2;D19;3
476;S7435;AR-A014418;D20;2;D;20;NA;b10;L2100-01;30831;487021-52-3;GSK-3;62;2010962992;<1;NA;http://www.selleckchem.com/products/ar-a014418.html;AR-A014418 is an ATP-competitive, and selective GSK3_ inhibitor with IC50 and Ki of 104 nM and 38 nM, without significant inhibition on 26 other kinases tested.;PI3K/Akt/mTOR;C12H12N4O4S;Free Base;GSK-3_ Inhibitor VIII;COC1=CC=C(CNC(=O)NC2=NC=C(S2)[N+]([O-])=O)C=C1 |c:13,20,t:2,4,11|;1,529;3;2;5;9;b;10;L2100-01;b10;100;2;D20;3
477;S7423;KN-93 Phosphate;D21;2;D;21;NA;b11;L1200-04;59903;1188890-41-6;CaMK;100;1669365474;92;153,5816236;http://www.selleckchem.com/products/kn-93-phosphate.html;KN-93 Phosphate is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.37 _M, no remarkable inhibitory effects on APK, PKC, MLCK or Ca2+-PDE activities.;Others;C26H32ClN2O8PS;Phosphate;N/A;OP(O)(O)=O.COC1=CC=C(C=C1)S(=O)(=O)N(CCO)C1=CC=CC=C1CN(C)C\C=C\C1=CC=C(Cl)C=C1 |c:8,10,22,24,38,t:6,20,33,35|;4,288;3;1;11;4;b;11;L1200-04;b11;100;2;D21;3
478;S7951;STA-21;D22;2;D;22;NA;b11;L2100-01;306.31;111540-00-2;STAT;61;19914;NA;NA;http://selleckchem.com/products/sta-21.html;STA-21 is a selective STAT3 inhibitor.;JAK/STAT;C19H14O4;Free Base;N/A;CC1CC(=O)C2=C(C1)C=CC1=C2C(=O)C2=C(C(O)=CC=C2)C1=O |c:5,9,11,19,21,t:16|;3,339;3;1;0;9;b;11;L2100-01;b11;100;2;D22;3
479;NA;DMSO;D23;2;D;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;D23;3
480;NA;DMSO;D24;2;D;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;D24;3
481;S2554;Daphnetin;E01;2;E;1;NA;c1;L1200-03;178.14;486-35-1;PKA/PKC/EGFR;35;19647;<1;NA;http://selleckchem.com/products/Daphnetin.html;Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 _M, 9.33 _M and 25.01 _M, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.;DNA Damage;C9H6O4;Free Base;N/A;OC1=CC=C2C=CC(=O)OC2=C1O |c:5,11,t:1,3|;1,415;2;2;0;3;c;1;L1200-03;c1;100;2;E01;3
482;S7627;LDN-214117;E02;2;E;2;NA;c2;L1200-05;419.52;1627503-67-6;TGF-beta/Smad;83;1978451564;<1;NA;http://www.selleckchem.com/products/ldn-214117.html;LDN-214117 is a potent and selective BMP type I receptor kinase ALK2 inhibitor with IC50 of 24 nM.;TGF-beta/Smad;C25H29N3O3;Free Base;N/A;COC1=CC(=CC(OC)=C1OC)C1=CC(=CN=C1C)C1=CC=C(C=C1)N1CCNCC1 |c:4,8,15,17,23,25,t:2,13,21|;3,533;4;1;6;5;c;2;L1200-05;c2;100;2;E02;3
483;S2635;CCT128930;E03;2;E;3;NA;c2;L1200-03;34184;885499-61-6;Akt;68;198923473;<1;NA;http://www.selleckchem.com/products/cct128930.html;CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM in a cell-free assay, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.;PI3K/Akt/mTOR;C18H20ClN5;Free Base;N/A;NC1(CC2=CC=C(Cl)C=C2)CCN(CC1)C1=C2C=CNC2=NC=N1 |c:8,17,19,23,25,t:3,5|;2,813;2;2;3;3;c;2;L1200-03;c2;100;2;E03;3
484;NA;DMSO;E04;2;E;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;E04;3
485;S2679;Flavopiridol HCl;E05;2;E;5;NA;c3;L1200-03;4383;131740-09-5;CDK;88;2007757244;<1;NA;http://www.selleckchem.com/products/flavopiridol-hydrochloride.html;Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.;Cell Cycle;C21H21Cl2NO5;Hydrochloride;N/A;Cl.[H][C@@]1(CCN(C)C[C@H]1O)C1=C2OC(=CC(=O)C2=C(O)C=C1O)C1=C(Cl)C=CC=C1 |r,c:10,13,21,25,28,30,t:18|;3,49;2;3;2;3;c;3;L1200-03;c3;100;2;E05;3
486;S7776;Akti-1/2;E06;2;E;6;NA;c4;L1200-05;551.64;612847-09-3;Akt;22;3988108186;<1;NA;http://www.selleck.cn/products/akti-1-2.html;Akti-1/2 is a highly selective Akt1/Akt2 inhibitor with IC50 of 58 nM/210 nM, respectively, about 36-fold selectivity for Akt1 over Akt3.;PI3K/Akt/mTOR;C34H29N7O;Free Base;N/A;O=C1NC2=C(C=CC=C2)N1C1CCN(CC2=CC=C(C=C2)C2=C(N=C3C=C4NC=NC4=CC3=N2)C2=CC=CC=C2)CC1 |c:5,7,19,21,31,34,37,42,44,t:3,17,24,26,28,40|;5,466;4;2;5;5;c;4;L1200-05;c4;100;2;E06;3
487;S2692;TG101209;E07;2;E;7;NA;c4;L1200-03;50967;936091-14-4;Flt, JAK, c-RET;102;2001294956;<1;NA;http://www.selleckchem.com/products/tg101209.html;TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.;JAK/STAT;C26H35N7O2S;Free Base;N/A;CN1CCN(CC1)C1=CC=C(NC2=NC=C(C)C(NC3=CC(=CC=C3)S(=O)(=O)NC(C)(C)C)=N2)C=C1 |c:22,24,34,37,t:8,10,13,15,20|;4,659;4;3;8;3;c;4;L1200-03;c4;100;2;E07;3
488;NA;DMSO;E08;2;E;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;E08;3
489;S2720;ZM 336372;E09;2;E;9;NA;c5;L1200-03;38945;208260-29-1;Raf;78;2002824496;<1;NA;http://www.selleckchem.com/products/zm-336372.html;ZM 336372 is a potent and selective c-Raf inhibitor with IC50 of 70 nM, 10-fold selectivity over B-RAF, no inhibition to PKA/B/C, AMPK, p70S6, etc.;MAPK;C23H23N3O3;Free Base;N/A;CN(C)C1=CC=CC(=C1)C(=O)NC1=CC(NC(=O)C2=CC=C(O)C=C2)=C(C)C=C1 |c:5,7,24,29,t:3,13,19,21,26|;3,805;2;3;5;3;c;5;L1200-03;c5;100;2;E09;3
490;S7980;VPS34-IN1;E10;2;E;10;NA;c6;L1200-05;425.91;1383716-33-3;PI3K;85;19957;<1;NA;http://selleckchem.com/products/vps34-in1.html;Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.;PI3K/Akt/mTOR;C21H24ClN7O;Free Base;Vps34-IN-1;CC(C)(O)CNC1=NC=C(C(CC2CC2)=N1)C1=CC=NC(NC2=CC=NC(Cl)=C2)=N1 |c:8,15,20,26,29,31,t:6,18,24|;3,672;5;2;8;5;c;6;L1200-05;c6;100;2;E10;3
491;S2743;PF-04691502;E11;2;E;11;NA;c6;L1200-03;42548;1013101-36-4;mTOR, PI3K, Akt;14;3290401429;<1;NA;http://www.selleckchem.com/products/pf-04691502.html;PF-04691502 is an ATP-competitive PI3K(_/_/_/_)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM in cell-free assays, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. Phase 2.;PI3K/Akt/mTOR;C22H27N5O4;Free Base;N/A;COC1=CC=C(C=N1)C1=CC2=C(C)N=C(N)N=C2N([C@H]2CC[C@@H](CC2)OCCO)C1=O |r,c:4,6,11,17,t:2,9,14|;1,616;6;2;6;3;c;6;L1200-03;c6;100;2;E11;3
492;NA;DMSO;E12;2;E;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;E12;3
493;S2759;CUDC-907;E13;2;E;13;NA;c7;L1200-03;50855;1339928-25-4;HDAC, PI3K;102;2005702487;<1;NA;http://www.selleckchem.com/products/cudc-907.html;CUDC-907 is a dual PI3K and HDAC inhibitor for PI3K_ and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. Phase 1.;Cytoskeletal Signaling;C23H24N8O4S;Free Base;N/A;COC1=CC=C(C=N1)C1=NC2=C(SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=C2)C(=N1)N1CCOCC1 |c:4,6,20,22,28,31,t:2,9,11,18|;2,303;8;1;7;3;c;7;L1200-03;c7;100;2;E13;3
494;S8041;Cobimetinib (GDC-0973, RG7420);E14;2;E;14;NA;c8;L1200-05;531.31;934660-93-2;MEK;100;188214037;<1;NA;http://www.selleckchem.com/products/cobimetinib-gdc-0973-rg7420.html;Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.;MAPK;C21H21F3IN3O2;Free Base;XL518;OC1(CN(C1)C(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1)[C@@H]1CCCCN1 |r,c:8,16,24,t:11,13,21|;3,701;1;2;4;5;c;8;L1200-05;c8;100;2;E14;3
495;S2784;TAK-285;E15;2;E;15;NA;c8;L1200-03;54796;871026-44-7;EGFR, HER2;110;2007445799;<1;NA;http://www.selleckchem.com/products/tak-285.html;TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.;Protein Tyrosine Kinase;C26H25ClF3N5O3;Free Base;N/A;CC(C)(O)CC(=O)NCCN1C=CC2=C1C(NC1=CC=C(OC3=CC=CC(=C3)C(F)(F)F)C(Cl)=C1)=NC=N2 |c:11,13,25,27,35,37,39,t:18,20,23|;5,586;4;2;10;3;c;8;L1200-03;c8;100;2;E15;3
496;NA;DMSO;E16;2;E;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;E16;3
497;S2811;INK 128 (MLN0128);E17;2;E;17;NA;c9;L1200-03;30933;1224844-38-5;mTOR;62;2004331943;<1;NA;http://www.selleckchem.com/products/ink128.html;"INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.";PI3K/Akt/mTOR;C15H15N7O;Free Base;N/A;CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC2=C(OC(N)=N2)C=C1 |c:4,6,9,21,24,t:11,15,17|;1,886;5;2;2;3;c;9;L1200-03;c9;100;2;E17;3
498;NA;DMSO;E18;2;E;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;E18;3
499;S2843;BI-D1870;E19;2;E;19;NA;c10;L1200-03;39142;501437-28-1;S6 Kinase;78;1992744367;<1;NA;http://www.selleckchem.com/products/bi-d1870.html;"BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3_, MARK3, CK1 and Aurora B.";PI3K/Akt/mTOR;C19H23F2N5O2;Free Base;N/A;CC(C)CCN1C(C)C(=O)N(C)C2=C1N=C(NC1=CC(F)=C(O)C(F)=C1)N=C2 |c:12,25,28,t:15,18,21|;4,069;3;2;5;3;c;10;L1200-03;c10;100;2;E19;3
500;NA;DMSO;E20;2;E;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;E20;3
501;S2891;GW441756;E21;2;E;21;NA;c11;L1200-03;275.3;504433-23-2;Trk Receptor;25;9081002543;<1;NA;http://www.selleckchem.com/products/gw-441756.html;GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2.;Protein Tyrosine Kinase;C17H13N3O;Free Base;N/A;CN1C=C(C=C2C(=O)NC3=CC=CN=C23)C2=C1C=CC=C2 |w:4.3,c:11,17,20,22,t:2,9,13|;2,508;2;1;1;3;c;11;L1200-03;c11;100;2;E21;3
502;NA;DMSO;E22;2;E;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;E22;3
503;NA;DMSO;E23;2;E;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;E23;3
504;NA;DMSO;E24;2;E;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;E24;3
505;S2913;BAY 11-7082;F01;2;F;1;NA;c1;L1200-04;20725;19542-67-7;I_B/IKK;41;1978287093;<1;NA;http://www.selleckchem.com/products/bay-11-7082-bay-11-7821.html;BAY 11-7082 is a NF-_B inhibitor, inhibits TNF_-induced I_B_ phosphorylation with IC50 of 10 _M in tumor cells. Also inhibiting components of the ubiquitin system.;NF-_B;C10H9NO2S;Free Base;N/A;CC1=CC=C(C=C1)S(=O)(=O)\C=C\C#N |c:3,5,t:1|;1,721;2;0;2;4;c;1;L1200-04;c1;100;2;F01;3
506;S1067;SB431542;F02;2;F;2;NA;c1;L2100-01;38439;301836-41-9;TGF-beta/Smad;77;200317386;<1;NA;http://www.selleckchem.com/products/SB-431542.html;SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM, 100-fold more selective for ALK5 than p38 MAPK and other kinases.;Others;C22H16N4O3;Free Base;N/A;NC(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=NC=CC=C1)C1=CC2=C(OCO2)C=C1 |c:5,7,12,18,20,31,t:3,10,16,23,25|;3,447;5;2;4;9;c;1;L2100-01;c1;100;2;F02;3
507;S4001;Cabozantinib malate (XL184);F03;2;F;3;NA;c2;L1200-04;63559;1140909-48-3;VEGFR;100;1573341305;<1;NA;http://www.selleckchem.com/products/cabozantinib-malate.html;Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.;Protein Tyrosine Kinase;C32H30FN3O10;Malate;N/A;O[C@@H](CC(O)=O)C(O)=O.COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2 |r,c:12,14,40,43,45,47,t:10,21,23,35,37|;3,331;8;3;11;4;c;2;L1200-04;c2;100;2;F03;3
508;S1459;Thiazovivin;F04;2;F;4;NA;c2;L2100-01;31136;1226056-71-8;ROCK;15;4817574512;<1;NA;http://www.selleckchem.com/products/Thiazovivin.html;Thiazovivin (Tzv) is a novel ROCK inhibitor with IC50 of 0.5 _M, promotes hESC survival after single-cell dissociation.;Cell Cycle;C15H13N5OS;Free Base;N/A;O=C(NCC1=CC=CC=C1)C1=CSC(NC2=CC=NC=N2)=N1 |c:6,8,18,20,22,t:4,11,16|;2,357;4;2;5;9;c;2;L2100-01;c2;100;2;F04;3
509;S7007;MEK162 (ARRY-162, ARRY-438162);F05;2;F;5;NA;c3;L1200-04;44123;606143-89-9;MEK;88;1994424676;<1;NA;http://www.selleckchem.com/products/mek162.html;Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.;MAPK;C17H15BrF2N4O3;Free Base;N/A;CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC1=C(F)C=C(Br)C=C1)=C2F |c:2,4,18,24,26,t:7,21|;2,775;3;3;6;4;c;3;L1200-04;c3;100;2;F05;3
510;S1621;Theophylline;F06;2;F;6;NA;c3;L2100-01;180.16;58-55-9;TGF-beta/Smad;36;19982;<1;NA;http://selleckchem.com/products/Theophylline(Theo-Dur).html;Theophylline (Theo-Dur) is a methylxanthine agent and has bronchodilator properties and is used in the treatment of asthma and COAD.;TGF-beta/Smad;C7H8N4O2;Free Base;NA;CN1C2=C(NC=N2)C(=O)N(C)C1=O |c:5,t:2|;-0,306;3;1;0;9;c;3;L2100-01;c3;100;2;F06;3
511;S7050;AZ20;F07;2;F;7;NA;c4;L1200-04;41251;1233339-22-4;ATM/ATR;83;2012072435;<1;NA;http://www.selleckchem.com/products/az20.html;AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.;PI3K/Akt/mTOR;C21H24N4O3S;Free Base;N/A;C[C@@H]1COCCN1C1=NC(=NC(=C1)C1(CC1)S(C)(=O)=O)C1=CC=CC2=C1C=CN2 |r,c:10,12,25,27,30,t:8,23|;3,038;5;1;4;4;c;4;L1200-04;c4;100;2;F07;3
512;S2219;CYT387;F08;2;F;8;NA;c4;L2100-01;41446;1056634-68-4;JAK;74;1785455774;<1;NA;http://www.selleckchem.com/products/Cyt387.html;CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 1/2.;JAK/STAT;C23H22N6O2;Free Base;CYT 11387;O=C(NCC#N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1 |c:8,10,19,21,30,32,t:6,13,17|;2,857;4;2;6;9;c;4;L2100-01;c4;100;2;F08;3
513;S7087;GSK2334470;F09;2;F;9;NA;c5;L1200-04;46259;1227911-45-6;PDK-1;90;1945567349;<1;NA;http://www.selleckchem.com/products/gsk2334470.html;GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.;PI3K/Akt/mTOR;C25H34N8O;Free Base;N/A;CNC1=NC(=CC(=N1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1)C1=CC2=C(C=C1)C(N)=NN2 |r,c:4,6,29,31,35,t:2,27|;4,516;4;4;5;4;c;5;L1200-04;c5;100;2;F09;3
514;S2686;NVP-BSK805 2HCl;F10;2;F;10;NA;c5;L2100-01;56347;1092499-93-8 (free base);JAK;113;2005430635;3;5324152129;http://www.selleckchem.com/products/nvp-bsk805.html;NVP-BSK805 is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM,>20-fold selectivity towards JAK1, JAK3 and TYK2.;JAK/STAT;C27H30Cl2F2N6O;dihydrochloride;N/A;Cl.Cl.FC1=CC(=CC(F)=C1CN1CCOCC1)C1=C2N=C(C=NC2=CC=C1)C1=CN(N=C1)C1CCNCC1 |c:3,6,17,19,21,24,26,32,t:1,29|;3,92;4;1;5;9;c;5;L2100-01;c5;100;2;F10;3
515;S7121;MLN2480;F11;2;F;11;NA;c6;L1200-04;506.29;1096708-71-2;Raf;100;19752;<1;NA;http://selleckchem.com/products/mln2480.html;MLN2480 is an oral, selective pan-Raf kinase inhibitor in chinical trials.;MAPK;C17H12Cl2F3N7O2S;Free Base;BIIB-024;C[C@@H](NC(=O)C1=C(Cl)C(N)=NC=N1)C1=NC=C(S1)C(=O)NC1=NC=C(Cl)C(=C1)C(F)(F)F |r,c:5,9,11,16,28,t:14,23,25|;2,932;6;3;6;4;c;6;L1200-04;c6;100;2;F11;3
516;S2777;PF-5274857;F12;2;F;12;NA;c6;L2100-01;436.96;1373615-35-0;Hedgehog/Smoothened;93;21283;93;2128341267;http://selleckchem.com/products/pf-5274857.html;PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the bloodÐbrain barrier.;Stem Cells &  Wnt;C20H25ClN4O3S;Free Base;N/A;CC1=CC(C)=C(N=C1)C1=CC(=NC=C1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O |c:4,6,11,13,t:1,9|;2,744;5;0;5;9;c;6;L2100-01;c6;100;2;F12;3
517;S7176;SKI II;F13;2;F;13;NA;c7;L1200-04;30278;312636-16-1;sphingosine kinase (SphK);61;2014664113;<1;NA;http://www.selleckchem.com/products/ski-ii.html;SKI II is a highly selective and non ATP-competitiveÊsphingosine kinase (SphK)Êinhibitor withÊIC50Êof 0.5 _M, while exhibiting no inhibitory action on other kinases including PI3K, PKC_ and ERK2.;GPCR & G Protein;C15H11ClN2OS;Free Base;SphK-I2, Sphingosine Kinase Inhibitor 2;OC1=CC=C(NC2=NC(=CS2)C2=CC=C(Cl)C=C2)C=C1 |c:8,17,20,t:1,3,6,12,14|;4,746;1;2;3;4;c;7;L1200-04;c7;100;2;F13;3
518;S2907;Pirfenidone;F14;2;F;14;NA;c7;L2100-01;18522;53179-13-8;TGF-beta/Smad;37;1997624447;<1;NA;http://www.selleckchem.com/products/pirfenidone.html;Pirfenidone is an inhibitor for TGF-_ production and TGF-_ stimulated collagen production, reduces production of TNF-_ and IL-1_, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.;TGF-beta/Smad;C12H11NO;Free Base;N/A;CC1=CN(C(=O)C=C1)C1=CC=CC=C1 |c:6,11,13,t:1,9|;1,905;1;0;1;9;c;7;L2100-01;c7;100;2;F14;3
519;S7214;Skepinone-L;F15;2;F;15;NA;c8;L1200-04;42542;1221485-83-1;p38 MAPK;85;1998025481;<1;NA;http://www.selleckchem.com/products/skepinone-l.html;Skepinone-L is a selective p38_-MAPK inhibitor with IC50 of 5 nM.;MAPK;C24H21F2NO4;Free Base;N/A;OC[C@@H](O)COC1=CC=C2CCC3=CC(NC4=CC=C(F)C=C4F)=CC=C3C(=O)C2=C1 |r,c:21,24,26,32,t:6,8,12,16,18|;4,729;2;3;6;4;c;8;L1200-04;c8;100;2;F15;3
520;S7096;KY02111;F16;2;F;16;NA;c8;L2100-01;37686;1118807-13-8;Wnt/beta-catenin;75;199012896;<1;NA;https://www.selleckchem.com/products/ky02111.html;KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, may act downstream of APC and GSK3_.;Stem Cells &  Wnt;C18H17ClN2O3S;Free Base;N/A;COC1=CC=C(CCC(=O)NC2=NC3=CC=C(Cl)C=C3S2)C=C1OC |c:18,23,t:2,4,11,13,15|;4,362;4;1;6;9;c;8;L2100-01;c8;100;2;F16;3
521;S7289;PFK15;F17;2;F;17;NA;c9;L1200-04;26029;4382-63-2;6-phosphofructo-2-kinase (PFKFB3);19;7299550501;<1;NA;http://www.selleckchem.com/products/pfk15.html;PFK15 is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) inhibitor with IC50 of 207 nM.;Others;C17H12N2O;Free Base;PFK-015;O=C(\C=C\C1=CC=C2C=CC=CC2=N1)C1=CC=NC=C1 |c:8,10,13,18,20,t:4,6,16|;3,166;3;0;3;4;c;9;L1200-04;c9;100;2;F17;3
522;S7208;GF109203X;F18;2;F;18;NA;c9;L2100-01;41248;133052-90-1;PKC;82;1987975175;<1;NA;http://www.selleckchem.com/products/gf109203x.html;GF109203X is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKC_, PKC_I, PKC_II, and PKC_, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.;TGF-beta/Smad;C25H24N4O2;Free Base;GO 6850;CN(C)CCCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CNC2=CC=CC=C12 |c:7,11,30,t:9,13,17,25,28,32|;3,557;2;2;6;9;c;9;L2100-01;c9;100;2;F18;3
523;S7343;URMC-099;F19;2;F;19;NA;c10;L1200-04;421.54;1229582-33-5;"Abl1; LRRK2; MLK3; MLK1";84;1992693457;<1;NA;http://www.selleckchem.com/products/urmc-099.html;URMC-099 is an orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor with IC50 of 19 nM, 42 nM, 14 nM, and 150 nM, for MLK1, MLK2, MLK3, and DLK, respectively, and also inhibits LRRK2 activity with IC50 of 11 nM.;Others;C27H27N5;Free Base;N/A;CN1CCN(CC2=CC=C(C=C2)C2=CC3=C(NC=C3C3=CC=C4NC=CC4=C3)N=C2)CC1 |c:8,10,18,26,29,32,t:6,13,15,21,23|;4,533;1;2;4;4;c;10;L1200-04;c10;100;2;F19;3
524;S7484;FH535;F20;2;F;20;NA;c10;L2100-01;3612;108409-83-2;Wnt/beta-catenin;72;1993355482;<1;NA;http://www.selleckchem.com/products/fh535.html;FH535 is a Wnt/_-catenin signaling inhibitor and also a dual PPAR_ and PPAR_ antagonist.;Stem Cells &  Wnt;C13H10Cl2N2O4S;Free Base;N/A;CC1=C(NS(=O)(=O)C2=C(Cl)C=CC(Cl)=C2)C=CC(=C1)[N+]([O-])=O |c:1,7,10,13,16,18|;4,027;2;1;4;9;c;10;L2100-01;c10;100;2;F20;3
525;S7435;AR-A014418;F21;2;F;21;NA;c11;L1200-04;30831;487021-52-3;GSK-3;62;2010962992;<1;NA;http://www.selleckchem.com/products/ar-a014418.html;AR-A014418 is an ATP-competitive, and selective GSK3_ inhibitor with IC50 and Ki of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.;PI3K/Akt/mTOR;C12H12N4O4S;Free Base;GSK-3_ Inhibitor VIII;COC1=CC=C(CNC(=O)NC2=NC=C(S2)[N+]([O-])=O)C=C1 |c:13,20,t:2,4,11|;1,529;3;2;5;4;c;11;L1200-04;c11;100;2;F21;3
526;S8004;ZM 39923 HCl;F22;2;F;22;NA;c11;L2100-01;36791;1021868-92-7;JAK;30;8154168139;<1;NA;http://www.selleckchem.com/products/zm-39923-hcl.html;"ZM 39923 is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.";JAK/STAT;C23H26ClNO;HCl;N/A;Cl.CC(C)N(CCC(=O)C1=CC=C2C=CC=CC2=C1)CC1=CC=CC=C1 |c:12,14,17,23,25,t:8,10,21|;5,424;1;0;7;9;c;11;L2100-01;c11;100;2;F22;3
527;NA;DMSO;F23;2;F;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;F23;3
528;NA;DMSO;F24;2;F;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;F24;3
529;S2617;TAK-733;G01;2;G;1;NA;d1;L1200-03;50423;1035555-63-5;MEK;101;2003054162;<1;NA;http://www.selleckchem.com/products/tak-733.html;TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.;MAPK;C17H15F2IN4O4;Free Base;N/A;CN1C(=O)C(F)=C(NC2=CC=C(I)C=C2F)C2=C1N=CN(C[C@@H](O)CO)C2=O |r,c:13,17,20,t:5,8,10|;0,383;3;3;5;3;d;1;L1200-03;d1;100;2;G01;3
530;S7636;SU9516;G02;2;G;2;NA;d2;L1200-05;241.25;377090-84-1;CDK;48;1989637306;<1;NA;http://www.selleckchem.com/products/su9516.html;SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.;Cell Cycle;C13H11N3O2;Free Base;N/A;COC1=CC=C2NC(=O)\C(=C/C3=CN=CN3)C2=C1 |c:13,18,t:2,4,11|;0,893;3;2;2;5;d;2;L1200-05;d2;100;2;G02;3
531;S2636;A66;G03;2;G;3;NA;d2;L1200-03;39353;1166227-08-2;PI3K;79;2007470841;<1;NA;http://www.selleckchem.com/products/a66.html;A66 is a potent and specific p110_ inhibitor with IC50 of 32 nM in a cell-free assay, >100 fold selectivity for p110_ over other class-I PI3K isoforms.;PI3K/Akt/mTOR;C17H23N5O2S2;Free Base;N/A;CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CSC(=N1)C(C)(C)C |r,c:16,22,t:1,19|;2,383;4;2;4;3;d;2;L1200-03;d2;100;2;G03;3
532;NA;DMSO;G04;2;G;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;G04;3
533;S2680;Ibrutinib (PCI-32765);G05;2;G;5;NA;d3;L1200-03;4405;936563-96-1;Src;88;1997729852;<1;NA;http://www.selleckchem.com/products/pci-32765.html;Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.;Angiogenesis;C25H24N6O2;Free Base;N/A;NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)C1CCCN(C1)C(=O)C=C |c:3,5,9,19,21,24,t:1,12,14,17,@:7|;3,985;5;1;5;3;d;3;L1200-03;d3;100;2;G05;3
534;S7793;Purvalanol A;G06;2;G;6;NA;d4;L1200-05;388.89;212844-53-6;CDK;60;1542852735;<1;NA;http://www.selleckchem.com/products/purvalanol-a.html;Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.;Cell Cycle;C19H25ClN6O;Free Base;N/A;CC(C)[C@H](CO)NC1=NC(NC2=CC=CC(Cl)=C2)=C2N=CN(C(C)C)C2=N1 |r,c:13,16,20,27,t:7,11,18|;4,462;3;3;7;5;d;4;L1200-05;d4;100;2;G06;3
535;S2696;GDC-0980 (RG7422);G07;2;G;7;NA;d4;L1200-03;4986;1032754-93-0;mTOR, PI3K;20;4011231448;<1;NA;http://www.selleckchem.com/products/GDC-0980-RG7422.html;Apitolisib (GDC-0980, RG7422) is a potent, class I PI3K inhibitor for PI3K_/_/_/_ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. Also a mTOR inhibitor with Ki of 17 nM in a cell-free assay, and highly selective versus other PIKK family kinases. Phase 2.;PI3K/Akt/mTOR;C23H30N8O3S;Free Base;N/A;C[C@H](O)C(=O)N1CCN(CC2=C(C)C3=NC(=NC(N4CCOCC4)=C3S2)C2=CN=C(N)N=C2)CC1 |r,c:10,15,24,34,t:13,29,31|;1,013;6;2;5;3;d;4;L1200-03;d4;100;2;G07;3
536;NA;DMSO;G08;2;G;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;G08;3
537;S2726;PH-797804;G09;2;G;9;NA;d5;L1200-03;4773;586379-66-0;p38 MAPK;96;2011313639;<1;NA;http://www.selleckchem.com/products/ph-797804.html;"PH-797804 is a novel pyridinone inhibitor of p38_ with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38_ and does not inhibit JNK2. Phase 2.";MAPK;C22H19BrF2N2O3;Free Base;N/A;CNC(=O)C1=CC(N2C(C)=CC(OCC3=CC=C(F)C=C3F)=C(Br)C2=O)=C(C)C=C1 |c:9,19,30,t:4,14,16,22,27|;3,801;3;1;5;3;d;5;L1200-03;d5;100;2;G09;3
538;S7998;Entrectinib (RXDX-101);G10;2;G;10;NA;d6;L1200-05;560.64;1108743-60-7;Trk receptor;100;1783675799;<1;NA;http://www.selleckchem.com/products/entrectinib-rxdx-101.html;Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.;Protein Tyrosine Kinase;C31H34F2N6O2;Free Base;NMS-E628;CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1 |c:18,27,30,33,44,t:8,10,15,21,24|;4,952;3;3;7;5;d;6;L1200-05;d6;100;2;G10;3
539;S2745;CHIR-98014;G11;2;G;11;NA;d6;L1200-03;486.31;252935-94-7;GSK-3;8;1645041229;<1;NA;http://www.selleckchem.com/products/chir-98014.html;CHIR-98014 is a potent GSK-3_/_ inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.;PI3K/Akt/mTOR;C20H17Cl2N9O2;Free Base;N/A;NC1=NC(NCCNC2=NC=C(N3C=CN=C3)C(=N2)C2=CC=C(Cl)C=C2Cl)=CC=C1[N+]([O-])=O |c:13,15,18,26,29,31,t:1,8,10,21,23|;3,859;4;3;8;3;d;6;L1200-03;d6;100;2;G11;3
540;NA;DMSO;G12;2;G;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;G12;3
541;S2761;NVP-BVU972;G13;2;G;13;NA;d7;L1200-03;34038;1185763-69-2;c-Met;68;1997767201;<1;NA;http://www.selleckchem.com/products/nvp-bvu972.html;NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.;Protein Tyrosine Kinase;C20H16N6;Free Base;N/A;CN1C=C(C=N1)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2C=C1 |c:2,4,16,18,21,23,25,28,t:7,12,14|;2,867;4;0;3;3;d;7;L1200-03;d7;100;2;G13;3
542;S8044;BMS-345541;G14;2;G;14;NA;d8;L1200-05;25532;445430-58-0;I_B/IKK;9;352498825;<1;NA;http://www.selleckchem.com/products/bms-345541.html;BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 _M and 4 _M in cell-free assays, respectively.;NF-_B;C14H17N5;Free Base;N/A;CC1=CN=C2N1C1=CC(C)=CC=C1N=C2NCCN |c:3,10,12,15,t:1,7|;1,472;2;2;3;5;d;8;L1200-05;d8;100;2;G14;3
543;S2789;Tofacitinib (CP-690550,Tasocitinib);G15;2;G;15;NA;d8;L1200-03;31237;477600-75-2;JAK;62;1984825687;<1;NA;http://www.selleckchem.com/products/tofacitinib-cp-690550.html;Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.;JAK/STAT;C16H20N6O;Free Base;Tasocitinib;C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N |r,c:10,12,16,18|;1,512;3;1;3;3;d;8;L1200-03;d8;100;2;G15;3
544;NA;DMSO;G16;2;G;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;G16;3
545;S2814;BYL719;G17;2;G;17;NA;d9;L1200-03;44147;1217486-61-7;PI3K;88;1993340431;<1;NA;http://www.selleckchem.com/products/byl719.html;Alpelisib (BYL719) is a potent and selective PI3K_ inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3K_/_/_. Phase 2.;PI3K/Akt/mTOR;C19H22F3N5O2S;Free Base;N/A;CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F |r,c:16,21,23,t:1,19|;2,826;4;2;5;3;d;9;L1200-03;d9;100;2;G17;3
546;NA;DMSO;G18;2;G;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;G18;3
547;S2845;Semaxanib (SU5416);G19;2;G;19;NA;d10;L1200-03;23828;194413-58-6;VEGFR;22;923283532;<1;NA;http://www.selleckchem.com/products/semaxanib-su5416.html;Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 _M, 20-fold more selective for VEGFR than PDGFR_, lack of activity against EGFR, InsR and FGFR. Phase 3.;Protein Tyrosine Kinase;C15H14N2O;Free Base;N/A;CC1=CC(C)=C(N1)\C=C1/C(=O)NC2=CC=CC=C12 |c:4,15,t:1,13,17|;2,747;1;2;1;3;d;10;L1200-03;d10;100;2;G19;3
548;NA;DMSO;G20;2;G;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;G20;3
549;S2895;Tyrphostin 9;G21;2;G;21;NA;d11;L1200-03;28238;10537-47-0;EGFR;56;1983143282;<1;NA;http://www.selleckchem.com/products/tyrphostin-9-sf-6847.html;Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 _M, but is also found to be more potent to PDGFR with IC50 of 0.5 _M.;Protein Tyrosine Kinase;C18H22N2O;Free Base;Tyrphostin AG 17, Malonaben, NSC 242557, RG-50872;CC(C)(C)C1=CC(C=C(C#N)C#N)=CC(=C1O)C(C)(C)C |c:12,14,t:4|;4,574;0;1;3;3;d;11;L1200-03;d11;100;2;G21;3
550;NA;DMSO;G22;2;G;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;G22;3
551;NA;DMSO;G23;2;G;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;G23;3
552;NA;DMSO;G24;2;G;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;G24;3
553;S2922;Icotinib;H01;2;H;1;NA;d1;L1200-04;39142;610798-31-7;EGFR;78;1992744367;<1;NA;http://www.selleckchem.com/products/icotinib.html;Icotinib is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).;Protein Tyrosine Kinase;C22H21N3O4;Free Base;BPI-2009H;C#CC1=CC(NC2=NC=NC3=C2C=C2OCCOCCOCCOC2=C3)=CC=C1 |c:8,10,26,28,30,t:2,6,13|;4,128;6;1;2;4;d;1;L1200-04;d1;100;2;H01;3
554;S1075;SB216763;H02;2;H;2;NA;d1;L2100-01;37122;280744-09-4;GSK-3;23;6195786865;<1;NA;http://www.selleckchem.com/products/SB-216763.html;SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3_ and equally effective at inhibiting human GSK-3_.;Others;C19H12Cl2N2O2;Free Base;N/A;CN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)C1=CC=C(Cl)C=C1Cl |c:2,4,7,9,25,t:12,20,22|;4,391;2;1;2;9;d;1;L2100-01;d1;100;2;H02;3
555;S4901;JNK-IN-8;H03;2;H;3;NA;d2;L1200-04;50759;1410880-22-6;JNK;100;1970093973;<1;NA;http://www.selleckchem.com/products/jnk-in-8.html;JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, >10-fold selectivity against MNK2, Fms and no inhibition to c-Kit, Met, PDGFR_in A375 cell line.;MAPK;C29H29N7O2;JNK;N/A;CN(C)C\C=C\C(=O)NC1=CC(=CC=C1)C(=O)NC1=CC=C(NC2=NC=CC(=N2)C2=CC=CN=C2)C(C)=C1 |c:11,13,26,28,33,35,39,t:9,19,21,24,31|;3,997;5;3;9;4;d;2;L1200-04;d2;100;2;H03;3
556;S1474;GSK429286A;H04;2;H;4;NA;d2;L2100-01;43237;864082-47-3;ROCK;87;2012165506;<1;NA;http://www.selleckchem.com/products/GSK429286A.html;GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.;Cell Cycle;C21H16F4N4O2;Free Base;N/A;CC1=C(C(CC(=O)N1)C1=CC=C(C=C1)C(F)(F)F)C(=O)NC1=C(F)C=C2NN=CC2=C1 |c:11,13,23,29,32,t:1,9,26|;3,033;3;3;4;9;d;2;L2100-01;d2;100;2;H04;3
557;S7008;PP2;H05;2;H;5;NA;d3;L1200-04;30177;172889-27-9;Src;60;1988269212;<1;NA;https://www.selleckchem.com/products/pp2.html;PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.;Angiogenesis;C15H16ClN5;Free Base;AG 1879;CC(C)(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C(Cl)C=C1 |c:5,7,10,21,t:12,16,18|;3,435;3;1;2;4;d;3;L1200-04;d3;100;2;H05;3
558;S2151;LDE225 (NVP-LDE225,Erismodegib);H06;2;H;6;NA;d3;L2100-01;4855;956697-53-3;Smoothened;97;1997940268;<1;NA;http://www.selleckchem.com/products/LDE225(NVP-LDE225).html;LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3.;Stem Cells &  Wnt;C26H26F3N3O3;Free Base;N/A;C[C@H]1CN(C[C@@H](C)O1)C1=CC=C(NC(=O)C2=C(C)C(=CC=C2)C2=CC=C(OC(F)(F)F)C=C2)C=N1 |r,c:16,19,21,33,36,t:9,11,24,26|;6,732;4;1;6;9;d;3;L2100-01;d3;100;2;H06;3
559;S7051;CGI1746;H07;2;H;7;NA;d4;L1200-04;57969;910232-84-7;BTK;100;1725059946;<1;NA;http://www.selleckchem.com/products/cgi1746.html;CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.;Angiogenesis;C34H37N5O4;Free Base;N/A;CN1C=C(N=C(NC2=CC=C(C=C2)C(=O)N2CCOCC2)C1=O)C1=CC=CC(NC(=O)C2=CC=C(C=C2)C(C)(C)C)=C1C |c:2,9,11,28,36,38,44,t:4,7,26,34|;3,513;5;2;7;4;d;4;L1200-04;d4;100;2;H07;3
560;S2230;LY2157299;H08;2;H;8;NA;d4;L2100-01;36942;700874-72-2;TGF-beta/Smad;74;2003140057;<1;NA;http://www.selleckchem.com/products/ly2157299.html;LY2157299 is a potent TGF_ receptor I (T_RI) inhibitor with IC50 of 56 nM. Phase 2.;TGF-beta/Smad;C22H19N5O;Free Base;N/A;CC1=CC=CC(=N1)C1=NN2CCCC2=C1C1=CC=NC2=C1C=C(C=C2)C(N)=O |c:3,5,15,20,22,25,27,t:1,8,18|;3,095;4;1;3;9;d;4;L2100-01;d4;100;2;H08;3
561;S7091;Zotarolimus(ABT-578);H09;2;H;9;NA;d5;L1200-04;96621;221877-54-9;mTOR;100;1034971694;<1;NA;http://www.selleckchem.com/products/zotarolimus-abt-578.html;Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.;PI3K/Akt/mTOR;C52H79N5O12;Free Base;N/A;[H][C@@]12CCCCN1C(=O)C(=O)[C@]1(O)O[C@@H](CC[C@H]1C)C[C@H](OC)\C(C)=C\C=C\C=C\[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)\C(C)=C\[C@@H](C)C(=O)C[C@H](OC2=O)[C@H](C)C[C@@H]1CC[C@@H]([C@@H](C1)OC)N1C=NN=N1 |r,c:70,72,t:26,28,30,45|;5,793;13;1;7;4;d;5;L1200-04;d5;100;2;H09;3
562;S2692;TG101209;H10;2;H;10;NA;d5;L2100-01;50967;936091-14-4;Flt, JAK, c-RET;102;2001294956;<1;NA;http://www.selleckchem.com/products/tg101209.html;TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.;JAK/STAT;C26H35N7O2S;Free Base;N/A;CN1CCN(CC1)C1=CC=C(NC2=NC=C(C)C(NC3=CC(=CC=C3)S(=O)(=O)NC(C)(C)C)=N2)C=C1 |c:22,24,34,37,t:8,10,13,15,20|;4,659;4;3;8;9;d;5;L2100-01;d5;100;2;H10;3
563;S7127;TIC10 Analogue;H11;2;H;11;NA;d6;L1200-04;38649;41276-02-2;Akt;11;2846127972;<1;NA;http://www.selleckchem.com/products/tic10.html;TIC10 Analogue is an analogue of TIC10, which inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.;PI3K/Akt/mTOR;C24H26N4O;Free Base;TRAIL-inducing Compound 10;CC1=C(CN2C3=NCCN3C(=O)C3=C2CCN(CC2=CC=CC=C2)C3)C=CC=C1 |c:1,13,22,24,29,31,t:5,20|;3,212;2;0;4;4;d;6;L1200-04;d6;100;2;H11;3
564;S2789;Tofacitinib (CP-690550,Tasocitinib);H12;2;H;12;NA;d6;L2100-01;31237;477600-75-2;JAK;62;1984825687;<1;NA;http://www.selleckchem.com/products/tofacitinib-cp-690550.html;Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.;JAK/STAT;C16H20N6O;Free Base;Tasocitinib;C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N |r,c:10,12,16,18|;1,512;3;1;3;9;d;6;L2100-01;d6;100;2;H12;3
565;S7177;PF-543;H13;2;H;13;NA;d7;L1200-04;4656;1415562-82-1;SphK1;93;199742268;<1;NA;http://www.selleckchem.com/products/pf-543.html;PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform.;GPCR & G Protein;C27H31NO4S;Free Base;N/A;CC1=CC(CS(=O)(=O)C2=CC=CC=C2)=CC(OCC2=CC=C(CN3CCC[C@@H]3CO)C=C2)=C1 |r,c:10,12,14,32,34,t:1,8,19,21|;5,016;3;1;9;4;d;7;L1200-04;d7;100;2;H13;3
566;S2911;Go 6983;H14;2;H;14;NA;d7;L2100-01;44251;133053-19-7;PKC;59;1333303202;<1;NA;http://www.selleckchem.com/products/go-6983.html;"Go 6983 is a pan-PKC inhibitor against for PKC_, PKC_, PKC_ and PKC_ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKC_ and inactive to PKC_.";TGF-beta/Smad;C26H26N4O3;Free Base;N/A;COC1=CC=C2N(CCCN(C)C)C=C(C2=C1)C1=C(C(=O)NC1=O)C1=CNC2=C1C=CC=C2 |c:13,16,30,33,35,t:2,4,19,27|;3,54;3;2;7;9;d;7;L2100-01;d7;100;2;H14;3
567;S7215;Losmapimod (GW856553X);H15;2;H;15;NA;d8;L1200-04;38346;585543-15-3;p38 MAPK;76;1981953789;<1;NA;http://www.selleckchem.com/products/losmapimod.html;Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38_ and p38_, respectively. Phase 3.;MAPK;C22H26FN3O2;Free Base;GW856553X, GW856553, GSK-AHAB;CC1=C(F)C=C(C=C1C1=CC=C(C=N1)C(=O)NCC(C)(C)C)C(=O)NC1CC1 |c:1,4,6,11,13,t:9|;3,689;3;2;6;4;d;8;L1200-04;d8;100;2;H15;3
568;S7138;BMS-833923;H16;2;H;16;NA;d8;L2100-01;47357;1059734-66-5;Hedgehog/Smoothened;95;2006039234;<1;NA;http://www.selleckchem.com/products/bms-833923.html;BMS-833923 is an orally bioavailable Smoothened antagonist. Phase 2.;GPCR & G Protein;C30H27N5O;Free Base;XL139;CNCC1=CC(NC(=O)C2=CC=C(NC3=NC4=CC=CC=C4C(=N3)C3=CC=CC=C3)C=C2)=C(C)C=C1 |c:18,20,23,28,30,33,38,t:3,9,11,14,16,26,35|;6,214;3;3;7;9;d;8;L2100-01;d8;100;2;H16;3
569;S7291;TAK-632;H17;2;H;17;NA;d9;L1200-04;55452;1228591-30-7;Raf;100;1803361466;<1;NA;http://www.selleckchem.com/products/tak-632.html;TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.;MAPK;C27H18F4N4O3S;Free Base;N/A;FC1=C(NC(=O)CC2=CC=CC(=C2)C(F)(F)F)C=C(OC2=C(C#N)C3=C(C=C2)N=C(NC(=O)C2CC2)S3)C=C1 |c:1,9,11,21,25,27,41,t:7,18,30|;5,74;4;2;8;4;d;9;L1200-04;d9;100;2;H17;3
570;S7223;RepSox;H18;2;H;18;NA;d9;L2100-01;28732;446859-33-2;TGF-beta/Smad;57;1983850759;<1;NA;http://www.selleckchem.com/products/repsox.html;RepSox is a potent and selective inhibitor of the TGF_R-1/ALK5 with IC50 of 23 nM and 4 nM for ATP binding to ALK5 and ALK5 autophosphorylation, respectively.;TGF-beta/Smad;C17H13N5;Free Base;E-616452, SJN 2511;CC1=CC=CC(=N1)C1=NNC=C1C1=CC=C2N=CC=CC2=N1 |c:3,5,11,18,20,23,t:1,8,14,16|;3,192;4;1;2;9;d;9;L2100-01;d9;100;2;H18;3
571;S7352;Bay 11-7085;H19;2;H;19;NA;d10;L1200-04;249.33;196309-76-9;I_B/IKK;50;2005374403;<1;NA;http://www.selleckchem.com/products/bay-11-7085.html;BAY 11-7085 is an irreversible inhibitor of TNF_-induced I_B_ phosphorylation with IC50 of 10 _M.;NF-_B;C13H15NO2S;Free Base;Bay 11-7083;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)\C=C\C#N |c:6,8,t:4|;2,635;2;0;3;4;d;10;L1200-04;d10;100;2;H19;3
572;S7490;WIKI4;H20;2;H;20;NA;d10;L2100-01;52159;838818-26-1;Wnt/beta-catenin;7;1342050269;<1;NA;http://www.selleckchem.com/products/wiki4.html;WIKI4 is a novel Tankyrase inhibitor with IC50 of 15 nM for TNKS2, and leads to inhibition of Wnt/beta-catenin signaling. ;Stem Cells &  Wnt;C29H23N5O3S;Free Base;N/A;COC1=CC=C(C=C1)N1C(SCCCN2C(=O)C3=CC=CC4=C3C(=CC=C4)C2=O)=NN=C1C1=CC=NC=C1 |c:4,6,20,25,27,32,34,39,41,t:2,18,37|;4,469;6;0;8;9;d;10;L2100-01;d10;100;2;H20;3
573;S7461;LDC000067;H21;2;H;21;NA;d11;L1200-04;37043;1073485-20-7;CDK;74;1997678374;<1;NA;http://www.selleckchem.com/products/ldc000067.html;LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.;Cell Cycle;C18H18N4O3S;Free Base;LDC067;COC1=CC=CC=C1C1=NC=NC(NC2=CC(CS(N)(=O)=O)=CC=C2)=C1 |c:4,6,11,22,24,26,t:2,9,15|;2,783;5;2;6;4;d;11;L1200-04;d11;100;2;H21;3
574;S8057;Pacritinib (SB1518);H22;2;H;22;NA;d11;L2100-01;47258;937272-79-2;JAK;11;2327648229;<1;NA;http://www.selleckchem.com/products/pacritinib-sb1518.html;Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM, respectively.;JAK/STAT;C28H32N4O3;Free Base;N/A;C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\C=C\COCC1=C2)=CC=C3 |c:16,18,33,35,37,t:9,11,14,21,27|;4,547;5;1;4;9;d;11;L2100-01;d11;100;2;H22;3
575;NA;DMSO;H23;2;H;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;H23;3
576;NA;DMSO;H24;2;H;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;H24;3
577;S2621;AZD5438;I01;2;I;1;NA;e1;L1200-03;37146;602306-29-6;CDK;74;1992139127;<1;NA;http://www.selleckchem.com/products/AZD5438.html;AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3_. Phase 1.;Cell Cycle;C18H21N5O2S;Free Base;N/A;CC(C)N1C(C)=NC=C1C1=NC(NC2=CC=C(C=C2)S(C)(=O)=O)=NC=C1 |c:5,7,16,18,24,26,t:10,14|;2,966;5;1;5;3;e;1;L1200-03;e1;100;2;I01;3
578;S7642;D 4476;I02;2;I;2;NA;e2;L1200-05;398.41;301836-43-1;CK;79;1982881956;<1;NA;http://www.selleckchem.com/products/d-4476.html;D 4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1_, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.;Metabolism;C23H18N4O3;Free Base;N/A;NC(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=CC=N1)C1=CC2=C(OCCO2)C=C1 |c:5,7,12,18,20,32,t:3,10,16,23,25|;3,464;5;2;4;5;e;2;L1200-05;e2;100;2;I02;3
579;S2658;GSK2126458 (GSK458);I03;2;I;3;NA;e2;L1200-03;5055;1086062-66-9;PI3K, mTOR;100;1978239367;<1;NA;http://www.selleckchem.com/products/gsk2126458.html;Omipalisib (GSK2126458, GSK458) is a highly selective and potent inhibitor of p110_/_/_/_, mTORC1/2 with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM in cell-free assays, respectively. Phase 1.;PI3K/Akt/mTOR;C25H17F2N5O3S;Free Base;N/A;COC1=NC=C(C=C1NS(=O)(=O)C1=CC=C(F)C=C1F)C1=CC=C2N=CC=C(C3=CC=NN=C3)C2=C1 |c:4,6,18,26,32,34,38,t:2,13,15,22,24,28,30|;3,705;7;1;6;3;e;2;L1200-03;e2;100;2;I03;3
580;NA;DMSO;I04;2;I;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;I04;3
581;S2681;AS-604850;I05;2;I;5;NA;e3;L1200-03;28522;648449-76-7;PI3K;57;1998457331;<1;NA;http://www.selleckchem.com/products/as-604850.html;AS-604850 is a selective, ATP-competitive PI3K_ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3K_ than PI3K_/_, and 18-fold more selective for PI3K_ than PI3K_.;PI3K/Akt/mTOR;C11H5F2NO4S;Free Base;N/A;FC1(F)OC2=C(O1)C=C(C=C2)\C=C1/SC(=O)NC1=O |c:4,8,10|;3,744;4;1;1;3;e;3;L1200-03;e3;100;2;I05;3
582;S7813;AMG319;I06;2;I;6;NA;e4;L1200-05;385.4;1608125-21-8;PI3K;77;1997924235;<1;NA;http://www.selleckchem.com/products/amg319.html;AMG319 is a potent and selective PI3K_ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.;PI3K/Akt/mTOR;C21H16FN7;Free Base;N/A;C[C@H](NC1=C2N=CNC2=NC=N1)C1=C(N=C2C=C(F)C=CC2=C1)C1=CC=CC=N1 |r,c:3,5,9,11,21,24,29,31,t:14,16,18,27|;3,691;5;2;4;5;e;4;L1200-05;e4;100;2;I06;3
583;S2697;A-769662;I07;2;I;7;NA;e4;L1200-03;36039;844499-71-4;AMPK;72;1997835678;<1;NA;http://www.selleckchem.com/products/a-769662.html;A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 _M in cell-free assays, little effect on GPPase/FBPase activity.;PI3K/Akt/mTOR;C20H12N2O3S;Free Base;N/A;OC1=CC=CC=C1C1=CC=C(C=C1)C1=CSC2=C1C(O)=C(C#N)C(=O)N2 |c:3,5,10,12,18,t:1,8,15,22|;3,135;1;3;2;3;e;4;L1200-03;e4;100;2;I07;3
584;NA;DMSO;I08;2;I;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;I08;3
585;S2727;Dacomitinib (PF299804, PF299);I09;2;I;9;NA;e5;L1200-03;46994;1110813-31-4;EGFR;19;4043069328;<1;NA;http://www.selleckchem.com/products/pf299804.html;Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay, effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Phase 2.;Protein Tyrosine Kinase;C24H25ClFN5O2;Free Base;N/A;COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 |c:2,27,29,31,34,t:17,21,24|;5,055;4;2;7;3;e;5;L1200-03;e5;100;2;I09;3
586;S8002;GSK2636771;I10;2;I;10;NA;e6;L1200-05;43342;1372540-25-4;PI3K;28;6460246412;<1;NA;http://www.selleckchem.com/products/gsk2636771.html;GSK2636771 is a potent, orally bioavailable, PI3K_-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.;PI3K/Akt/mTOR;C22H22F3N3O3;Free Base;N/A;CC1=NC2=C(C=C(C=C2N1CC1=CC=CC(=C1C)C(F)(F)F)N1CCOCC1)C(O)=O |c:5,7,15,17,t:1,3,13|;4,303;3;0;5;5;e;6;L1200-05;e6;100;2;I10;3
587;S2746;AZ 628;I11;2;I;11;NA;e6;L1200-03;45152;878739-06-1;Raf;90;1993267186;<1;NA;http://www.selleckchem.com/products/az628.html;AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM in cell-free assays, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.;MAPK;C27H25N5O2;Free Base;N/A;CN1C=NC2=C(C=C(NC3=CC(NC(=O)C4=CC(=CC=C4)C(C)(C)C#N)=CC=C3C)C=C2)C1=O |c:2,17,19,26,28,32,t:4,6,9,15|;4,57;3;2;5;3;e;6;L1200-03;e6;100;2;I11;3
588;NA;DMSO;I12;2;I;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;I12;3
589;S2767;3-Methyladenine;I13;2;I;13;NA;e7;L1200-03;14915;5142-23-4;PI3K;3;2011397922;20;134,0931948;http://www.selleckchem.com/products/3-methyladenine.html;"3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3K_ with IC50 of 25 _M and 60 _M in HeLa cells;  blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.";PI3K/Akt/mTOR;C6H7N5;Free Base;3-MA;CN1C=NC(N)=C2N=CN=C12 |c:2,7,t:5,9|;-0,236;3;1;0;3;e;7;L1200-03;e7;100;2;I13;3
590;S8050;ETP-46464;I14;2;I;14;NA;e8;L1200-05;47052;1345675-02-6;mTOR;6;1275184902;<1;NA;http://www.selleckchem.com/products/etp-46464.html;ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.;PI3K/Akt/mTOR;C30H22N4O2;Free Base;N/A;CC(C)(C#N)C1=CC=C(C=C1)N1C(=O)OCC2=C1C1=C(C=CC(=C1)C1=CN=C3C=CC=CC3=C1)N=C2 |c:7,9,17,22,24,31,33,36,39,t:5,20,27,29|;5,813;4;0;3;5;e;8;L1200-05;e8;100;2;I14;3
591;S2791;Sotrastaurin;I15;2;I;15;NA;e8;L1200-03;43848;425637-18-9;PKC;87;1984126984;<1;NA;http://www.selleckchem.com/products/sotrastaurin-aeb071.html;"Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKC_ with Ki of 0.22 nM in a cell-free assay; inactive to PKC_. Phase 2.";TGF-beta/Smad;C25H22N6O2;Free Base;N/A;CN1CCN(CC1)C1=NC(C2=C(C(=O)NC2=O)C2=CNC3=C2C=CC=C3)=C2C=CC=CC2=N1 |c:22,25,27,31,33,36,t:8,11,19,29|;3,483;4;2;3;3;e;8;L1200-03;e8;100;2;I15;3
592;NA;DMSO;I16;2;I;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;I16;3
593;S2816;Tyrphostin AG 879;I17;2;I;17;NA;e9;L1200-03;31646;148741-30-4;HER2;36;1137584529;<1;NA;http://www.selleckchem.com/products/tyrphostin-ag-879-ag-879.html;Tyrphostin AG 879 potently inhibits HER2/ErbB2 with IC50 of 1 _M, 100- and 500-fold higher selective to ErbB2 than PDGFR and EGFR.;Protein Tyrosine Kinase;C18H24N2OS;Free Base;N/A;CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)\C=C(/C#N)C(N)=S |c:6,8,t:4|;4,565;0;2;4;3;e;9;L1200-03;e9;100;2;I17;3
594;NA;DMSO;I18;2;I;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;I18;3
595;S2859;Golvatinib (E7050);I19;2;I;19;NA;e10;L1200-03;63369;928037-13-2;c-Met, VEGFR;20;3156117344;<1;NA;http://www.selleckchem.com/products/golvatinib-e7050.html;Golvatinib (E7050) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, does not inhibit bFGF-stimulated HUVEC growth (up to 1000 nM). Phase 1/2.;Protein Tyrosine Kinase;C33H37F2N7O4;Free Base;E7050;CN1CCN(CC1)C1CCN(CC1)C(=O)NC1=NC=CC(OC2=CC(F)=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C2)=C1 |c:20,44,47,49,t:18,24,27,39,41|;3,173;5;3;8;3;e;10;L1200-03;e10;100;2;I19;3
596;NA;DMSO;I20;2;I;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;I20;3
597;S2896;ZM 323881 HCl;I21;2;I;21;NA;e11;L1200-03;41186;193000-39-4;VEGFR;10;2428009518;<1;NA;http://www.selleckchem.com/products/zm-323881-hcl.html;ZM 323881 is a potent and selective VEGFR2 inhibitor with IC50 of <2 nM, almost no activity on VEGFR1, PDGFR_, FGFR1, EGFR and ErbB2.;Protein Tyrosine Kinase;C22H19ClFN3O2;HCl;N/A;Cl.CC1=CC(F)=C(NC2=C3C=CC(OCC4=CC=CC=C4)=CC3=NC=N2)C=C1O |c:7,9,16,18,20,23,25,28,t:1,4,14|;5,876;3;2;5;3;e;11;L1200-03;e11;100;2;I21;3
598;NA;DMSO;I22;2;I;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;I22;3
599;NA;DMSO;I23;2;I;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;I23;3
600;NA;DMSO;I24;2;I;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;I24;3
601;S2924;CHIR-99021 (CT99021) HCl;J01;2;J;1;NA;e1;L1200-04;5018;252917-06-9 (free base);PI3K/Akt/mTOR;93;1853328019;<1;NA;http://www.selleckchem.com/products/chir-99021-ct99021-hcl.html;"CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3_/_ inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.";PI3K/Akt/mTOR;C22H19Cl3N8;HCl;N/A;Cl.CC1=CNC(=N1)C1=CN=C(NCCNC2=NC=C(C=C2)C#N)N=C1C1=CC=C(Cl)C=C1Cl |c:4,17,19,24,32,t:1,7,9,15,27,29|;4,858;4;3;7;4;e;1;L1200-04;e1;100;2;J01;3
602;S1082;Vismodegib (GDC-0449);J02;2;J;2;NA;e1;L2100-01;4213;879085-55-9;Hedgehog, P-gp;84;1993828626;<1;NA;http://www.selleckchem.com/products/GDC-0449.html;Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 _M.;Neuronal Signaling;C19H14Cl2N2O3S;Free Base;N/A;CS(=O)(=O)C1=CC=C(C(=O)NC2=CC(=C(Cl)C=C2)C2=NC=CC=C2)C(Cl)=C1 |c:16,21,23,27,t:4,6,11,13,19|;4,265;4;1;4;9;e;1;L2100-01;e1;100;2;J02;3
603;S4907;SC-514;J03;2;J;3;NA;e2;L1200-04;2243;354812-17-2;I_B/IKK;45;2006241641;<1;NA;http://www.selleckchem.com/products/sc-514.html;SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 _M, blocks NF-_B-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.;NF-_B;C9H8N2OS2;Free Base;N/A;NC(=O)C1=C(N)C=C(S1)C1=CSC=C1 |c:3,6,13,t:10|;1,51;1;2;2;4;e;2;L1200-04;e2;100;2;J03;3
604;S1476;SB525334;J04;2;J;4;NA;e2;L2100-01;34342;356559-20-1;TGF-beta/Smad;68;1980082698;<1;NA;http://www.selleckchem.com/products/SB-525334.html;SB525334 is a potent and selective inhibitor of TGF_ receptor I (ALK5) with IC50 of 14.3 nM, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.;TGF-beta/Smad;C21H21N5;Free Base;N/A;CC1=NC(=CC=C1)C1=C(NC(=N1)C(C)(C)C)C1=CC=C2N=CC=NC2=C1 |c:3,5,11,22,24,27,t:1,8,18,20|;4,305;4;1;3;9;e;2;L2100-01;e2;100;2;J04;3
605;S7016;VS-5584 (SB2343);J05;2;J;5;NA;e3;L1200-04;35441;1246560-33-7;PI3K;71;2003329477;<1;NA;http://www.selleckchem.com/products/vs-5584-sb2343.html;VS-5584 (SB2343) is a potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3K_/_/_/_ with IC50 of 3.4 nM and 2.6-21 nM, respectively. Phase 1.;PI3K/Akt/mTOR;C17H22N8O;Free Base;N/A;CC(C)N1C(C)=NC2=C1N=C(N=C2C1=CN=C(N)N=C1)N1CCOCC1 |c:5,7,10,12,20,t:15,17|;1,272;6;1;3;4;e;3;L1200-04;e3;100;2;J05;3
606;S2157;Taladegib (LY2940680);J06;2;J;6;NA;e3;L2100-01;512.5;1258861-20-9;Hedgehog,Hedgehog/Smoothened;NA;1000;NA;NA;http://selleckchem.com/products/ly2940680.html;Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.;Stem Cells &  Wnt;C26H24F4N6O;Free Base;N/A;CN(C1CCN(CC1)C1=NN=C(C2=CC=NN2C)C2=C1C=CC=C2)C(=O)C1=C(C=C(F)C=C1)C(F)(F)F |c:15,20,23,25,35,t:9,11,13,30,32|;NA;NA;NA;NA;9;e;3;L2100-01;e3;100;2;J06;3
607;S7060;PP1;J07;2;J;7;NA;e4;L1200-04;28136;172889-26-8;Src;4;1421666193;<1;NA;http://www.selleckchem.com/products/pp1.html;PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.;Angiogenesis;C16H19N5;Free Base;N/A;CC1=CC=C(C=C1)C1=NN(C2=NC=NC(N)=C12)C(C)(C)C |c:3,5,13,t:1,8,11,16|;3,257;3;1;2;4;e;4;L1200-04;e4;100;2;J07;3
608;S2308;Hesperetin;J08;2;J;8;NA;e4;L2100-01;30227;520-33-2;Histamine Receptor;60;1984980316;<1;NA;http://www.selleckchem.com/products/Hesperetin.html;Hesperetin is a bioflavonoid and, to be more specific, a flavanone.;TGF-beta/Smad;C16H14O6;Free Base;N/A;COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1 |r,c:4,6,14,20,t:2,17|;2,357;3;3;2;9;e;4;L2100-01;e4;100;2;J08;3
609;S7093;IPA-3;J09;2;J;9;NA;e5;L1200-04;35045;42521-82-4;PAK;70;1997431873;<1;NA;https://www.selleckchem.com/products/ipa-3.html;IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 _M in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).;Cytoskeletal Signaling;C20H14O2S2;Free Base;N/A;OC1=CC=C2C=CC=CC2=C1SSC1=C2C=CC=CC2=CC=C1O |c:5,7,10,15,17,19,22,24,t:1,3|;5,871;0;2;3;4;e;5;L1200-04;e5;100;2;J09;3
610;S2711;YO-01027;J10;2;J;10;NA;e5;L2100-01;46348;209984-56-5;Gamma-secretase;92;1984983171;<1;NA;http://www.selleckchem.com/products/yo-01027.html;YO-01027 (Dibenzazepine, DBZ) is a dipeptidic _-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.;Proteases;C26H23F2N3O3;Free Base;N/A;C[C@H](NC(=O)CC1=CC(F)=CC(F)=C1)C(=O)N[C@H]1C2=C(C=CC=C2)C2=C(C=CC=C2)N(C)C1=O |r,c:9,12,21,23,28,30,t:6,19,26|;3,277;3;2;5;9;e;5;L2100-01;e5;100;2;J10;3
611;S7136;CGK 733;J11;2;J;11;NA;e6;L1200-04;55584;905973-89-9;ATM/ATR;100;1799078872;<1;NA;http://www.selleckchem.com/products/cgk-733.html;CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.;DNA Damage;C23H18Cl3FN4O3S;Free Base;N/A;[O-][N+](=O)C1=CC(NC(=S)NC(NC(=O)C(C2=CC=CC=C2)C2=CC=CC=C2)C(Cl)(Cl)Cl)=CC=C1F |c:17,19,24,26,32,34,t:3,15,22|;6,795;1;3;10;4;e;6;L1200-04;e6;100;2;J11;3
612;S2791;Sotrastaurin;J12;2;J;12;NA;e6;L2100-01;43848;425637-18-9;PKC;87;1984126984;<1;NA;http://www.selleckchem.com/products/sotrastaurin-aeb071.html;"Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKC_ with Ki of 0.22 nM; inactive to PKC_. Phase 1/2.";TGF-beta/Smad;C25H22N6O2;Free Base;N/A;CN1CCN(CC1)C1=NC(C2=C(C(=O)NC2=O)C2=CNC3=C2C=CC=C3)=C2C=CC=CC2=N1 |c:22,25,27,31,33,36,t:8,11,19,29|;3,483;4;2;3;9;e;6;L2100-01;e6;100;2;J12;3
613;S7194;GZD824;J13;2;J;13;NA;e7;L1200-04;72477;1421783-64-3;Bcr-Abl;100;1379748058;100;137,9748058;http://www.selleckchem.com/products/gzd824.html;GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.;Angiogenesis;C31H35F3N6O7S2;Dimesylate;N/A;CS(O)(=O)=O.CS(O)(=O)=O.CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CC5=C(NN=C5)N=C4)=C(C)C=C3)C=C2)C(F)(F)F)CC1 |c:31,34,39,42,t:14,16,21,26,28,36|;4,047;3;2;7;4;e;7;L1200-04;e7;100;2;J13;3
614;S2924;CHIR-99021 (CT99021) HCl;J14;2;J;14;NA;e7;L2100-01;5018;252917-06-9 (free base);PI3K/Akt/mTOR;93;1853328019;<1;NA;http://www.selleckchem.com/products/chir-99021-ct99021-hcl.html;"CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3_/_ inhibitor with IC50 of 10 nM/6.7 nM; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.";PI3K/Akt/mTOR;C22H19Cl3N8;HCl;N/A;Cl.CC1=CNC(=N1)C1=CN=C(NCCNC2=NC=C(C=C2)C#N)N=C1C1=CC=C(Cl)C=C1Cl |c:4,17,19,24,32,t:1,7,9,15,27,29|;4,858;4;3;7;9;e;7;L2100-01;e7;100;2;J14;3
615;S7248;Ro3280;J15;2;J;15;NA;e8;L1200-04;54361;1062243-51-9;PLK;100;1839554092;<1;NA;http://www.selleckchem.com/products/ro3280.html;RO3280 is a potent, highly selective inhibitor of  Polo-like kinase 1 (PLK1) with IC50 of 3_nM.;Cell Cycle;C27H35F2N7O3;Free Base;Ro5203280;COC1=C(NC2=NC3=C(C=N2)N(C)C(=O)C(F)(F)CN3C2CCCC2)C=CC(=C1)C(=O)NC1CCN(C)CC1 |c:2,7,9,28,30,t:5|;3,245;5;2;6;4;e;8;L1200-04;e8;100;2;J15;3
616;S7143;LGK-974;J16;2;J;16;NA;e8;L2100-01;39644;1243244-14-5;Wnt/beta-catenin;79;1992735345;<1;NA;http://www.selleckchem.com/products/lgk-974.html;LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM. Phase 1.;Stem Cells &  Wnt;C23H20N6O;Free Base;N/A;CC1=CC(=CC=N1)C1=C(C)C=C(CC(=O)NC2=CC=C(C=N2)C2=CN=CC=N2)C=N1 |c:3,5,8,19,21,26,28,31,t:1,11,17,24|;2,098;6;1;5;9;e;8;L2100-01;e8;100;2;J16;3
617;S7297;AZD9291;J17;2;J;17;NA;e9;L1200-04;49961;1421373-65-0;EGFR;99;1981545606;<1;NA;http://www.selleckchem.com/products/azd9291.html;Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.;Protein Tyrosine Kinase;C28H33N7O2;Free Base;N/A;COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C |c:2,7,9,16,19,21,31,t:5,12,24|;4,671;4;2;10;4;e;9;L1200-04;e9;100;2;J17;3
618;S7253;AZD2858;J18;2;J;18;NA;e9;L2100-01;45352;486424-20-8;GSK-3;7;1543482096;<1;NA;http://www.selleckchem.com/products/azd2858.html;AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.;PI3K/Akt/mTOR;C21H23N7O3S;Free Base;N/A;CN1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CN=C(N)C(=N1)C(=O)NC1=CN=CC=C1 |c:13,15,23,31,33,t:11,18,20,29|;0,405;6;2;5;9;e;9;L2100-01;e9;100;2;J18;3
619;S7356;HS-173;J19;2;J;19;NA;e10;L1200-04;42246;1276110-06-5;PI3K;84;1988353927;<1;NA;http://www.selleckchem.com/products/hs-173.html;HS-173 is a potent PI3K_ inhibitor with IC50 of 0.8 nM.;PI3K/Akt/mTOR;C21H18N4O4S;Free Base;N/A;CCOC(=O)C1=CN=C2C=CC(=CN12)C1=CN=CC(NS(=O)(=O)C2=CC=CC=C2)=C1 |c:9,11,18,27,29,31,t:5,7,16,25|;2,058;6;1;7;4;e;10;L1200-04;e10;100;2;J19;3
620;S7501;HO-3867;J20;2;J;20;NA;e10;L2100-01;46455;1172133-28-6;STAT;13;2798407061;<1;NA;http://www.selleckchem.com/products/ho-3867.html;HO-3867, an analog of curcumin, is a selective STAT3 inhibitor.;JAK/STAT;C28H30F2N2O2;Free Base;N/A;[H]ON1C(C)(C)C=C(CN2C\C(=C/C3=CC=C(F)C=C3)C(=O)\C(C2)=C\C2=CC=C(F)C=C2)C1(C)C |c:18,32,t:6,13,15,27,29|;5,209;1;0;4;9;e;10;L2100-01;e10;100;2;J20;3
621;S7492;Uprosertib (GSK2141795);J21;2;J;21;NA;e11;L1200-04;429.25;1047634-65-0;Akt;93;21666;<1;NA;http://selleckchem.com/products/gsk2141795.html;Uprosertib (GSK2141795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.;PI3K/Akt/mTOR;C18H16Cl2F2N4O2;Free Base;GSK795;CN1N=CC(Cl)=C1C1=C(Cl)OC(=C1)C(=O)N[C@H](CN)CC1=CC(F)=C(F)C=C1 |r,c:2,5,8,12,28,t:22,25|;3,531;3;2;6;4;e;11;L1200-04;e11;100;2;J21;3
622;S8178;Wnt agonist 1;J22;2;J;22;NA;e11;L2100-01;386.83;853220-52-7(free-base);Wnt/beta-catenin;77;19905;<1;NA;http://selleckchem.com/products/wnt-agonist-1.html;Wnt agonist 1 is a cell permeable Wnt signaling pathway activator, which induces _-catenin- and TCF-dependent transcriptional activity with EC50 of 0.7 _M.;Stem Cells &  Wnt;C19H19ClN4O3;Salt;N/A;Cl.COC1=CC(=CC=C1)C1=NC(N)=NC(NCC2=CC=C3OCOC3=C2)=C1 |c:4,6,12,25,27,t:2,9,17,19|;3,837;5;2;5;9;e;11;L2100-01;e11;100;2;J22;3
623;NA;DMSO;J23;2;J;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;J23;3
624;NA;DMSO;J24;2;J;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;J24;3
625;S2622;PP121;K01;2;K;1;NA;f1;L1200-03;31936;1092788-83-4;DNA-PK, mTOR, PDGF;64;2004008016;<1;NA;http://www.selleckchem.com/products/PP121.html;PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.;Protein Tyrosine Kinase;C17H17N7;Free Base;N/A;NC1=NC=NC2=C1C(=NN2C1CCCC1)C1=CN=C2NC=CC2=C1 |c:3,5,8,23,26,t:1,18,20|;2,583;4;2;2;3;f;1;L1200-03;f1;100;2;K01;3
626;S7644;PF-431396;K02;2;K;2;NA;f2;L1200-05;506.5;717906-29-1;FAK;100;1974333662;<1;NA;http://www.selleckchem.com/products/pf-431396.html;PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.;Angiogenesis;C22H21F3N6O3S;Free Base;N/A;CN(C1=CC=CC=C1CNC1=C(C=NC(NC2=CC=C3NC(=O)CC3=C2)=N1)C(F)(F)F)S(C)(=O)=O |c:4,6,13,26,28,t:2,11,17,19|;3,102;5;3;8;5;f;2;L1200-05;f2;100;2;K02;3
627;S2661;WYE-125132 (WYE-132);K03;2;K;3;NA;f2;L1200-03;5196;1144068-46-1;mTOR;104;2001539646;<1;NA;http://www.selleckchem.com/products/wye-125132.html;"WYE-125132 (WYE-132) is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.";PI3K/Akt/mTOR;C27H33N7O4;Free Base;N/A;CNC(=O)NC1=CC=C(C=C1)C1=NC2=C(C=NN2C2CCC3(CC2)OCCO3)C(=N1)N1CC2CCC(C1)O2 |c:7,9,16,32,t:5,12,14|;2,093;7;2;4;3;f;2;L1200-03;f2;100;2;K03;3
628;NA;DMSO;K04;2;K;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;K04;3
629;S2682;CAY10505;K05;2;K;5;NA;f3;L1200-03;289.28;1218777-13-9;PI3K;58;20050;<1;NA;http://selleckchem.com/products/cay10505.html;CAY10505 is dehydroxyl of AS-252424, which is a PI3K_ inhibitor with IC50 of 33 nM.;PI3K/Akt/mTOR;C14H8FNO3S;Free Base;N/A;FC1=CC=C(C=C1)C1=CC=C(O1)\C=C1\SC(=O)NC1=O |c:3,5,10,t:1,8|;3,352;3;1;2;3;f;3;L1200-03;f3;100;2;K05;3
630;S7847;SGI-7079;K06;2;K;6;NA;f4;L1200-05;455.53;1239875-86-5;VEGFR;91;19977;<1;NA;http://selleckchem.com/products/sgi-7079.html;SGI-7079 ,a novel selective Axl inhibitor, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance.;Protein Tyrosine Kinase;C26H26FN7;Free Base;N/A;CN1CCN(CC1)C1=CC=C(NC2=NC3=C(C(C)=CN3)C(=N2)C2=CC(CC#N)=CC=C2)C=C1F |c:18,22,30,32,35,t:8,10,13,15,25|;5,286;2;2;5;5;f;4;L1200-05;f4;100;2;K06;3
631;S2699;CH5132799;K07;2;K;7;NA;f4;L1200-03;37742;1007207-67-1;PI3K, mTOR;12;3179481744;<1;NA;http://www.selleckchem.com/products/ch5132799.html;"CH5132799 inhibits class I PI3Ks, particularly PI3K_ with IC50 of 14 nM; less potent to PI3K___, while sensitive in PIK3CA mutations cell lines. Phase 1.";PI3K/Akt/mTOR;C15H19N7O3S;Free Base;N/A;CS(=O)(=O)N1CCC2=C(N=C(N=C12)N1CCOCC1)C1=CN=C(N)N=C1 |c:9,27,t:7,11,22,24|;0,095;7;1;3;3;f;4;L1200-03;f4;100;2;K07;3
632;NA;DMSO;K08;2;K;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;K08;3
633;S2728;AG-1478 (Tyrphostin AG-1478);K09;2;K;9;NA;f5;L1200-03;31575;153436-53-4;EGFR;25;7917656374;<1;NA;http://www.selleckchem.com/products/ag-1478-tyrphostin-ag-1478.html;AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.;Protein Tyrosine Kinase;C16H14ClN3O2;Free Base;Tyrphostin AG-1478;COC1=C(OC)C=C2C(NC3=CC(Cl)=CC=C3)=NC=NC2=C1 |c:2,13,15,17,19,22,t:6,10|;4,109;4;1;4;3;f;5;L1200-03;f5;100;2;K09;3
634;S8003;PQ 401;K10;2;K;10;NA;f6;L1200-05;34179;196868-63-0;IGF-1R;32;9362474034;<1;NA;http://www.selleckchem.com/products/pq-401.html;PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 _M.;Protein Tyrosine Kinase;C18H16ClN3O2;Free Base;N/A;COC1=C(NC(=O)NC2=C3C=CC=CC3=NC(C)=C2)C=C(Cl)C=C1 |c:2,8,10,12,15,18,24,t:21|;3,639;3;2;3;5;f;6;L1200-05;f6;100;2;K10;3
635;S2747;AMG-458;K11;2;K;11;NA;f6;L1200-03;53958;913376-83-7;c-Met;21;3891915935;<1;NA;http://www.selleckchem.com/products/amg458.html;AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.;Protein Tyrosine Kinase;C30H29N5O5;Free Base;N/A;COC1=CC2=NC=CC(OC3=CN=C(NC(=O)C4=C(C)N(CC(C)(C)O)N(C4=O)C4=CC=CC=C4)C=C3)=C2C=C1 |c:6,17,32,34,37,39,42,t:2,4,10,12,30|;3,125;6;1;8;3;f;6;L1200-03;f6;100;2;K11;3
636;NA;DMSO;K12;2;K;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;K12;3
637;S2768;Dinaciclib (SCH727965);K13;2;K;13;NA;f7;L1200-03;39649;779353-01-4;CDK;26;6557542435;<1;NA;http://www.selleckchem.com/products/dinaciclib-sch727965.html;Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.;Cell Cycle;C21H28N6O2;Free Base;N/A;CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N1CCCC[C@H]1CCO |r,c:2,4,12,15,20,t:6,10|;2,152;2;2;7;3;f;7;L1200-03;f7;100;2;K13;3
638;S8054;ASP3026;K14;2;K;14;NA;f8;L1200-05;580.74;1097917-15-1;ALK;14;2411;<1;NA;http://selleckchem.com/products/asp3026.html;ASP3026 is a novel and selective inhibitor for ALK  with IC50 of 3.5 nM. Phase 1.;Protein Tyrosine Kinase;C29H40N8O3S;Free Base;N/A;COC1=CC(=CC=C1NC1=NC(=NC=N1)NC1=CC=CC=C1S(=O)(=O)C(C)C)N1CCC(CC1)N1CCN(C)CC1 |c:4,6,12,14,20,22,t:2,10,18|;4,554;6;2;9;5;f;8;L1200-05;f8;100;2;K14;3
639;S2796;WP1066;K15;2;K;15;NA;f8;L1200-03;35622;857064-38-1;JAK;71;19931503;<1;NA;http://www.selleckchem.com/products/wp1066.html;"WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 _M and 2.43 _M in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. Phase 1.";JAK/STAT;C17H14BrN3O;Free Base;N/A;C[C@H](NC(=O)C(=C\C1=NC(Br)=CC=C1)\C#N)C1=CC=CC=C1 |r,c:10,12,19,21,t:7,17|;3,566;2;1;4;3;f;8;L1200-03;f8;100;2;K15;3
640;NA;DMSO;K16;2;K;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;K16;3
641;S2817;Torin 2;K17;2;K;17;NA;f9;L1200-03;4324;1223001-51-1;mTOR;20;4625346901;<1;NA;http://www.selleckchem.com/products/torin-2.html;"Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53_/_ MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively.";PI3K/Akt/mTOR;C24H15F3N4O;Free Base;N/A;NC1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C(=O)C=C3)C3=CC=CC(=C3)C(F)(F)F)C2=C1 |c:3,5,12,19,24,26,34,t:1,8,10,14,22|;4,323;3;1;3;3;f;9;L1200-03;f9;100;2;K17;3
642;NA;DMSO;K18;2;K;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;K18;3
643;S2864;IMD 0354;K19;2;K;19;NA;f10;L1200-03;38367;978-62-1;IKK;10;2606406547;<1;NA;http://www.selleckchem.com/products/imd-0354.html;IMD-0354 is an IKK_ inhibitor and blocks I_B_ phosphorylation in NF-_B pathway.;NF-_B;C15H8ClF6NO2;Free Base;N/A;OC1=C(C=C(Cl)C=C1)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F |c:6,14,16,t:1,3,12|;4,921;1;2;4;3;f;10;L1200-03;f10;100;2;K19;3
644;NA;DMSO;K20;2;K;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;K20;3
645;S2897;ZM 306416;K21;2;K;21;NA;f11;L1200-03;33374;690206-97-4;VEGFR;67;2007550788;<1;NA;http://www.selleckchem.com/products/zm-306416.html;ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 _M, but also found to inhibit EGFR with IC50 of <10 nM.;Protein Tyrosine Kinase;C16H13ClFN3O2;Free Base;N/A;COC1=CC2=NC=NC(NC3=C(F)C=C(Cl)C=C3)=C2C=C1OC |c:6,10,16,18,21,t:2,4,13|;4,314;4;1;4;3;f;11;L1200-03;f11;100;2;K21;3
646;NA;DMSO;K22;2;K;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;K22;3
647;NA;DMSO;K23;2;K;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;K23;3
648;NA;DMSO;K24;2;K;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;K24;3
649;S2926;TDZD-8;L01;2;L;1;NA;f1;L1200-04;222.26;327036-89-5;GSK-3;44.5;2002159633;<1;NA;http://www.selleckchem.com/products/tdzd-8.html;"TDZD-8 is a non-ATP competitive GSK-3_ inhibitor with IC50 of 2 _M; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.";PI3K/Akt/mTOR;C10H10N2O2S;Free Base;N/A;CN1SC(=O)N(CC2=CC=CC=C2)C1=O |c:9,11,t:7|;2,145;2;0;2;4;f;1;L1200-04;f1;100;2;L01;3
650;S1134;AT9283;L02;2;L;2;NA;f1;L2100-01;38143;896466-04-9;Bcr-Abl, JAK, Aurora Kinase;76;1992501901;<1;NA;http://www.selleckchem.com/products/AT9283.html;"AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM; also potent to Aurora A/B, Abl(T315I). Phase 1/2.";Others;C19H23N7O2;Free Base;N/A;O=C(NC1CC1)NC1=CNN=C1C1=NC2=CC(CN3CCOCC3)=CC=C2N1 |c:11,26,28,t:8,14,16|;1,51;4;4;5;9;f;1;L2100-01;f1;100;2;L02;3
651;S5001;Tofacitinib (CP-690550) Citrate;L03;2;L;3;NA;f2;L1200-04;50449;540737-29-9;JAK;100;1982199845;<1;NA;http://www.selleckchem.com/products/CP-690550.html;Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.;JAK/STAT;C22H28N6O8;Citrate;N/A;OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N |r,c:22,24,28,30|;0,193;6;1;8;4;f;2;L1200-04;f2;100;2;L03;3
652;S1528;LY2811376;L04;2;L;4;NA;f2;L2100-01;32036;1194044-20-6;5-alpha Reductase;16;4994381321;<1;NA;http://www.selleckchem.com/products/LY2811376.html;LY2811376 is the first orally available non-peptidic _-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease A_ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.;Proteases;C15H14F2N4S;Free Base;LY 2811376;C[C@]1(CCSC(N)=N1)C1=CC(=C(F)C=C1F)C1=CN=CN=C1 |r,c:6,14,20,22,t:9,11,18|;2,478;3;1;2;9;f;2;L2100-01;f2;100;2;L04;3
653;S7018;CZC24832;L05;2;L;5;NA;f3;L1200-04;3644;1159824-67-5;PI3K_;5;1372118551;<1;NA;http://www.selleckchem.com/products/czc24832.html;CZC24832 is the first selective PI3K_ inhibitor with IC50 of 27 nM, with 10-fold selectivity over PI3K_ and >100-fold selectivity over PI3K_ and PI3K_.;PI3K/Akt/mTOR;C15H17FN6O2S;Free Base;N/A;CC(C)(C)NS(=O)(=O)C1=CN=CC(=C1)C1=CN2N=C(N)N=C2C(F)=C1 |c:10,12,21,25,t:8,15,18|;0,815;5;2;4;4;f;3;L1200-04;f3;100;2;L05;3
654;S2162;AZD1480;L06;2;L;6;NA;f3;L2100-01;34877;935666-88-9, 1260222-79-4 (TFA);JAK;69;1978381168;<1;NA;http://www.selleckchem.com/products/AZD1480.html;AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.;JAK/STAT;C14H14ClFN8;Free Base;N/A;C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1 |r,c:14,16,24,t:3,5,10,19,21|;2,645;5;3;5;9;f;3;L2100-01;f3;100;2;L06;3
655;S7063;LY2090314;L07;2;L;7;NA;f4;L1200-04;512.53;603288-22-8;GSK-3;100;1951105301;<1;NA;http://www.selleckchem.com/products/ly2090314.html;"LY2090314 is a potent GSK-3 inhibitor for GSK-3_/_ with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 2.";PI3K/Akt/mTOR;C28H25FN6O3;Free Base;603288-22-8;FC1=CC2=C3N(CCN(C2)C(=O)N2CCCCC2)C=C(C3=C1)C1=C(C(=O)NC1=O)C1=CN=C2C=CC=CN12 |c:20,23,38,40,t:1,3,26,34,36|;2,707;4;1;2;4;f;4;L1200-04;f4;100;2;L07;3
656;S2386;Indirubin;L08;2;L;8;NA;f4;L2100-01;26226;479-41-4;GSK-3;53;2020895295;<1;NA;http://www.selleckchem.com/products/Indirubin.html;"Indirubin is a potent cyclin-dependent kinases and GSK-3_ inhibitor with IC50 of about 5 &mu;M and 0.6 &mu;M.";PI3K/Akt/mTOR;C16H10N2O2;Free Base;N/A;O=C1NC2=CC=CC=C2\C1=C1/NC2=C(C=CC=C2)C1=O |c:5,7,16,18,t:3,14|;1,876;2;2;0;9;f;4;L2100-01;f4;100;2;L08;3
657;S7094;PF-3758309;L09;2;L;9;NA;f5;L1200-04;49062;898044-15-0;PAK;98;1997472586;<1;NA;http://www.selleckchem.com/products/pf-3758309.html;PF-03758309 is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4  with IC50 of 1.3 nM.;Cytoskeletal Signaling;C25H30N8OS;Free Base;PF-03758309;CN(C)C[C@@H](NC(=O)N1CC2=C(NN=C2NC2=NC(C)=NC3=C2SC=C3)C1(C)C)C1=CC=CC=C1 |r,c:13,20,22,26,35,37,t:10,17,33|;4,077;4;3;6;4;f;5;L1200-04;f5;100;2;L09;3
658;S2714;LY411575;L10;2;L;10;NA;f5;L2100-01;47948;209984-57-6;Gamma-secretase;95;1981313089;<1;NA;http://www.selleckchem.com/products/ly-411575.html;LY411575 is a potent _-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM.;Proteases;C26H23F2N3O4;Free Base;N/A;C[C@H](NC(=O)[C@@H](O)C1=CC(F)=CC(F)=C1)C(=O)N[C@H]1C2=C(C=CC=C2)C2=C(C=CC=C2)N(C)C1=O |r,c:10,13,22,24,29,31,t:7,20,27|;2,625;3;3;5;9;f;5;L2100-01;f5;100;2;L10;3
659;S7145;AZD1080;L11;2;L;11;NA;f6;L1200-04;33437;612487-72-6;GSK-3;52;1555163442;<1;NA;http://www.selleckchem.com/products/azd1080.html;AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3_ and GSK3_ with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.;PI3K/Akt/mTOR;C19H18N4O2;Free Base;N/A;OC1=C(C2=CC(=CC=C2N1)C#N)C1=CC=C(CN2CCOCC2)C=N1 |c:5,7,26,t:1,3,14,16|;2,442;2;2;3;4;f;6;L1200-04;f6;100;2;L11;3
660;S2796;WP1066;L12;2;L;12;NA;f6;L2100-01;35622;857064-38-1;JAK;71;19931503;<1;NA;http://www.selleckchem.com/products/wp1066.html;"WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 _M and 2.43 _M in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3.";JAK/STAT;C17H14BrN3O;Free Base;N/A;C[C@H](NC(=O)C(=C\C1=NC(Br)=CC=C1)\C#N)C1=CC=CC=C1 |r,c:10,12,19,21,t:7,17|;3,566;2;1;4;9;f;6;L2100-01;f6;100;2;L12;3
661;S7195;RKI-1447;L13;2;L;13;NA;f7;L1200-04;32637;1342278-01-6;ROCK;65;1991604621;<1;NA;http://www.selleckchem.com/products/rki-1447.html;RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.;Cell Cycle;C16H14N4O2S;Free Base;N/A;OC1=CC(CNC(=O)NC2=NC(=CS2)C2=CC=NC=C2)=CC=C1 |c:11,17,19,21,23,t:1,9,15|;2,081;3;3;4;4;f;7;L1200-04;f7;100;2;L13;3
662;S5001;Tofacitinib (CP-690550) Citrate;L14;2;L;14;NA;f7;L2100-01;50449;540737-29-9;JAK;100;1982199845;<1;NA;http://www.selleckchem.com/products/CP-690550.html;Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.;JAK/STAT;C22H28N6O8;Citrate;N/A;OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N |r,c:22,24,28,30|;0,193;6;1;8;9;f;7;L2100-01;f7;100;2;L14;3
663;S7253;AZD2858;L15;2;L;15;NA;f8;L1200-04;45352;486424-20-8;GSK-3;7;1543482096;<1;NA;http://www.selleckchem.com/products/azd2858.html;AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.;PI3K/Akt/mTOR;C21H23N7O3S;Free Base;N/A;CN1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CN=C(N)C(=N1)C(=O)NC1=CN=CC=C1 |c:13,15,23,31,33,t:11,18,20,29|;0,405;6;2;5;4;f;8;L1200-04;f8;100;2;L15;3
664;S7145;AZD1080;L16;2;L;16;NA;f8;L2100-01;33437;612487-72-6;GSK-3;52;1555163442;<1;NA;http://www.selleckchem.com/products/azd1080.html;AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3_ and GSK3_ with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.;PI3K/Akt/mTOR;C19H18N4O2;Free Base;N/A;OC1=C(C2=CC(=CC=C2N1)C#N)C1=CC=C(CN2CCOCC2)C=N1 |c:5,7,26,t:1,3,14,16|;2,442;2;2;3;9;f;8;L2100-01;f8;100;2;L16;3
665;S7317;WZ4003;L17;2;L;17;NA;f9;L1200-04;49699;1214265-58-3;AMPK;7;1408479044;<1;NA;http://www.selleckchem.com/products/wz4003.html;WZ4003 is a highly specific NUAK kinase inhibitor with IC50 of 20 nM and 100 nM for NUAK1 and NUAK2 in cell-base assays, respectively, without significant inhibition on 139 other kinases.;PI3K/Akt/mTOR;C25H29ClN6O3;Free Base;N/A;CCC(=O)NC1=CC=CC(OC2=NC(NC3=C(OC)C=C(C=C3)N3CCN(C)CC3)=NC=C2Cl)=C1 |c:7,15,19,21,31,33,36,t:5,11|;4,776;5;2;8;4;f;9;L1200-04;f9;100;2;L17;3
666;S7269;PD173955;L18;2;L;18;NA;f9;L2100-01;44335;260415-63-2;Bcr-Abl;15;3383331454;<1;NA;http://www.selleckchem.com/products/pd173955.html;PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.;Angiogenesis;C21H18Cl2N4OS;Free Base;N/A;CSC1=CC(NC2=NC3C(C=N2)C=C(C(=O)N3C)C2=C(Cl)C=CC=C2Cl)=CC=C1 |c:10,13,20,23,25,28,30,t:2,6|;4,854;3;1;4;9;f;9;L2100-01;f9;100;2;L18;3
667;S7367;GNE-0877;L19;2;L;19;NA;f10;L1200-04;33932;1374828-69-9;leucine-rich repeat kinase 2 (LRRK2);67;197453731;<1;NA;http://www.selleckchem.com/products/gne-0877.html;GNE-0877 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki of 0.7 nM.;Autophagy;C14H16F3N7;Free Base;N/A;CNC1=NC(NC2=CN(N=C2C)C(C)(C)C#N)=NC=C1C(F)(F)F |c:9,17,19,t:2,6|;2,871;3;2;5;4;f;10;L1200-04;f10;100;2;L19;3
668;S7526;GNF-5;L20;2;L;20;NA;f10;L2100-01;41837;778277-15-9;Bcr-Abl;83;1983889858;<1;NA;http://www.selleckchem.com/products/gnf-5.html;GNF-5 is a selective and allosteric Bcr-Abl inhibitor with IC50 of 220 nM.;Angiogenesis;C20H17F3N4O3;Free Base;N/A;OCCNC(=O)C1=CC=CC(=C1)C1=CC(NC2=CC=C(OC(F)(F)F)C=C2)=NC=N1 |c:8,10,26,28,30,t:6,13,17,19|;4,876;4;3;8;9;f;10;L2100-01;f10;100;2;L20;3
669;S7498;DDR1-IN-1;L21;2;L;21;NA;f11;L1200-04;552.59;1449685-96-4;DDR(receptor tyrosine kinase);100;1809659965;<1;NA;http://www.selleckchem.com/products/ddr1-in-1.html;DDR1-IN-1 is a potent and selective discoidin domain receptor 1 (DDR1) receptor tyrosine kinase inhibitor with IC50 of 105 nM, about 3-fold selectivity over DDR2.;Others;C30H31F3N4O3;Free Base;N/A;CCN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC2=CC(OC3=CC=C4NC(=O)CC4=C3)=C(C)C=C2)CC1 |c:9,11,34,39,t:7,21,25,27,36|;4,972;3;2;8;4;f;11;L1200-04;f11;100;2;L21;3
670;S8195;Oclacitinib;L22;2;L;22;NA;f11;L2100-01;453.51;1640292-55-2;JAK;90;19845;18;3969041476;http://selleckchem.com/products/oclacitinib-maleate.html;Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.;JAK/STAT;C19H27N5O6S;Maleate;PF-03394197;OC(=O)\C=C/C(O)=O.CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(C)C1=C2C=CNC2=NC=N1 |r,c:22,24,28,30|;1,758;6;2;7;9;f;11;L2100-01;f11;100;2;L22;3
671;NA;DMSO;L23;2;L;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;L23;3
672;NA;DMSO;L24;2;L;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;L24;3
673;S2624;OSI-027;M01;2;M;1;NA;g1;L1200-03;40644;936890-98-1;mTOR;18;4428697963;<1;NA;http://www.selleckchem.com/products/OSI027.html;OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM in cell-free assays, and more than 100-fold selectivity observed for mTOR than PI3K_, PI3K_, PI3K_ or DNA-PK. Phase 1.;PI3K/Akt/mTOR;C21H22N6O3;Free Base;N/A;COC1=CC=CC2=C1NC(=C2)C1=C2N(N=CN=C2N)C(=N1)[C@H]1CC[C@@H](CC1)C(O)=O |r,c:4,6,10,16,18,22,t:2,13|;3,376;5;2;4;3;g;1;L1200-03;g1;100;2;M01;3
674;S7664;GSK2578215A;M02;2;M;2;NA;g2;L1200-05;399.42;1285515-21-0;LRRK2;79;1977867908;<1;NA;http://www.selleckchem.com/products/gsk2578215a.html;GSK2578215A is a potent and selective LRRK2 kinase inhibitor with IC50 of 8.9 nM and 10.9 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.;Autophagy;C24H18FN3O2;Free Base;N/A;FC1=NC=CC(=C1)C1=CC(C(=O)NC2=CC=CN=C2)=C(OCC2=CC=CC=C2)C=C1 |c:3,5,16,18,26,28,31,t:1,8,14,20,24|;3,985;4;1;6;5;g;2;L1200-05;g2;100;2;M02;3
675;S2670;A-674563;M03;2;M;3;NA;g2;L1200-03;35844;552325-73-2;Akt, CDK, PKA;72;2008704386;72;200,8704386;http://www.selleckchem.com/products/a-674563.html;A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.;PI3K/Akt/mTOR;C22H22N4O;Free Base;N/A;CC1=NNC2=C1C=C(C=C2)C1=CN=CC(OC[C@@H](N)CC2=CC=CC=C2)=C1 |r,c:4,7,9,14,24,26,28,t:1,12,22|;3,212;3;2;6;3;g;2;L1200-03;g2;100;2;M03;3
676;NA;DMSO;M04;2;M;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;M04;3
677;S2683;CHIR-124;M05;2;M;5;NA;g3;L1200-03;41991;405168-58-3;Chk;7;1667023886;<1;NA;http://www.selleckchem.com/products/chir-124.html;CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.;Cell Cycle;C23H22ClN5O;Free Base;N/A;ClC1=CC2=C(NC(=O)C(C3=NC4=C(N3)C=CC=C4)=C2N[C@@H]2CN3CCC2CC3)C=C1 |r,c:11,15,17,19,33,t:1,3,9|;3,089;2;3;3;3;g;3;L1200-03;g3;100;2;M05;3
678;S7854;Ulixertinib (BVD-523, VRT752271);M06;2;M;6;NA;g4;L1200-05;433.33;869886-67-9;ERK;86;1984630651;<1;NA;http://www.selleckchem.com/products/ulixertinib-bvd-523-vrt752271.html;Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.;MAPK;C21H22Cl2N4O2;Free Base;N/A;CC(C)NC1=NC=C(Cl)C(=C1)C1=CNC(=C1)C(=O)N[C@H](CO)C1=CC(Cl)=CC=C1 |r,c:9,15,27,29,t:4,6,12,24|;4,266;2;4;7;5;g;4;L1200-05;g4;100;2;M06;3
679;S2700;KX2-391;M07;2;M;7;NA;g4;L1200-03;43153;897016-82-9;Src;86;1992908952;<1;NA;http://www.selleckchem.com/products/kx2-391.html;KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.;Angiogenesis;C26H29N3O3;Free Base;N/A;O=C(CC1=CC=C(C=N1)C1=CC=C(OCCN2CCOCC2)C=C1)NCC1=CC=CC=C1 |c:5,7,24,31,33,t:3,10,12,29|;3,262;4;1;9;3;g;4;L1200-03;g4;100;2;M07;3
680;NA;DMSO;M08;2;M;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;M08;3
681;S2729;SB415286;M09;2;M;9;NA;g5;L1200-03;35972;264218-23-7;GSK-3;72;2001556766;<1;NA;http://www.selleckchem.com/products/sb-415286.html;SB415286 is a potent GSK3_ inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3_.;PI3K/Akt/mTOR;C16H10ClN3O5;Free Base;N/A;OC1=C(Cl)C=C(NC2=C(C(=O)NC2=O)C2=C(C=CC=C2)[N+]([O-])=O)C=C1 |c:1,17,19,25,t:4,7,15|;2,49;2;3;4;3;g;5;L1200-03;g5;100;2;M09;3
682;S8004;ZM 39923 HCl;M10;2;M;10;NA;g6;L1200-05;36791;1021868-92-7;JAK;30;8154168139;<1;NA;http://www.selleckchem.com/products/zm-39923-hcl.html;"ZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.";JAK/STAT;C23H26ClNO;HCl;N/A;Cl.CC(C)N(CCC(=O)C1=CC=C2C=CC=CC2=C1)CC1=CC=CC=C1 |c:12,14,17,23,25,t:8,10,21|;5,424;1;0;7;5;g;6;L1200-05;g6;100;2;M10;3
683;S2749;BGT226 (NVP-BGT226);M11;2;M;11;NA;g6;L1200-03;6506;1245537-68-1;PI3K, mTOR;30;4611128189;<1;NA;http://www.selleckchem.com/products/nvp-bgt226.html;BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3K_/_/_ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.;PI3K/Akt/mTOR;C32H29F3N6O6;Free Base;N/A;OC(=O)\C=C/C(O)=O.COC1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C(=O)N3C)C3=CC=C(N4CCNCC4)C(=C3)C(F)(F)F)C2=C1 |c:11,13,20,41,49,t:9,16,18,22,30,32|;1,618;6;1;7;3;g;6;L1200-03;g6;100;2;M11;3
684;NA;DMSO;M12;2;M;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;M12;3
685;S2769;Dovitinib (TKI-258) Dilactic Acid;M13;2;M;13;NA;g7;L1200-03;57259;852433-84-2;Flt, FGFR, PDGFR, VEGFR, c-Kit;90;1571805306;70;122,2515238;http://www.selleckchem.com/products/dovitinib.html;Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.;Angiogenesis;C27H33FN6O7;Dilactic Acid;CHIR-258 Dilactic acid;CC(O)C(O)=O.CC(O)C(O)=O.CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F |c:22,26,29,32,38,40,t:18,20|;-2,038;4;5;4;3;g;7;L1200-03;g7;100;2;M13;3
686;S8057;Pacritinib (SB1518);M14;2;M;14;NA;g8;L1200-05;47258;937272-79-2;JAK;11;2327648229;<1;NA;http://www.selleckchem.com/products/pacritinib-sb1518.html;Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.;JAK/STAT;C28H32N4O3;Free Base;N/A;C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\C=C\COCC1=C2)=CC=C3 |c:16,18,33,35,37,t:9,11,14,21,27|;4,547;5;1;4;5;g;8;L1200-05;g8;100;2;M14;3
687;S2801;AZD4547;M15;2;M;15;NA;g8;L1200-03;46357;1035270-39-3;FGFR;92;1984597795;<1;NA;http://www.selleckchem.com/products/azd4547.html;AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.;Angiogenesis;C26H33N5O3;Free Base;N/A;COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N3C[C@H](C)N[C@H](C)C3)=NN2)=C1 |r,c:6,19,21,32,35,t:2,11,17|;4,204;4;3;8;3;g;8;L1200-03;g8;100;2;M15;3
688;NA;DMSO;M16;2;M;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;M16;3
689;S2820;TAE226 (NVP-TAE226);M17;2;M;17;NA;g9;L1200-03;46894;761437-28-9;FAK;94;2004520834;<1;NA;http://www.selleckchem.com/products/nvp-tae226.html;TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.;Angiogenesis;C23H25ClN6O3;Free Base;N/A;CNC(=O)C1=C(NC2=C(Cl)C=NC(NC3=C(OC)C=C(C=C3)N3CCOCC3)=N2)C=CC=C1 |c:4,7,10,14,18,20,29,32,34|;3,917;5;3;7;3;g;9;L1200-03;g9;100;2;M17;3
690;NA;DMSO;M18;2;M;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;M18;3
691;S2867;WHI-P154;M19;2;M;19;NA;g10;L1200-03;3762;211555-04-3;JAK, EGFR;75;1993620415;<1;NA;http://www.selleckchem.com/products/whi-p154.html;WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 _M, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.;JAK/STAT;C16H14BrN3O3;Free Base;N/A;COC1=CC2=NC=NC(NC3=CC=C(O)C(Br)=C3)=C2C=C1OC |c:6,16,18,21,t:2,4,10,12|;3,95;4;2;4;3;g;10;L1200-03;g10;100;2;M19;3
692;NA;DMSO;M20;2;M;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;M20;3
693;S2899;GNF-2;M21;2;M;21;NA;g11;L1200-03;37432;778270-11-4;Bcr-Abl;74;1976918145;<1;NA;http://www.selleckchem.com/products/gnf-2.html;GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.;Angiogenesis;C18H13F3N4O2;Free Base;N/A;NC(=O)C1=CC=CC(=C1)C1=NC=NC(NC2=CC=C(OC(F)(F)F)C=C2)=C1 |c:5,7,12,25,27,t:3,10,16,18|;5,209;4;2;6;3;g;11;L1200-03;g11;100;2;M21;3
694;NA;DMSO;M22;2;M;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;M22;3
695;NA;DMSO;M23;2;M;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;M23;3
696;NA;DMSO;M24;2;M;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;M24;3
697;S2928;TAK-715;N01;2;N;1;NA;g1;L1200-04;39951;303162-79-0;p38 MAPK;80;2002453005;<1;NA;http://www.selleckchem.com/products/tak-715.html;TAK-715 is a p38 MAPK inhibitor for p38_ with IC50 of 7.1 nM, 28-fold more selective for p38_ over p38_, no inhibition to p38_/_, JNK1, ERK1, IKK_, MEKK1 or TAK1. Phase 2.;MAPK;C24H21N3OS;Free Base;N/A;CCC1=NC(=C(S1)C1=CC(NC(=O)C2=CC=CC=C2)=NC=C1)C1=CC=CC(C)=C1 |c:4,16,18,20,22,27,30,t:2,8,14,25|;5,629;3;1;5;4;g;1;L1200-04;g1;100;2;N01;3
698;S1143;AG-490 (Tyrphostin B42);N02;2;N;2;NA;g1;L2100-01;2943;133550-30-8;JAK, EGFR;59;2004757051;<1;NA;http://www.selleckchem.com/products/AG-490.html;AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 _M, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.;Others;C17H14N2O3;Free Base;N/A;OC1=C(O)C=C(\C=C(/C#N)C(=O)NCC2=CC=CC=C2)C=C1 |c:1,16,18,21,t:4,14|;2,444;1;3;4;9;g;1;L2100-01;g1;100;2;N02;3
699;S5002;Fingolimod (FTY720) HCl;N03;2;N;3;NA;g2;L1200-04;3439;162359-56-0;S1P Receptor, Bcr-Abl, PKC;69;2006397208;69;200,6397208;http://www.selleckchem.com/products/FTY720.html;Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.;GPCR & G Protein;C19H34ClNO2;Hydrochloride;Gilenia;Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 |c:20,t:8,10|;4,58;0;3;12;4;g;2;L1200-04;g2;100;2;N03;3
700;S1573;Fasudil (HA-1077) HCl;N04;2;N;4;NA;g2;L2100-01;32783;105628-07-7;ROCK;5;1525180734;65;1982734954;http://www.selleckchem.com/products/Fasudil-HCl(HA-1077).html;Fasudil (HA-1077) is a potent inhibitor of ROCK-II, PKA,  PKG,  PKC, and MLCK with Ki of 0.33 _M, 1.6 _M, 1.6 _M, 3.3 _M and 36 _M, respectively.;Cell Cycle;C14H18ClN3O2S;Hydrochloride;AT-877;Cl.O=S(=O)(N1CCCNCC1)C1=C2C=CN=CC2=CC=C1 |c:11,13,15,18,20|;0,57;3;1;2;9;g;2;L2100-01;g2;100;2;N04;3
701;S7028;IPI-145 (INK1197);N05;2;N;5;NA;g3;L1200-04;41686;1201438-56-3;PI3K;83;1991076141;<1;NA;http://www.selleckchem.com/products/ipi-145-ink1197.html;Duvelisib (IPI-145, INK1197) is a novel and selective PI3K _/_ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K _/_ than other protein kinases. Phase 3.;Angiogenesis;C22H17ClN6O;Free Base;N/A;C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 |r,c:5,7,10,18,21,30,32,t:3,14,16,28|;3,648;4;2;4;4;g;3;L1200-04;g3;100;2;N05;3
702;S2179;LY2784544;N06;2;N;6;NA;g3;L2100-01;46994;1229236-86-5;JAK;94;2000255352;<1;NA;http://www.selleckchem.com/products/LY2784544.html;LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.;JAK/STAT;C23H25ClFN7O;Free Base;N/A;CC1=NNC(NC2=NN3C(CC4=CC=C(Cl)C=C4F)=C(C)N=C3C(CN3CCOCC3)=C2)=C1 |c:16,22,33,35,t:1,6,11,13,19|;3,938;4;2;6;9;g;3;L2100-01;g3;100;2;N06;3
703;S7065;MK-8745;N07;2;N;7;NA;g4;L1200-04;43191;885325-71-3;Aurora Kinase;86;1991155565;<1;NA;http://www.selleckchem.com/products/mk-8745.html;MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.;Cell Cycle;C20H19ClFN5OS;Free Base;N/A;FC1=C(C=CC=C1Cl)C(=O)N1CCN(CC2=CC=CC(NC3=NC=CS3)=N2)CC1 |c:3,5,18,24,27,t:1,16,22|;3,805;3;1;5;4;g;4;L1200-04;g4;100;2;N07;3
704;S2391;Quercetin;N08;2;N;8;NA;g4;L2100-01;30224;117-39-5;PI3K, PKC, Src, Sirtuin;61;2018263632;<1;NA;http://www.selleckchem.com/products/Quercetin(Sophoretin).html;"Quercetin is a natural flavonoid present in vegetables, fruit and wine and is a PI3K inhibitor with IC50 of 2.4 Ð 5.4 &mu;M.";Epigenetics;C15H10O7;Free Base;Meletin, Quercetine;OC1=CC(O)=C2C(=O)C(O)=C(OC2=C1)C1=CC=C(O)C(O)=C1 |c:9,13,22,t:1,4,16,18|;1,63;2;5;1;9;g;4;L2100-01;g4;100;2;N08;3
705;S7102;VE-822;N09;2;N;9;NA;g5;L1200-04;46355;1232416-25-9;ATM/ATR;36;7766152519;<1;NA;http://www.selleckchem.com/products/ve-822.html;VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.;PI3K/Akt/mTOR;C24H25N5O3S;Free Base;N/A;CNCC1=CC=C(C=C1)C1=NOC(=C1)C1=C(N)N=CC(=N1)C1=CC=C(C=C1)S(=O)(=O)C(C)C |c:5,7,13,16,19,21,26,28,t:3,10,24|;3,697;6;2;7;4;g;5;L1200-04;g5;100;2;N09;3
706;S2729;SB415286;N10;2;N;10;NA;g5;L2100-01;35972;264218-23-7;GSK-3;72;2001556766;<1;NA;http://www.selleckchem.com/products/sb-415286.html;SB415286 is a potent GSK3_ inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3_.;PI3K/Akt/mTOR;C16H10ClN3O5;Free Base;N/A;OC1=C(Cl)C=C(NC2=C(C(=O)NC2=O)C2=C(C=CC=C2)[N+]([O-])=O)C=C1 |c:1,17,19,25,t:4,7,15|;2,49;2;3;4;9;g;5;L2100-01;g5;100;2;N10;3
707;S7153;10058-F4;N11;2;N;11;NA;g6;L1200-04;24935;403811-55-2;c-Myc;50;2005213555;<1;NA;https://www.selleckchem.com/products/10058-f4.html;10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression.;Cell Cycle;C12H11NOS2;Free Base;N/A;CCC1=CC=C(\C=C2\SC(=S)NC2=O)C=C1 |c:15,t:2,4|;3,783;1;1;2;4;g;6;L1200-04;g6;100;2;N11;3
708;S2806;CEP-33779;N12;2;N;12;NA;g6;L2100-01;46257;1257704-57-6;JAK;93;2010506518;<1;NA;http://www.selleckchem.com/products/cep33779.html;CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.;JAK/STAT;C24H26N6O2S;Free Base;N/A;CN1CCN(CC1)C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C2=CC=C(C=C2)S(C)(=O)=O)=C1 |c:10,17,19,22,27,29,35,t:8,14,25|;3,86;4;1;5;9;g;6;L2100-01;g6;100;2;N12;3
709;S7198;BIO;N13;2;N;13;NA;g7;L1200-04;35617;667463-62-9;GSK-3;71;1993430104;<1;NA;http://www.selleckchem.com/products/bio.html;BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3_/_ in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.;PI3K/Akt/mTOR;C16H10BrN3O2;Free Base;GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime;O\N=C1C2=CC=CC=C2NC/1=C1\C(=O)NC2=C1C=CC(Br)=C2 |c:5,7,17,20,23,t:3|;2,692;2;2;0;4;g;7;L1200-04;g7;100;2;N13;3
710;S7036;XL019;N14;2;N;14;NA;g7;L2100-01;44453;945755-56-6;JAK;16;3599307133;<1;NA;http://www.selleckchem.com/products/xl019.html;XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.;JAK/STAT;C25H28N6O2;Free Base;N/A;O=C(NC1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1)[C@@H]1CCCN1 |r,c:5,7,12,18,20,29,t:3,10,16|;3,106;4;3;6;9;g;7;L2100-01;g7;100;2;N14;3
711;S7257;CNX-774;N15;2;N;15;NA;g8;L1200-04;4995;1202759-32-7;BTK;100;2002002002;<1;NA;http://www.selleckchem.com/products/cnx-774.html;CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.;Angiogenesis;C26H22FN7O3;Free Base;N/A;CNC(=O)C1=CC(OC2=CC=C(NC3=NC(NC4=CC=CC(NC(=O)C=C)=C4)=C(F)C=N3)C=C2)=CC=N1 |c:19,26,31,34,36,38,t:4,8,10,13,17,28|;4,281;6;4;9;4;g;8;L1200-04;g8;100;2;N15;3
712;S7193;1-Azakenpaullone;N16;2;N;16;NA;g8;L2100-01;32816;676596-65-9;GSK-3;66;2011214042;<1;NA;http://www.selleckchem.com/products/1-azakenpaullone.html;1-Azakenpaullone is a potent and selective GSK-3_ inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.;PI3K/Akt/mTOR;C15H10BrN3O;Free Base;N/A;BrC1=CC2=C(NC3=C2CC(=O)NC2=C3N=CC=C2)C=C1 |c:6,13,16,18,21,t:1,3|;2,949;2;2;0;9;g;8;L2100-01;g8;100;2;N16;3
713;S7318;HTH-01-015;N17;2;N;17;NA;g9;L1200-04;468.55;1613724-42-7;AMPK;58;1237861488;<1;NA;http://www.selleckchem.com/products/hth-01-015.html;HTH-01-015 is a potent and selective NUAK1 inhibitor with IC50 of 100 nM, >100-fold selectivity over NUAK2.;PI3K/Akt/mTOR;C26H28N8O;Free Base;N/A;CN1C2=NC(NC3=CN(N=C3)C3CCNCC3)=NC(C)=C2N(C)C(=O)C2=C1C=C1C=CC=CC1=C2 |c:9,18,21,28,33,35,38,t:2,6,31|;2,993;4;2;3;4;g;9;L1200-04;g9;100;2;N17;3
714;S7301;IWP-L6;N18;2;N;18;NA;g9;L2100-01;47258;1427782-89-5;Wnt/beta-catenin;25;5290109611;<1;NA;http://www.selleckchem.com/products/iwp-l6.html;IWP-L6 is a highly potent Porcn inhibitor with EC50 of 0.5 nM.;Stem Cells &  Wnt;C25H20N4O2S2;Free Base;Porcn Inhibitor III;O=C(CSC1=NC2=C(SCC2)C(=O)N1C1=CC=CC=C1)NC1=NC=C(C=C1)C1=CC=CC=C1 |c:18,20,26,28,33,35,t:4,6,16,24,31|;4,072;4;1;6;9;g;9;L2100-01;g9;100;2;N18;3
715;S7368;GNE-9605;N19;2;N;19;NA;g10;L1200-04;44983;1536200-31-3;LRRK2;89;1978525221;<1;NA;http://www.selleckchem.com/products/gne-9605.html;GNE-9605 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki and IC50 of 2 nM and 19 nM, respectively.;Autophagy;C17H20ClF4N7O;Free Base;N/A;CNC1=NC(NC2=C(Cl)N(N=C2)[C@H]2CCN(C[C@@H]2F)C2COC2)=NC=C1C(F)(F)F |r,c:6,10,25,27,t:2|;2,715;4;2;6;4;g;10;L1200-04;g10;100;2;N19;3
716;S7541;Decernotinib (VX-509);N20;2;N;20;NA;g10;L2100-01;392.38;944842-54-0;JAK;78;19879;<1;NA;http://selleckchem.com/products/decernotinib-vx-509.html;Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.;JAK/STAT;C18H19F3N6O;Free Base;N/A;CC[C@@](C)(NC1=NC(=NC=C1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F |r,c:7,9,17,t:5,12,15,19|;2,747;4;3;7;9;g;10;L2100-01;g10;100;2;N20;3
717;S7508;JNK Inhibitor IX;N21;2;N;21;NA;g11;L1200-04;33242;312917-14-9;JNK;20;6016485169;<1;NA;http://www.selleckchem.com/products/jnk-inhibitor-ix.html;JNK inhibitor IX is a selective and potent JNK inhibitor with pIC50 of 6.5 and 6.7 for JNK2 and JNK3, respectively.;MAPK;C20H16N2OS;Free Base;TCS JNK 5a;O=C(NC1=C(C#N)C2=C(CCCC2)S1)C1=CC=CC2=C1C=CC=C2 |c:3,18,20,23,25,t:7,16|;4,571;1;1;2;4;g;11;L1200-04;g11;100;2;N21;3
718;S8262;PRI-724;N22;2;N;22;NA;g11;L2100-01;548.63;847591-62-2;Wnt/beta-catenin;100;18227;<1;NA;http://selleckchem.com/products/pri-724.html;PRI-724 is a potent, specific inhibitor of the canonical Wnt signaling pathway in cancer stem cells with potential antineoplastic activity. PRI-724 specifically inhibits the recruiting of beta-catenin with its coactivator CBP.;Stem Cells &  Wnt;C33H32N4O4;Free Base;N/A;[H][C@]12CN(CC3=CC=CC4=C3C=CC=C4)C(=O)[C@H](CC3=CC=C(O)C=C3)N1C(=O)CCN2C(=O)NCC1=CC=CC=C1 |r,c:7,9,12,14,26,43,45,t:5,21,23,41|;4,065;3;2;6;9;g;11;L2100-01;g11;100;2;N22;3
719;NA;DMSO;N23;2;N;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;N23;3
720;NA;DMSO;N24;2;N;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;N24;3
721;S2625;Fostamatinib (R788);O01;2;O;1;NA;h1;L1200-03;58046;901119-35-5;Syk;116;199841505;<1;NA;http://www.selleckchem.com/products/R7935788-Fostamatinib.html;Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.;Angiogenesis;C23H26FN6O9P;Free Base;N/A;COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=N2)=CC(OC)=C1OC |c:31,33,35,39,t:2,6,8,13,15|;3,458;9;2;10;3;h;1;L1200-03;h1;100;2;O01;3
722;S7693;AZD6738;O02;2;O;2;NA;h2;L1200-05;412.51;1352226-88-0;ATM/ATR;82;1987830598;<1;NA;http://www.selleckchem.com/products/azd6738.html;AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.;PI3K/Akt/mTOR;C20H24N6O2S;Free Base;N/A;C[C@@H]1COCCN1C1=NC(=NC(=C1)C1(CC1)S(C)(=N)=O)C1=C2C=CNC2=NC=C1 |r,c:10,12,23,25,29,31,t:8|;2,427;5;1;4;5;h;2;L1200-05;h2;100;2;O02;3
723;S2671;AS-252424;O03;2;O;3;NA;h2;L1200-03;30528;900515-16-4;PI3K;61;1998165618;<1;NA;http://www.selleckchem.com/products/as-252424.html;AS-252424 is a novel, potent PI3K_ inhibitor with IC50 of 30 nM in a cell-free assay with 30-fold selectivity for PI3K_ than PI3K_, and low inhibitory activity towards PI3K_/_.;PI3K/Akt/mTOR;C14H8FNO4S;Free Base;N/A;OC1=C(C=CC(F)=C1)C1=CC=C(O1)\C=C1/SC(=O)NC1=O |c:3,6,11,t:1,9|;3,11;3;2;2;3;h;2;L1200-03;h2;100;2;O03;3
724;NA;DMSO;O04;2;O;4;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;O04;3
725;S2686;NVP-BSK805 2HCl;O05;2;O;5;NA;h3;L1200-03;56347;1092499-93-8 (free base);JAK;113;2005430635;3;5,324152129;http://www.selleckchem.com/products/nvp-bsk805.html;NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM,>20-fold selectivity towards JAK1, JAK3 and TYK2.;JAK/STAT;C27H30Cl2F2N6O;dihydrochloride;N/A;Cl.Cl.FC1=CC(=CC(F)=C1CN1CCOCC1)C1=C2N=C(C=NC2=CC=C1)C1=CN(N=C1)C1CCNCC1 |c:3,6,17,19,21,24,26,32,t:1,29|;3,92;4;1;5;3;h;3;L1200-03;h3;100;2;O05;3
726;S7870;LJH685;O06;2;O;6;NA;h4;L1200-05;381.42;1627710-50-2;S6 Kinase;76;19926;<1;NA;http://selleckchem.com/products/ljh685.html;LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.;PI3K/Akt/mTOR;C22H21F2N3O;Free Base;N/A;CN1CCN(CC1)C1=CC=C(C=C1)C1=C(C=NC=C1)C1=CC(F)=C(O)C(F)=C1 |c:10,12,17,19,29,t:8,15,22,25|;4,004;1;1;3;5;h;4;L1200-05;h4;100;2;O06;3
727;S2703;GSK1838705A;O07;2;O;7;NA;h4;L1200-03;53257;1116235-97-2;IGF-1, ALK;107;2009125561;<1;NA;http://www.selleckchem.com/products/gsk1838705a.html;GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.;Protein Tyrosine Kinase;C27H29FN8O3;Free Base;N/A;CNC(=O)C1=C(F)C=CC=C1NC1=C2C=CNC2=NC(NC2=C(OC)C=C3CCN(C(=O)CN(C)C)C3=C2)=N1 |c:4,7,9,13,15,19,23,39,41,t:27|;3,508;5;4;8;3;h;4;L1200-03;h4;100;2;O07;3
728;NA;DMSO;O08;2;O;8;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;O08;3
729;S2730;Crenolanib (CP-868596);O09;2;O;9;NA;h5;L1200-03;44354;670220-88-9;PDGFR;89;2006583397;<1;NA;http://www.selleckchem.com/products/crenolanib-cp-868596.html;Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFR_/_ with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.;Protein Tyrosine Kinase;C26H29N5O2;Free Base;N/A;CC1(COC2=CC3=C(C=C2)N(C=N3)C2=NC3=C(C=CC=C3C=C2)N2CCC(N)CC2)COC1 |c:6,8,12,19,21,24,t:4,15,17|;3,192;4;1;5;3;h;5;L1200-03;h5;100;2;O09;3
730;S8005;SMI-4a;O10;2;O;10;NA;h6;L1200-05;27323;438190-29-5;Pim;55;2012956118;<1;NA;http://www.selleckchem.com/products/smi-4a.html;SMI-4a is a potent inhibitor ofÊPim1ÊwithÊIC50Êof 17 nM, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.;JAK/STAT;C11H6F3NO2S;Free Base;N/A;FC(F)(F)C1=CC(=CC=C1)\C=C1/SC(=O)NC1=O |c:6,8,t:4|;2,884;2;1;2;5;h;6;L1200-05;h6;100;2;O10;3
731;S2751;Milciclib (PHA-848125);O11;2;O;11;NA;h6;L1200-03;46057;802539-81-7;CDK;92;1997524806;<1;NA;http://www.selleckchem.com/products/pha-848125.html;Milciclib (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.;Cell Cycle;C25H32N8O;Free Base;N/A;CNC(=O)C1=NN(C)C2=C1C(C)(C)CC1=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C21 |c:8,22,24,t:4,15,17,20,35|;3,825;4;2;4;3;h;6;L1200-03;h6;100;2;O11;3
732;NA;DMSO;O12;2;O;12;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;O12;3
733;S2770;MK-5108 (VX-689);O13;2;O;13;NA;h7;L1200-03;46194;1010085-13-8;Aurora Kinase;92;1991600641;<1;NA;http://www.selleckchem.com/products/mk-5108-vx-689.html;MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.;Cell Cycle;C22H21ClFN3O3S;Free Base;N/A;OC(=O)[C@@]1(CC2=CC=CC(NC3=NC=CS3)=N2)CC[C@@H](CC1)OC1=C(F)C(Cl)=CC=C1 |r,c:7,13,16,26,30,32,t:5,11|;5,574;4;1;7;3;h;7;L1200-03;h7;100;2;O13;3
734;S8058;P276-00;O14;2;O;14;NA;h8;L1200-05;4383;920113-03-7;CDK;88;2007757244;88;200,7757244;https://www.selleckchem.com/products/p276-00.html;P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.;Cell Cycle;C21H21Cl2NO5;hydrochloride;N/A;Cl.CN1CC[C@H]([C@@H]1CO)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=C(Cl)C=CC=C1 |r,c:9,15,19,24,27,29,t:12|;3,49;2;3;3;5;h;8;L1200-05;h8;100;2;O14;3
735;S2806;CEP-33779;O15;2;O;15;NA;h8;L1200-03;46257;1257704-57-6;JAK;93;2010506518;<1;NA;http://www.selleckchem.com/products/cep33779.html;CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.;JAK/STAT;C24H26N6O2S;Free Base;N/A;CN1CCN(CC1)C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C2=CC=C(C=C2)S(C)(=O)=O)=C1 |c:10,17,19,22,27,29,35,t:8,14,25|;3,86;4;1;5;3;h;8;L1200-03;h8;100;2;O15;3
736;NA;DMSO;O16;2;O;16;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;O16;3
737;S2823;Tideglusib;O17;2;O;17;NA;h9;L1200-03;334.39;865854-05-3;GSK-3;66;19737;<1;NA;http://selleckchem.com/products/tideglusib.html;"Tideglusib is an irreversible, non ATP-competitive GSK-3_ inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.";PI3K/Akt/mTOR;C19H14N2O2S;Free Base;N/A;O=C1SN(C(=O)N1CC1=CC=CC=C1)C1=C2C=CC=CC2=CC=C1 |c:11,13,16,18,20,23,25,t:9|;4,63;2;0;3;3;h;9;L1200-03;h9;100;2;O17;3
738;NA;DMSO;O18;2;O;18;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;O18;3
739;S2872;GW5074;O19;2;O;19;NA;h10;L1200-03;52094;220904-83-6;Raf;104;1996391139;<1;NA;http://www.selleckchem.com/products/gw5074.html;GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.;MAPK;C15H8Br2INO2;Free Base;N/A;OC1=C(Br)C=C(\C=C2/C(=O)NC3=CC=C(I)C=C23)C=C1Br |c:1,20,t:4,11,13,16|;4,564;1;2;1;3;h;10;L1200-03;h10;100;2;O19;3
740;NA;DMSO;O20;2;O;20;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;O20;3
741;S2902;S-Ruxolitinib (INCB018424);O21;2;O;21;NA;h11;L1200-03;30637;941685-37-6;JAK;61;1991056566;5;16,32013578;http://www.selleckchem.com/products/s-ruxolitinib.html;S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.;JAK/STAT;C17H18N6;Free Base;N/A;N#CC[C@@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |r,c:11,13,18,20,23,t:16|;2,88;3;1;4;3;h;11;L1200-03;h11;100;2;O21;3
742;NA;DMSO;O22;2;O;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;NA;NA;DMSO-source;1;100;2;O22;3
743;NA;DMSO;O23;2;O;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;NA;NA;DMSO-source;1;100;2;O23;3
744;NA;DMSO;O24;2;O;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;DMSO-source;1;100;2;O24;3
745;S3012;Pazopanib;P01;2;P;1;NA;h1;L1200-04;43752;444731-52-6;VEGFR;87;1988480527;<1;NA;http://www.selleckchem.com/products/pazopanib.html;Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.;Protein Tyrosine Kinase;C21H23N7O2S;Free Base;N/A;CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1 |c:9,12,24,30,32,t:2,4,15,19,21|;3,741;5;2;5;4;h;1;L1200-04;h1;100;2;P01;3
746;S1180;XAV-939;P02;2;P;2;NA;h1;L2100-01;31231;284028-89-3;Wnt/beta-catenin;12;384233614;<1;NA;http://www.selleckchem.com/products/XAV-939.html;XAV-939 selectively inhibits Wnt/_-catenin-mediated transcription through tankyrase1/2 inhibition with IC50 of 11 nM/4 nM, regulates axin levels and does not affect CRE, NF-_B or TGF-_.;Stem Cells &  Wnt;C14H11F3N2OS;Free Base;N/A;OC1=C2CSCCC2=NC(=N1)C1=CC=C(C=C1)C(F)(F)F |c:1,8,10,15,17,t:13|;3,676;2;1;2;9;h;1;L2100-01;h1;100;2;P02;3
747;S6005;VX-702;P03;2;P;3;NA;h2;L1200-04;4043;745833-23-2;p38 MAPK;81;2003462775;<1;NA;http://www.selleckchem.com/products/VX-702.html;VX-702 is a highly selective inhibitor of p38_ MAPK, 14-fold higher potency against the p38_ versus p38_. Phase 2.;MAPK;C19H12F4N4O2;Free Base;N/A;NC(=O)N(C1=NC(=C(C=C1)C(N)=O)C1=C(F)C=C(F)C=C1)C1=C(F)C=CC=C1F |c:6,8,14,20,23,26,28,t:4,17|;3,682;3;2;4;4;h;2;L1200-04;h2;100;2;P03;3
748;S1575;RO4929097;P04;2;P;4;NA;h2;L2100-01;4694;847925-91-1;Y-Secretase;94;2002556455;<1;NA;http://www.selleckchem.com/products/RO4929097.html;RO4929097 is a _ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of A_40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.;Proteases;C22H20F5N3O3;Free Base;RO-4929097;CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C2=C(NC1=O)C=CC=C2 |r,c:20,22,25,31,33,t:18|;3,184;3;3;6;9;h;2;L2100-01;h2;100;2;P04;3
749;S7036;XL019;P05;2;P;5;NA;h3;L1200-04;44453;945755-56-6;JAK;16;3599307133;<1;NA;http://www.selleckchem.com/products/xl019.html;XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.;JAK/STAT;C25H28N6O2;Free Base;N/A;O=C(NC1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1)[C@@H]1CCCN1 |r,c:5,7,12,18,20,29,t:3,10,16|;3,106;4;3;6;4;h;3;L1200-04;h3;100;2;P05;3
750;S2186;SB505124;P06;2;P;6;NA;h3;L2100-01;3354;694433-59-5;TGF-beta/Smad;67;1997614788;<1;NA;http://www.selleckchem.com/products/sb-505124.html;SB505124 is a selective inhibitor of TGF_R for ALK4, ALK5 with IC50 of 129 nM and 47 nM, respectively, also inhibits ALK7, but does not inhibit ALK1, 2, 3, or 6.;TGF-beta/Smad;C20H21N3O2;Free Base;N/A;CC1=CC=CC(=N1)C1=C(N=C(N1)C(C)(C)C)C1=CC2=C(OCO2)C=C1 |c:3,5,10,26,t:1,8,18,20|;4,609;4;1;3;9;h;3;L2100-01;h3;100;2;P06;3
751;S7067;Tepotinib (EMD 1214063);P07;2;P;7;NA;h4;L1200-04;492.57;1100598-32-0;c-Met;5;101508415;<1;NA;http://www.selleckchem.com/products/emd-1214063.html;Tepotinib (EMD 1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Phase 1.;Protein Tyrosine Kinase;C29H28N6O2;Free Base;N/A;CN1CCC(COC2=CN=C(N=C2)C2=CC=CC(CN3N=C(C=CC3=O)C3=CC(=CC=C3)C#N)=C2)CC1 |c:9,11,16,21,23,30,32,36,t:7,14,28|;3,629;5;0;7;4;h;4;L1200-04;h4;100;2;P07;3
752;S2415;Astragaloside A;P08;2;P;8;NA;h4;L2100-01;78497;83207-58-3;others;100;1273934036;<1;NA;http://www.selleckchem.com/products/astragaloside-a.html;Astragaloside A (Astragaloside IV) is the primary pure saponin isolated from Astragalus membranaceus, which has been widely used for the treatment of cardiovascular diseases.;TGF-beta/Smad;C41H68O14;Free Base;Cyclosiversioside F;[H][C@@]1([C@@H](O)C[C@@]2(C)[C@]3([H])C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@]4([H])[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C)[C@]1(C)CC[C@@H](O1)C(C)(C)O |r|;-0,348;5;8;7;9;h;4;L2100-01;h4;100;2;P08;3
753;S7104;AZD1208;P09;2;P;9;NA;h5;L1200-04;37948;1204144-28-4;Pim;75;1976388742;<1;NA;http://www.selleckchem.com/products/azd-1208.html;AZD1208 is a potent, and orally available Pim kinase inhibitor with IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively. Phase 1.;JAK/STAT;C21H21N3O2S;Free Base;N/A;N[C@@H]1CCCN(C1)C1=C(\C=C2/SC(=O)NC2=O)C=CC=C1C1=CC=CC=C1 |r,c:8,19,21,26,28,t:24|;3,283;2;2;3;4;h;5;L1200-04;h5;100;2;P09;3
754;S2736;TG101348 (SAR302503);P10;2;P;10;NA;h5;L2100-01;52468;936091-26-8;JAK;100;1905923611;<1;NA;http://www.selleckchem.com/products/tg-101348.html;TG-101348 (SAR302503) is a selective inhibitor of JAK2 with IC50 of 3 nM, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 1/2.;JAK/STAT;C27H36N6O3S;Free Base;N/A;CC1=C(NC2=CC=CC(=C2)S(=O)(=O)NC(C)(C)C)N=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1 |c:1,6,8,35,38,t:4,19,22,24|;5,123;5;3;11;9;h;5;L2100-01;h5;100;2;P10;3
755;S7158;LY2835219;P11;2;P;11;NA;h6;L1200-04;6027;1231930-82-7;CDK;83;137713622;100;165,9200265;http://www.selleckchem.com/products/ly2835219.html;LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.;Cell Cycle;C28H36F2N8O3S;Mesylate;N/A;CS(O)(=O)=O.CCN1CCN(CC2=CC=C(NC3=NC(C4=CC(F)=C5N=C(C)N(C(C)C)C5=C4)=C(F)C=N3)N=C2)CC1 |c:32,37,40,t:11,13,16,19,22,24,34|;4,543;4;1;7;4;h;6;L1200-04;h6;100;2;P11;3
756;S2851;Baricitinib (LY3009104, INCB028050);P12;2;P;12;NA;h6;L2100-01;37142;1187594-09-7;JAK;74;199235367;<1;NA;http://www.selleckchem.com/products/baricitinib-ly3009104.html;Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3.;Epigenetics;C16H17N7O2S;Free Base;INCB 28050;CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |c:14,16,21,23,26,t:19|;0,36;5;1;5;9;h;6;L2100-01;h6;100;2;P12;3
757;S7206;CNX-2006;P13;2;P;13;NA;h7;L1200-04;54553;1375465-09-0;EGFR;100;1833079757;<1;NA;http://www.selleckchem.com/products/cnx-2006.html;CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.;Protein Tyrosine Kinase;C26H27F4N7O2;Free Base;N/A;COC1=C(NC2=NC=C(C(NC3=CC=CC(NC(=O)C=C)=C3)=N2)C(F)(F)F)C=CC(NC2CN(CCF)C2)=C1 |c:2,7,13,20,22,29,40,t:5,11|;5,15;4;4;12;4;h;7;L1200-04;h7;100;2;P13;3
758;S7037;Wnt-C59 (C59);P14;2;P;14;NA;h7;L2100-01;37945;1243243-89-1;Wnt/beta-catenin;76;2002898933;<1;NA;http://www.selleckchem.com/products/wnt-c59-c59.html;Wnt-C59 (C59) is a PORCN inhibitor for Wnt3A-mediated activation of a multimerized TCF-binding site driving luciferase with IC50 of 74 pM.;Stem Cells &  Wnt;C25H21N3O;Free Base;N/A;CC1=NC=CC(=C1)C1=CC=C(CC(=O)NC2=CC=C(C=C2)C2=CC=CN=C2)C=C1 |c:3,5,18,20,25,27,30,t:1,8,10,16,23|;3,667;3;1;5;9;h;7;L2100-01;h7;100;2;P14;3
759;S7269;PD173955;P15;2;P;15;NA;h8;L1200-04;44335;260415-63-2;Bcr-Abl;15;3383331454;<1;NA;http://www.selleckchem.com/products/pd173955.html;PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.;Angiogenesis;C21H18Cl2N4OS;Free Base;N/A;CSC1=CC(NC2=NC3C(C=N2)C=C(C(=O)N3C)C2=C(Cl)C=CC=C2Cl)=CC=C1 |c:10,13,20,23,25,28,30,t:2,6|;4,854;3;1;4;4;h;8;L1200-04;h8;100;2;P15;3
760;S7195;RKI-1447;P16;2;P;16;NA;h8;L2100-01;32637;1342278-01-6;ROCK;65;1991604621;<1;NA;http://www.selleckchem.com/products/rki-1447.html;RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.;Cell Cycle;C16H14N4O2S;Free Base;N/A;OC1=CC(CNC(=O)NC2=NC(=CS2)C2=CC=NC=C2)=CC=C1 |c:11,17,19,21,23,t:1,9,15|;2,081;3;3;4;9;h;8;L2100-01;h8;100;2;P16;3
761;S7319;EHop-016;P17;2;P;17;NA;h9;L1200-04;43055;1380432-32-5;Rac;86;1997445128;<1;NA;http://www.selleckchem.com/products/ehop-016.html;EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 _M for Rac1 in MDA-MB-435 and MDA-MB-231 cells, equally potent inhibition for Rac3.;Cell Cycle;C25H30N6O;Free Base;N/A;CCN1C2=C(C=CC=C2)C2=C1C=CC(NC1=NC(NCCCN3CCOCC3)=NC=C1)=C2 |c:5,7,10,13,30,32,34,t:3,17|;4,407;3;2;8;4;h;9;L1200-04;h9;100;2;P17;3
762;S7337;SH-4-54;P18;2;P;18;NA;h9;L2100-01;61059;1456632-40-8;STAT;100;1637760199;<1;NA;http://www.selleckchem.com/products/sh-4-54.html;SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively.;JAK/STAT;C29H27F5N2O5S;Free Base;N/A;CN(CC(=O)N(CC1=CC=C(C=C1)C1CCCCC1)C1=CC=C(C=C1)C(O)=O)S(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F |c:9,11,23,25,34,42,t:7,21,38|;6,221;4;0;9;9;h;9;L2100-01;h9;100;2;P18;3
763;S7397;Sorafenib;P19;2;P;19;NA;h10;L1200-04;46482;284461-73-0;Raf;63;1355363366;<1;NA;http://www.selleckchem.com/products/sorafenib.html;Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.;MAPK;C21H16ClF3N4O3;Free Base;BAY 43-9006;CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 |c:21,28,30,32,t:4,8,10,16,18|;4,175;4;3;6;4;h;10;L1200-04;h10;100;2;P19;3
764;S7566;IM-12;P20;2;P;20;NA;h10;L2100-01;37741;1129669-05-1;GSK-3;75;1987228743;<1;NA;http://www.selleckchem.com/products/im-12.html;IM-12 is a selective GSK-3_ inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling. ;PI3K/Akt/mTOR;C22H20FN3O2;Free Base;N/A;CN1C(=O)C(NCCC2=CC=C(F)C=C2)=C(C1=O)C1=C(C)NC2=C1C=CC=C2 |c:13,15,20,24,27,29,t:8,10|;3,074;2;2;5;9;h;10;L2100-01;h10;100;2;P20;3
765;S7525;XMD8-92;P21;2;P;21;NA;h11;L1200-04;47455;1234480-50-2;ERK;73;1538299442;<1;NA;http://www.selleckchem.com/products/xmd8-92.html;XMD8-92 is a potent and selective BMK1/ERK5 inhibitor with Kd of 80 nM.;MAPK;C26H30N6O3;Free Base;N/A;CCOC1=CC(=CC=C1NC1=NC2=C(C=N1)N(C)C(=O)C1=C(C=CC=C1)N2C)N1CCC(O)CC1 |c:5,7,13,15,24,26,t:3,11,22|;3,505;4;2;5;4;h;11;L1200-04;h11;100;2;P21;3
766;NA;DMSO;P22;2;P;22;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;P22;3
767;NA;DMSO;P23;2;P;23;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;4;NA;NA;DMSO-source;1;100;2;P23;3
768;NA;DMSO;P24;2;P;24;NA;NA;DMSO-source;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;NA;NA;DMSO-source;1;100;2;P24;3